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Abstract 
People with Autism Spectrum Disorders (ASD) are at increased risk of 
having challenging behaviours and comorbid mental disorders. Pharmacological 
interventions for these are common; however, the use of medication in this 
population is controversial and its efficacy remains unclear. The experience and 
perspectives of individuals with ASD and their caregivers regarding the 
effectiveness of pharmacological interventions have been largely neglected in the 
literature. Consequently, the present study aimed to explore the use of 
psychotropic medications to manage maladaptive emotions and behaviours from 
the perspectives of self-reporting adults with an ASD and caregivers of dependent 
children and adults with an ASD within an Australian context. An anonymous 
questionnaire (online or paper version) was completed by 245 caregivers of 
people with an ASD and 63 individuals with an ASD. Results were presented on 
the extent and types of medications prescribed; the reasons provided for use and 
the perspectives of individuals with ASD and caregivers regarding therapeutic 
outcomes. Medication use was examined with respect to comorbid mental health 
conditions, challenging behaviours and sleep difficulties and practice issues were 
also discussed. Individual and caregiver perspectives provided insights that are 
important to ongoing debate about psychotropic medication use among people 
with ASD. 
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Thesis Overview 
Autism Spectrum Disorders (ASD) are a group of neurodevelopmental 
disorders that affect individuals in the core domains of behaviour, social 
communication, and social interaction (APA, 2013). Due to the pervasive nature 
of these disorders, a comprehensive body of research has explored the impact of 
ASD on individuals and their caregivers. It has been established that individuals 
with an ASD are at increased risk of developing comorbid mental or psychiatric 
disorders, sleep difficulties, and challenging behaviours (Bradley & Bolton, 2006; 
Brylewski & Duggan, 2004; Matson & Nebel-Shwalm, 2007). This has added an 
increased complexity to understanding ASD and has made treating this population 
problematic. 
The medical conceptualisation and treatment of ASD has been widely 
applied to address comorbid problems in people with an ASD (Holden & Glisten, 
2009). Despite this, the use of psychotropic medications for people with an ASD 
has been surrounded by controversy (Antonacci, Manuel & Davis, 2008; 
Brylewski & Duggan, 1999; Gralton, James & Lindsey, 1998). More specifically, 
concerns have been raised regarding the use of psychotropic medication in the 
management of ASD-related challenging behaviours (Antonacci et al., 2008; de 
Bruin, Ferdinand, Meester, de Nijs & Verheij, 2007). Both positive (e.g., 
decreased anxiety) and negative outcomes (e.g., weight gain) have been identified 
as a consequence of pharmacological interventions for people with an ASD (e.g., 
Jesner, Aref-Adib & Coren, 2009). The equivocal nature of these findings  
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suggests a need for further analysis into what is known about the current practice 
and therapeutic outcomes regarding the use of psychotropic medication in people 
with an ASD. 
Despite the controversy surrounding the use of pharmacological 
interventions for people with ASD, psychotropic medication continues to be a 
widely used treatment option in this population (Liptak, Stuart & Auinger, 2006). 
For example, only risperidone (an anti-psychotic medication) has been approved 
for treating severe behavioural disturbance in children and adolescents with an 
ASD (Victorian Government, 2009); however, researchers have identified that 
many other medications have been prescribed to address maladaptive emotions 
and behaviours associated with ASD (e.g., Lakhan & Jaggar-Johnson, 2007). This 
highlights a significant disparity between research and clinical practice. 
The prevalence of the use of psychotropic medication among people with 
ASD has been explored in countries such as the Unites States of America (USA) 
and Iran (e.g., Aman et al., 2005; Esbensen et al., 2009; Memari et al., 2012), yet 
few studies have been undertaken in Australia (e.g., McGillivray & McCabe, 
2005; Webber, Chan & McVilly, 2010. Further, previous research has primarily 
focused on individuals who have resided in state-based accommodation, and have 
examined this as part of larger intellectual disability research (e.g., McGillivray & 
McCabe, 2005; Webber et al., 2010). This means that there has been little 
exploration of psychotropic medication use in individuals with ASD who reside in 
home-based care within the community. Moreover, there has been little 
exploration of the perspectives of the individuals with an ASD or their caregivers 
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regarding psychotropic medication. A need was therefore identified, for an 
Australian study of community-based individuals with an ASD and their 
caregivers to explore their perspectives regarding the use of psychotropic 
medications. 
This thesis conducted an audit of the use of psychotropic medication in 
individuals with ASD, where the primary intent of the medication was to assist 
with the management of emotions or behaviours associated with the ASD. The 
aim of the thesis was to provide an overview of the nature, extent, reasons for and 
outcomes related to the use of psychotropic medication in a community-based 
ASD Australian population. Specifically, the primary purpose was to examine the 
use of psychotropic medication in children and dependent adults with an ASD as 
reported by their caregivers (Study 1), and from self-reporting adults with an ASD 
(Study 2). A further exploratory aim was to investigate the narrative perspectives 
of individuals with an ASD (Study 3a) and their caregivers (Study 3b) on the use 
of psychotropic medication. 
A description of psychotropic medication use in children and dependent 
adults, with their caregiver serving as an informant, was provided in Study 1. In 
Study 2, psychotropic medication use in independent adults who were self- 
reporting on their own circumstances was examined. Both studies commence with 
a detailed description of the participants. Given that Study 1 involved reports 
from caregivers and Study 2 involved self-reports from independent adults with 
an ASD, a comparison between the two groups was deemed inappropriate 
because the studies capture two different populations. Independent adults are 
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likely able to make their own decisions and are active participants in the decision 
to use psychotropic medication. Whereas children and dependent adults 
caregivers were likely acting on the person’s behalf and making the decision to 
use psychotropic medication on behalf of the child/dependent adult. Study 3 
presents a qualitative analysis of both caregivers and individuals perspectives of 
psychotropic medication use. This third study is presented in two parts: Study 3a 
focused on the insights and perceptions of caregivers into psychotropic 
medication use, whereas Study 3b focused on the insights and perceptions of self- 
reporting adults with an ASD. 
The thesis comprises 11 chapters. A review of the literature is presented in 
the first three chapters. Chapter 1 explores the links between ASD, challenging 
behaviour, comorbid mental health conditions and sleep difficulties. In Chapter 2, 
the use of psychotropic medication among individuals with an ASD is reviewed. 
In Chapter 3, the relationships between psychotropic medication use and 
challenging behaviours, comorbid mental health conditions and sleep difficulties 
are systematically explored. The rationale for the study is presented in Chapter 4 
and the methodology and data analysis is provided in Chapter 5. Chapter 6 reports 
the findings of Study 1, with the discussion presented as Chapter 7. The results 
and discussion for Study 2 are presented in Chapters 8 and 9, and the qualitative 
results and discussion of Study 3 are presented in Chapter 10. Finally, in Chapter 
11, the three studies are drawn together and overall reflections from the thesis are 
provided.  
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Please note, this thesis is an applied study and the data utilised is largely 
an audit of psychotropic medication use in an Australian population, however, 
this is examined with reference to the available literature and it adds to what is 
known by including the perspectives of the individuals themselves. The thesis 
offers a unique perspective by including qualitative data on individual and 
caregivers thoughts surrounding medication for the purpose of behavioural or 
emotional alteration. 
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Chapter 1: Autism Spectrum Disorders 
There have been recent changes to diagnosing Autism Spectrum Disorder 
(ASD) in the Diagnostic and Statistical Manual for Mental Disorders, fifth edition 
(DSM-V), which was released in mid-2013 (American Psychiatric Association, 
(APA), 2013). The changes consolidated autistic disorder, Asperger’s disorder, 
pervasive developmental disorder–not otherwise specified (PDD–NOS), and 
childhood disintegrative disorder under one diagnosis, ASD (APA, 2013). The 
consolidation was designed to represent an ASD continuum from mild to severe, 
rather than individual disorders. The new diagnosis has an indicator of severity 
and describes an individual’s overall developmental state, in terms of motor, 
cognitive and social communication (APA, 2013). The aim of the new category is 
to assist clinicians to diagnose individuals more accurately and ultimately to 
provide consistency across clinicians and settings for diagnostic labels. Since the 
studies within this thesis were completed prior to the release of DSM-V, the ASD 
definitions applied throughout this thesis are consistent with the Diagnostic and 
Statistical Manual of Mental Disorders fourth edition- text revised (DSM-IV-TR) 
diagnostic criteria (APA, 2000). 
ASD refers to a grouping of people who have been diagnosed with autistic 
disorder, Asperger’s disorder and PDD–NOS. These diagnoses can significantly 
affect a person over their lifespan (Fombonne, 2003a, 2003b). ASDs are 
characterised by significant impairment in social interactions and communication,  
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and are accompanied by restricted patterns of behaviour, interest and activity 
(Fombonne, 2008). The characteristics of ASD represent a spectrum of abilities; 
therefore, each individual with the condition is uniquely affected (Happé & Frith, 
2006). 
For a child or adult to receive a diagnosis of an ASD within Australia, it is 
considered best practice for the individual to receive an inter-disciplinary 
assessment prior to diagnosis (O'Reily, 2013). This includes detailed assessments 
conducted by a psychologist, developmental paediatrician, speech pathologist and 
occupational therapist (Hillman & Snyder, 2007). 
1.1 Autistic Disorder 
The DSM-IV-TR (APA, 2000) specifies that a person with autistic 
disorder displays impairments in social interaction, which may include: 
impairment in the utilisation of non-verbal behaviours (e.g., eye contact); failure 
to acquire developmentally appropriate peer relationships; difficulty with social 
and emotional reciprocity; and/or an absence of spontaneous engagement with 
others in the sharing of interests, achievements or enjoyment (APA, 2000). The 
individual must also display impairments in their communication, which may 
present as: significant impairment in the individual’s ability to commence or 
maintain a conversation; spoken language involving stereotyped and repetitive 
use of words; an absence of spontaneous imaginative play or social imitative play; 
delayed or absent spoken language without compensatory attempts at  
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communication (e.g., gesture) (APA, 2000). For an individual to be diagnosed 
with an autistic disorder, delays or abnormal functioning in the aforementioned 
areas need to be present prior to three years of age (APA, 2000). 
1.2 Asperger’s Disorder 
Similarly to individuals with autistic disorder, an individual who is 
diagnosed with Asperger’s disorder must have a delay in social impairment, 
together with restricted, repetitive and stereotyped patterns of interests, behaviour 
and activities (APA, 2000). In contrast to autistic disorder, people with 
Asperger’s disorder do not display clinically significant delays in the acquisition 
of language (APA, 2000). Their use of language is often associated with deficits 
in pragmatics, pitch, stress and rhythm of speech (Ghaziuddin, 2005). Individuals 
with Asperger’s disorder also do not display clinically significant delays in 
cognitive development (APA, 2000). 
1.3 Pervasive Developmental Delay–Not Otherwise Specified 
A PDD-NOS is diagnosed when an individual experiences severe and 
pervasive impairments in the development of social interaction, along with 
associated verbal and non-verbal communication deficits or the occurrence of 
repetitive stereotyped behaviours or interests (APA, 2000). This diagnosis is used 
for presentations that do not fully meet the criteria for autistic disorder due to a 
later age of onset, different symptomatology or the absence of impairment in all 
three areas of communication, social interaction and behaviour (APA, 2000). 
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1.4 Prevalence of Autism Spectrum Disorders 
Recent international research suggests that the prevalence of ASD within a 
community is approximately 60 in 10,000 (Fombonne, 2005). However, 
Australian research suggests that the prevalence may be slightly lower; with 
between 10 to 50 people in 10,000 diagnosed with an ASD (Icasiano, Hewson, 
Machet, Cooper & Marshall, 2004). These prevalence rates were recently 
supported by Williams et al. (2008), who found between 12 to 36 per 10,000 
people were diagnosed with an ASD, based on their analysis of children aged up 
to 16 years, known to have an ASD in Australia. 
In a meta-analysis conducted earlier this year to explore the specific 
prevalence of autistic disorder and Asperger’s disorder, French, Bertone, Hyde 
and Fombonne, (2013) reported significant variability in rates. However, the 
majority of studies consistently estimated higher rates of autistic disorder than 
Asperger’s disorder. The authors highlighted an apparent discrepancy amongst 
the studies as to whether high functioning ASD was included as Asperger's 
disorder, or whether this was regarded as a diagnosis of autistic disorder. French 
et al. suggested this definition issue may have contributed to the differing 
prevalence rates between autistic and Asperger’s disorder. 
Lower prevalence rates of ASD were found in a meta-analysis of 42 
studies, published between 1966 and 2003, conducted by Williams, Higgins and 
Brayne (2006). Williams and colleagues established a prevalence estimate of 7.1 
per 10,000 for autistic disorder, and 20.0 per 10,000 for ASD. The review 
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established that more recent studies (post year 2000) demonstrated higher 
prevalence rates of ASD compared with earlier studies (Williams et al., 2006). 
Research conducted in Australia over the past two decades supports this 
proposition, and indicates that the prevalence of ASD has increased two-fold 
during this period (Birnbrauer, Bradly, Brigg et al., 1988; Glasson, 2002; 
Williams, Macdermott, Ridley, Glassons & Ray, 2008). Several suggestions have 
been proposed to explain this increase in ASD (Williams et al., 2008). First, the 
diagnostic criteria have changed over time, resulting in more people meeting the 
diagnostic requirements than previously. Second, it is plausible that the 
development of the diagnostic criteria for Asperger’s disorder has resulted in the 
inclusion of individuals who were previously not recognised. Finally, an increase 
in the awareness of the disorder may be resulting in greater rates of diagnosis 
(Bryson & Smith, 1998). Regardless, it is important that research continues 
explore the effect of this disorder on individuals and their caregivers due to the 
large number of people who are affected. 
1.5 Aetiology of Autism Spectrum Disorders. 
ASDs are pervasive and affect individual’s daily functioning in a myriad 
of ways. Many theories exist as to the aetiology of ASD and the rising occurrence 
of this disorder. What is accepted in the literature is that ASDs have a 
neurobiological basis and that they are pervasive (O'Reilly & Benison, 2013). 
While there is a large body of research suggesting that ASD has a genetic 
component (see Rutter, 2005), a common causative factor remains elusive. Most 
cases are considered idiopathic (arising from unknown causes; Marshall, 2013). 
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Moreover, it appears there may be multiple explanations for the development of 
ASD, with recent research suggesting differing causes for those who experience a 
regressive form as opposed to those with who exhibit symptomatology from birth 
(O'Reilly & Benison, 2013). 
1.5.1 Gender. 
ASDs are diagnosed more predominantly in males than females, with ratio 
estimates of 4:1 (Fombonne, 2003; Holtmann, Bōlte & Poustka, 2007; Morgan, et 
al., 2002). However, inconsistent findings have been demonstrated with regard to 
the gender breakdown of autistic disorder, Asperger’s disorder and PDD-NOS 
(Holtmann et al., 2007). Most studies suggest that more males are affected by 
autistic disorder than females—at a rate of 2:1—with rates being higher in 
Asperger’s disorder, 6:1 (Fombonne, 2003a). While a consensus exists that ASD 
affects more males than females, recent research has investigated the differences 
in core symptoms between males and females (Holtmann et al. 2007; Westman, 
Andersson, Gillberg & Miniscalo, 2013). Holtman and colleagues (2007) 
explored the different presentations of 23 males and 23 females with an ASD. No 
significant differences were identified in the symptoms of repetitive and 
stereotyped behaviour, communication or social interactions; however, parents 
reported greater impairment in females on social, attention and thought domains 
(Holtman et al., 2007). Holtman et al. suggested this may be a consequence of 
different societal expectations for females in terms of communication, rather than 
true differences in this specific area of ASD psychopathology. 
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1.5.2 Autism spectrum disorder and intellectual disability. 
People with an ASD also often are diagnosed with an intellectual 
disability. Fombonne, Simmons, Ford, Meltzer and Goodman (2003) found that 
44 per cent of people with an ASD had a co-occurring intellectual disability. An 
Australian study by Icasiano et al. (2004) similarly found that of 131 children 
diagnosed with an ASD, 47 per cent had an intellectual disability (as measured by 
an IQ of less than 70). It is important to note that this co-occurrence varies within 
the type of ASD. For instance, people who are diagnosed with Asperger’s 
disorder rarely meet the criteria for intellectual disability (O'Reily, 2013). In 
contrast, intellectual disability is commonly found in individuals with autistic 
disorder, with 70–75 per cent having an associated intellectual disability (Deb & 
Prasad, 1994; Fombonne, 2003b; Morgan et al., 2002). The results from this 
collective group of studies indicate that intellectual disability and ASD often co-
exist. 
In summary, ASDs are a group of disorders that predominate in males, 
with speculation that there may be perceived differences in symptomatology 
between males and females. Intellectual disabilities are highly comorbid with 
ASD, in particular the subtype of autistic disorder. 
1.5.3 Autism spectrum disorders and challenging behaviours. 
In addition to the core symptoms of ASD, individuals with an ASD 
commonly exhibit a range of  “challenging” behaviours, a term that is often used 
interchangeably with ‘behaviours of concern’, ‘problematic behaviours’, and 
‘difficult behaviours’, replacing previous terms such as ‘abnormal’, ‘aberrant’, 
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‘disordered’, ‘disturbed’ and ‘retarded’ behaviours (Brylewski & Duggan, 2004). 
Challenging behaviours have been  defined by Emerson (1995) as “culturally 
abnormal behaviour(s) of such an intensity, frequency or duration that the 
physical safety of the person or others is likely to be placed in serious jeopardy, or 
behaviour which is likely to seriously limit use of, or result in the person being 
denied access to, ordinary community facilities (p7)”.  Brylewski and Duggan 
(2004) reported that challenging behaviours in people with ASD are behaviours 
that are difficult to manage, may be harmful to people or property, may limit a 
person’s access to the community, and affect their life and caregivers in a 
negative manner.  
It is important to note that the concept of what constitutes a challenging 
behaviour can differ depending on the context in which it occurs – that is the 
individual, family, culture or socio-political norms relevant to the individual 
(Hanbury, 2007). For example, a person with an ASD who uses coarse language 
may be deemed to have a challenging behaviour in China, but not in Australia. 
Behavioural presentations in those with an ASD vary widely and are 
largely heterogeneous (Kim & Lord, 2013). Kim and Lord suggested this 
variability is influenced by a number of individual factors (e.g., developmental 
trajectories, communication skills, cognitive ability, gender & adaptive skills) and 
external factors (e.g., living environment, level of support & socio-economic 
status).   While not all individuals with an ASD will have challenging behaviours, 
these behaviours can be of greater concern to individuals and their caregivers than 
the core diagnostic symptoms of ASD (Pearson et al., 2006). 
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The available literature on challenging behaviour has not yet established a 
consensus on the categories of behaviours most commonly displayed by 
individuals with an ASD. For the purpose of this thesis, five domains of 
challenging behaviours will be referred to: (1) aggressive, (2) self- 
injurious/stereotyped, (3) emotion-related, (4) impulse control, and (5) other 
disruptive behaviours. Aggressive behaviours are the most commonly researched 
behaviours reported in the literature (Matson, Stipes, Fodstad & Fitzgerald, 2011; 
Matson & Nebel-Schwalm, 2007). Aggressive behaviours include physical 
antisocial acts, such as hitting, kicking, biting or destroying objects. Research has 
suggested these behaviours occur across the whole spectrum of ASD, regardless 
of severity or comorbid intellectual disability (Matson et al., 2011). 
The second category of challenging behaviours involves self- 
injurious/stereotyped behaviours. These behaviours often occur in a rhythmical 
and repetitive manner (Matson et al., 2011); for example, hand biting, skin 
pinching, head banging, compulsive touching, hand flapping and other ritualistic 
behaviours (Brereton & Tonge, 2002). Self-injurious behaviours can result in 
tissue damage in the form of lacerations, contusions or abrasions and often can 
cause significant lifelong injuries to an individual (Taylor et al., 2011).  
In contrast to aggressive and self-injurious challenging behaviours, which 
both involve physical acts, emotion-related behavioural concerns are more covert 
and refer to a difficulty expressing emotions appropriately. For example, people 
with an ASD often experience problems communicating feelings of anger, 
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sadness, stress or irritability. The final two categories of challenging behaviours 
include impulse control difficulties and other disruptive behaviours. 
Impulse control behaviours refer to difficulties concentrating on tasks or 
behaviours that are characterised by poor judgment (McDougle, Posey & Stigler, 
2006). For instance, people with an ASD may walk across a road without 
checking it is safe to do so, or may find it difficult to follow instructions. The fifth 
challenging behaviour category, described as ‘other disruptive behaviours’, 
includes a variety of behaviours that are not captured by the other four categories. 
Behaviours in this category include spitting, tantrums, crying, agitation, and 
manipulation (Tonge, Brereton, Gray & Einfeld, 1999). 
Individuals with ASD will often display more than one type of challenging 
behaviour, with some individuals experiencing a range of behaviours across 
differing circumstances (Matson & Rivet, 2008b). These inter-related behaviours 
often compromise the wellbeing of the person with an ASD by serving as a 
barrier to participation in education, employment, social interactions and 
community integration (Koegal, Koegal, & Dunlap, 1996; Matson & Rivet, 
2008). While a lack of consensus exists on the specific categories of challenging 
behaviours, these behaviours of concern are receiving increasing attention in the 
ASD literature due to their association with negative outcomes (Matson et al., 
2011). 
1.5.4 Prevalence of challenging behaviour. 
Prevalence estimates of challenging behaviour among people with an ASD 
vary significantly, with rates ranging from five to 50 per cent (e.g., Emerson et 
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al., 2001; Kerth, Progar & Morales, 2009; Murphy, Macdonald, Hall & Oliver, 
2000; Myers & Johnson, 2007). This variation in prevalence rates may be a result 
of several methodological issues. First, challenging behaviour has been 
interpreted broadly in the literature; consequently, different studies have used 
different criteria to define the term. Second, certain types of challenging 
behaviour, such as aggression, have been studied more frequently than other 
challenging behaviours (Carr & Owen-DeSchryver, 2007). It is likely that this 
category of behaviour has been more highly researched due to its seriousness, and 
the greater implications they have for the community and caregivers (Carr & 
Owen-DeSchryver, 2007). Third, ASD is a broad term used to define individuals 
with varying levels of impairment, with or without intellectual disabilities; as 
such, it is likely that the rates of challenging behaviour among this population will 
vary accordingly. Finally, prevalence rates of challenging behaviour in people 
with ASD may reflect the rate at which people are referred to intervention 
services, rather than the actual rates of occurrence within the community.  
Challenging behaviours in individuals with an ASD are commonly 
associated with intellectual disability (Kozlowki, Matson & Sipes, 2012). 
Accordingly, this relationship has received substantial attention within the 
research literature. It has been established that individuals with both an ASD and 
intellectual disability more frequently display challenging behaviours than those 
with an intellectual disability only (Matson & Rivet, 2008a). It is proposed that 
the association between challenging behaviour and intellectual disability is due to  
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the frequency and intensity of such behaviours—in particular self-injurious 
behaviours—increasing with impairment of cognitive functioning (Lennox, 
2007). 
It has been suggested that people with both an ASD and intellectual 
disability are at increased risk of exhibiting challenging behaviour (Matson & 
Nebel-Schwalm, 2007; McClintock, Hall & Oliver, 2003); specifically stereotypy 
and self-injurious behaviours (Baghdadli, Pascal, Grisi & Aussilloux, 2003; 
Baghdadli et al., 2008). Moreover, challenging behaviours have been found to 
persist throughout adulthood. A study by Matson and Rivet (2008a) investigated 
the rates of challenging behaviour in 161 adults with an ASD and intellectual 
disability, compared with 159 adults with an intellectual disability only, who 
resided in residential care facilities. The findings indicated that people with both 
ASD and an intellectual disability had more frequent challenging behaviour 
across the four domains measured (aggression/destruction, stereotypy, self-
injurious behaviour and disruptive behaviour). Further, the study found that 
individuals with a diagnosis of intellectual disability and ASD were more likely to 
have a co-occurrence of challenging behaviour across the four domains, compared 
to people with an intellectual disability only. 
A further study by Matson and Rivet (2008b) focused on the relationship 
between severity of ASD traits and the frequency and type of challenging 
behaviour in 298 adults with severe intellectual disabilities. The findings 
indicated that people with ASD and intellectual disability engaged in a range of 
challenging behaviour, including: harm to others, self-injury and other disruptive 
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behaviours. In addition, the results suggested that severe core traits of ASD were 
associated with a higher likelihood of challenging behaviour. Matson and Rivet 
(2008b) also investigated the role of communication and adaptive behaviours in 
the presentation of challenging behaviour. Findings indicated that the core 
symptoms of ASD were related to disruptive and self-injurious behaviour beyond 
what might be expected from their adaptive skills and communication. Despite 
Matson and Rivet’s results, a significant limitation of their study was that all 
participants permanently resided at the same residential facility. Consequently, it 
is uncertain whether these findings are generalisable to other groups of people 
with an ASD in different settings. 
One of the most extensive studies on challenging behaviour was 
conducted by Murphy et al. (2005). This longitudinal study investigated skills 
(self-care, motor, visual-spatial, language and communication), social 
impairments and challenging behaviour in 166 children with an ASD and/or 
intellectual disability residing in home-based care, using the Schedule of 
Handicaps Behaviour Skills (Wing, 1996; Wing & Gould, 1978). Twelve years 
after initial measurement, 141 of the original participants were re-assessed. 
Findings indicated that abnormal behaviours (e.g., self-injury, repetitive 
movements, aggressiveness and hyperactivity) reduced with increasing age. 
1.5.5 Aetiology of challenging behaviour. 
Currently, there is no direct causal link between challenging behaviour 
and ASD (Hanbury, 2007). However, various theoretical models have been used 
to explain this relationship. One such model, commonly accepted to explain the 
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reasons why a person with ASD displays challenging behaviours, is the 
‘biopsychosocial’ model (Campbell & Rohrbaugh, 2013; Engel, 1980; Ingham, 
Clarke & James, 2008). This model posits that an individual’s behaviour is 
influenced by a dynamic combination of biological, social and psychological 
factors (Campbell & Rohrbaugh, 2013). This model suggests that formulation of 
behaviours needs to take into consideration all factors in order to provide a 
holistic understanding of the reasons for the behaviour. This model views 
behaviours as a symptom, shifting focus to the influences that may have produced 
it, rather than on the behaviour itself.  
Biological influences of challenging behaviour may include factors such 
as genetics, neurobiological influences, neurological abnormalities, pain and 
physical illness (Boucher, 2009). It has been noted that those with an ASD may 
be more predisposed to neurological comorbidities associated with challenging 
behaviours, such as intellectual disability and epilepsy (Bonora et al., 2006; 
Boucher, 2009; Taylor, Oliver & Murphy, 2011;). Moreover, those with 
behavioural problems are more likely to have different neurobiology to those 
without (Boucher, 2009; Taylor et al., 2011).  
Social factors also assist in explaining the development and perpetuation 
of challenging behaviours. This component of the biopsychosocial model 
involves the environment (including the people) within which the ASD individual 
resides (Boucher, 2009). For example, an individual with an ASD may have 
limited capacity to clearly communicate their wants and needs. Consequently, if 
the context does not support this individual’s communication deficit, 
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inappropriate behaviours may develop and be reinforced (Aylott, 2001; Chiang, 
2008; Jensen, McConachie & Pierson, 2001; McConachie & Diggle, 2007). As a 
result, social factors play an important role in understanding challenging 
behaviour.  
A psychological explanation of challenging behaviour among people with 
an ASD may be the result of deficits in cognitive functioning (Boucher, 2009). An 
individual may lack adaptive behaviour skills, which places them at risk of 
demonstrating behaviours deemed challenging. Individuals with an ASD are 
characterised by an impairment in social interactions, which places them at risk of 
behaviours that may be deemed socially inappropriate and thus challenging.  
While, it is important to consider the three distinct elements of the model, the 
interactions of these factors and how this may impact the presentation of 
challenging behaviours is paramount to this model.  
An alternate model to understanding challenging behaviour is Durand and 
Carr’s (1985) social communicative theory of behaviours. This model posits that 
individuals use some behaviours as nonverbal forms of communication. 
According to this theory, when individuals are provided with a means to 
communicate their needs and wants (replacement behaviours), difficult 
behaviours are less likely to be exhibited. Carr and Durand’s model has served as 
the precursor for functional behavioural analysis, which is central to 
understanding the reason why an individual engages in particular behaviours 
(Webber, Ramcharan & McLean, 2010). It focuses on antecedents to the 
behaviour, the behaviour itself, and the consequence of the behaviour. Moreover, 
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it views the behaviour as possibly an adaptive response to a maladaptive 
environment (Webber et al., 2010). Thus, functional analysis can assist in 
identifying salient factors involved in explaining an individual’s challenging 
behaviour. 
In summary, challenging behaviours are common among individuals with 
an ASD. These behaviours significantly impact functioning and ability to engage 
in activities in individuals with ASDs. While challenging behaviours may pose an 
issue for the individual’s safety and wellbeing, these behaviours may serve a 
purpose for that individual and as such, an examination of their function is 
paramount. 
1.6 Comorbid Mental Health Conditions 
While it is evident that a large proportion of people with ASD display 
challenging behaviours, it has been suggested that these behaviours may, at least 
partly, be the result of a comorbid psychiatric condition (e.g., Brylewski & 
Duggan, 2004). According to Matson & Nebel-Schwalm (2007), individuals with 
an ASD are at significant risk of experiencing a comorbid mental health 
condition, defined as the presence of two or more forms of psychopathology 
occurring in the same person simultaneously. Psychiatric conditions commonly 
comorbid with ASD include mood disorders (e.g., depression); anxiety disorders 
(e.g., generalised anxiety); attention disorders (e.g., attention deficit and 
hyperactivity disorder (ADHD)) and psychotic illnesses (e.g., schizophrenia). 
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Although a significant overlap in symptoms is acknowledged (Brylewski 
& Duggan), the recognition of challenging behaviour in individuals with an ASD 
often implies the absence of a formal comorbid psychiatric condition. Comorbid 
mental health conditions can be missed in assessments and assumed to be 
‘challenging behaviour’ rather than symptomatic of the mental illness. Moreover, 
the ability to diagnose comorbid psychiatric conditions in a person with an ASD 
is often complicated by inter-related pathology that requires a highly skilled 
clinician (Brylewski & Duggan, 2004). 
1.6.1 Prevalence of comorbid mental health conditions. 
The prevalence of comorbid psychiatric disorders among individuals with 
ASD varies considerably, with estimates ranging from 11 to 70 per cent (e.g., 
Bradley & Bolton, 2006; Lunegard, Hallerback & Gillberg, 2011; Moseley et al., 
2011; Skokauskas & Gallaher, 2012). For example Morgan, Roy and Chance 
(2003) reported that 65 per cent of adults with an ASD met the diagnostic criteria 
for at least one other psychiatric condition (e.g., anxiety disorder), whereas 
Moseley and colleagues (2011) identified a 42 per cent rate of comorbidity in 84 
adolescents and young adults with autistic disorder. The differences in estimates 
between these studies may be attributed to the differences in samples; as the later 
study had a large percentage of participants in the later study (79%) with a 
concurrent intellectual disability or alternatively in the differing assessment 
processes. 
In an investigation of the rates of episodic psychiatric disorders in 
adolescents with intellectual disabilities, with and without autism, Bradley and 
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Bolton (2006) reported that significantly more individuals with ASD and 
intellectual disability experienced comorbid mental health conditions (most 
commonly depression) than those with an intellectual disability alone. This was 
assessed via semi-structured interview, however the study failed to account for 
behavioural difficulties and whether these were impacting diagnoses. This 
highlights the association between enhanced risk of a comorbid mental health 
condition and ASD. 
Despite the large variation in prevalence estimates of comorbid mental 
health conditions, it is clear that people with an ASD are more likely to 
experience a comorbid mental health condition. Moseley and colleagues (2011) 
indicated that the prevalence of comorbid mental health conditions is 
approximately four times that of the general population. As such, it is important to 
explore what mental health conditions are more prevalent in the ASD population. 
1.6.2 Mood disorders. 
Mood disorders, including major depressive disorder and bipolar affective 
disorder, are debilitating episodic illnesses (Matson & Nebel-Schwalm, 2007). 
Major depression is defined as a negative mood state usually accompanied by 
diminished energy, interest or pleasure in daily activities, lessened feelings of 
self-worth or ability to concentrate (APA, 2000). It is the most commonly 
diagnosed psychological disturbance, affecting approximately one in five people 
at some point in their life (Lefton & Brannon, 2003). It has been suggested that 
people with an ASD have higher rates of depression than the general population 
(Ghaziuddin & Greden, 1998; Ghaziuddin & Tsai, 1991; Stewart, Barnard, 
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Pearson, Hasan & O'Brien, 2006). For instance, on the basis of a semi-structured 
interview, Ghaziuddin and Greden (1998) reported that 37 per cent of adolescents 
and young adults with Asperger’s disorder met the diagnostic criteria for major 
depression. However, this finding was based on an inpatient sample who had 
severe psychopathology and it is thus unknown the extent to which they may 
generalise to a community based population.  
Similar results were found in an earlier study by Wing (1981), which 
indicated that 30 per cent of adults with Asperger’s disorder also experience 
symptoms consistent with major depression. A more recent study by Lugnegard 
and colleagues (2011) found that up to 70 per cent of adults with Asperger’s 
disorder had experienced at least one major depressive episode. These studies 
have highlighted the high incidence of depression among individuals with an 
ASD, particularly Asperger’s disorder. 
In contrast, there has been limited examination of the prevalence of 
depression among people with both an ASD and an intellectual disability. It has 
been suggested that the presence of depression manifests itself differently among 
this subgroup (Matson & Nebel-Schwalm, 2007). For instance, people with an 
intellectual disability may display depressive-like symptoms through 
unwillingness to participate in activities, social withdrawal, and possibly 
vegetative states (Ghaziuddin, Ghaziuddin & Greden, 2002; Shu, 2009). Further, 
a person’s ASD characteristics may disguise or alter how depression presents. In 
particular, people with an ASD commonly have difficulty recognising and 
expressing emotions; as such, they may display depression through increased 
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obsessive compulsive behaviours, increased social withdrawal, irritability or 
change in the character of obsessions (Ghaziuddin, 2005). Consequently, people 
with an ASD and an intellectual disability may have a greater likelihood of 
experiencing depression, due to a combination of their symptoms resulting from 
each condition. 
Although there has been considerable research into the prevalence 
between ASD and depression, little is currently known about the prevalence of 
bipolar affective disorder within the ASD population. One recent study identified 
two individuals with bipolar affective disorder when screening 36 people with 
autism and intellectual disability for psychiatric disorders (Bradley & Bolton, 
2006). Another study by Morgan et al. (2003) screened 164 individuals with ASD 
to examine comorbid psychiatric conditions. The findings identified that 16 
individuals (11%) in their study had a comorbid diagnosis of bipolar disorder. 
This may suggest a higher relative comorbidity of bipolar disorder in those with 
an ASD compared to those without an ASD. 
1.6.3 Anxiety disorders. 
In contrast to the widespread acceptance that depression is highly 
comorbid with ASD, there is considerable debate as to whether anxiety is a 
comorbid condition or is an inherent element of ASD (Matson & Nebel-Schwalm, 
2007). That is, whether trait based anxiety is part of the disorder. Anxiety is 
characterised by symptoms of physical tension and feelings of fear or 
apprehension about the future that impair an individual’s functioning (Barlow & 
Durand, 2005). As people with ASDs experience a restricted range of interests 
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and a general dislike for change, it is often accepted that these individuals may 
experience higher levels of trait based anxiety as a part of their condition (Cath, 
Ran, Smit, van Balkom & Comijs, 2008). As a result, there is a potential for 
under-diagnosing anxiety disorders, or state based anxiety, among people with 
ASD who may consequently fail to receive adequate treatment for anxiety 
problems (Cath et al., 2008). 
The diagnosis of anxiety disorders in people with ASD is further 
complicated by the possibility that they may present with different signs and 
symptoms, in comparison to neurotypical people (Matson & Nebel-Schwalm, 
2007). For example, Brereton and Tonge (2002) suggested that the signs of 
anxiety in children with ASD include: school refusal; pervasive worry and 
fearfulness; restlessness and irritability; timidity, shyness and withdrawal; 
associated headache and stomach pains; restless sleep and nightmares; poor 
concentration and distractibility; and reliving stressful events in repetitive play. 
This diversity in presentation demonstrates the difficulties that professionals face 
when assessing and treating people with ASD and comorbid anxiety. 
Due to the lack of consensus in the literature regarding the relationship 
between ASD and anxiety, it is not surprising that previous prevalence studies 
have produced substantial variation in results, ranging from 5 to 84 per cent (e.g., 
Bellini, 2004; Muris, Steerneman, Merckelbach, Holdrinet & Meesters, 1998). 
Despite a lack of consensus in this area, most studies suggest that rates of anxiety  
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in those with an ASD are significantly higher than the general population, or 
when compared to others with disabilities (e.g., Bradley et al., 2004; Evans et al., 
2005; Melfsen et al., 2006). 
1.6.4 Attention deficit hyperactivity disorder. 
One of the most common psychiatric conditions diagnosed concurrently 
with ASD has been ADHD (e.g., Eisenmajer et al., 1996; Frazier et al., 2001; 
Goldstein & Schebach, 2004). Goldstein and Schebach (2004) indicated that 
ADHD was the most prevalent disorder comorbid with ASD, with prevalence 
rates estimated between 17 to 83 per cent (Eisenmajer et al., 1996; Frazier et al., 
2001; Goldstein & Schebach, 2004). There is nonetheless much debate 
surrounding whether ADHD is a separate disorder in people with ASD. For 
example, hyperactivity and impulsivity are regularly displayed by people with 
ASD, thus making differential diagnosis difficult (Kadesjō & Gillberg, 2001). 
Ghaziuddin (2002) suggests that in circumstances where the severity of symptoms 
affects a person’s life, ADHD may be diagnosed and become the focus of 
treatment rather than the ASD. However, a diagnosis of ADHD has not been 
possible to make in the context of an ASD, because the DSM-IV-TR stipulates 
that ADHD should not be diagnosed with a PDD (APA, 2000). Consequently, 
researchers have found it difficult to ascertain an accurate prevalence rate of 
ADHD among people with an ASD. However, the DSM-V has removed this 
specifier; as such it is likely there will be a change in the availability of 
prevalence rates of ADHD in ASD (APA, 2013). 
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1.6.5 Psychotic disorders. 
ASDs were historically viewed as childhood onset schizophrenia (APA, 
2000). As knowledge about ASD increased, these two conditions became separate 
entities, with ASD classified as a PDD and schizophrenia as a psychotic disorder 
(APA, 2000). It has been acknowledged in previous research that the intense 
preoccupations and interests exhibited by people with an ASD may superficially 
resemble psychotic features (Trevarthen, Aitken, Papoudi & Robarts, 1996). 
Abnell and Hare’s (2005) investigated the phenomenology of delusional beliefs in 
46 adults with Asperger’s disorder. The findings indicated that those with 
Asperger’s disorder tended to report higher levels of delusional beliefs than the 
general population. However this study did not have a matched control group and 
participants self-selected and were thus were more likely to have an interested in 
delusional beliefs.  
In addition to delusional beliefs, idiosyncratic speech may be 
misconstrued as a response to perceptual disturbances (Trevarthen et al., 1996). 
Although there is potential for misdiagnosis due to the perceived symptom 
overlap, researchers who specialise in this field have reported that psychotic 
disorders are not commonly comorbid with ASD (Lunegard et al., 2011; Matson 
& Nebel-Schwalm, 2007). 
1.6.6 Aetiology of comorbid mental health conditions. 
The biopsychosocial model has been a useful template to explain the 
development of comorbid psychiatric conditions in people with an ASD (Ford, 
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Goodman, & Meltzer, 2004; Gadow et al., 2008; Gurung, 2006; Hill, 2002). 
Bradley & Bolton (2006) posit that consideration of biological (e.g., genetics) and 
psychosocial factors (e.g., psychological impact of ASD, coping strategies, social 
supports) and life-span issues need to be considered when understanding the onset 
of mental health disorders in this population. 
Moreover, the different components of the biopSychosocial model 
(biological, psychological and social) have been identified in people with ASD 
that act as risk or protective factors in the development of a comorbid psychiatric 
condition. A study by Gadow and colleagues (2008) investigated the potential risk 
and protective factors associated with psychiatric comorbid conditions in 238 
children (aged 6 to 12 years), with a diagnosis of ASD. The use of medication, a 
family history of mental illness, prenatal pregnancy complications, and medical 
conditions were identified as the most significant risk factors for current 
psychiatric symptomatology among children with ASD. Protective factors 
included the individual child’s characteristics, and higher levels of social 
functioning at school. Gadow et al. (2008) concluded their findings supported the 
biopsychosocial model of psychopathology in children with an ASD. 
1.6.7 Comorbid mental health conditions and challenging behaviour. 
While the biopsychosocial model has been used to explain the 
development of both psychiatric comorbidities and challenging behaviour in 
people with ASD (Ford et al., 2004), the relationship between challenging 
behaviour and comorbid psychiatric conditions remains unclear. A collection of 
studies over the past ten years has reported differing opinions regarding ASD- 
 Psychotropic Medication and ASD
   
 
 
30 
 
related comorbid conditions and challenging behaviours (e.g., Holden & Gitlesen, 
2003, 2009; Ross & Oliver, 2002). One approach to explaining challenging 
behaviour among individuals with an ASD has involved interpreting these 
behaviours as symptoms of psychiatric illnesses (Holden & Gitlesen, 2003, 2009). 
Holden and Gitlesen (2009) investigated the association between psychiatric 
symptoms and challenging behaviour of people with ASD from the perspective of 
caregivers. The results suggested a significant positive relationship between 
psychiatric symptom severity and levels of challenging behaviour. According to 
Ross & Oliver (2002), symptoms such as self-injury, can be interpreted as a 
consequence of a psychiatric illness (e.g., depression), when in fact the self-injury 
could have been a risk factor for depression (Ross & Oliver, 2002). That is, 
individuals who self-harm may experience greater isolation from their 
community, rejection from their peers, and be less able to participate in activities; 
consequently developing depression (Holden & Gitlesen, 2009). Although these 
studies all acknowledge that a relationship exists between psychiatric conditions 
and challenging behaviour among people with an ASD, there is a lack of 
consensus regarding how these factors relate to each other. Consequently, future 
research that seeks to clarify the relationship between comorbid mental health 
conditions and challenging behaviour among people with an ASD is warranted. 
In summary, ASD is a pervasive neurodevelopmental disorder with no 
single accepted causative factor. Current theories suggest a multitude of factors 
that influence diagnosis. It is accepted that people with an ASD are at increased 
risk of experiencing a concomitant psychiatric condition. Given the wide range in 
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prevalence figures for comorbidity and the difficulties associated with differential 
diagnosis among this population, it is important that future research continues to 
explore how these problems are expressed among people with ASD. Research is 
also needed to clarify the relationship between mental health conditions and 
challenging behaviour in people with an ASD. 
1.6.8 Sleep difficulties and autism spectrum disorders. 
Another factor commonly associated with mental health difficulties and 
challenging behaviours in those with an ASD is persistent sleep difficulties. 
Individuals of all ages with an ASD report higher sleep difficulties than those who 
are developing typically (e.g., Barlow & Durand, 2005; Polimeni, Richdale & 
Francis, 2005; Richdale, 2001). Polimeni et al. (2005) found that children with 
autistic disorder and Asperger’s disorder were more likely to experience sleep 
disturbance than typically developing children. Sleep problems have been 
estimated to occur in up to two thirds of children with an ASD (Richdale, 2001). 
Both subjective and objective data have demonstrated that children with ASD 
have difficulty falling asleep or maintaining sleep (Polimeni et al., 2005). In 
addition, sleep problems in children with an ASD have been found to affect a 
child’s daily functioning, including increased challenging behaviours, drowsiness 
and increased learning difficulties (Paavonen et al., 2003).  
A study by Goldman, Richdale, Clemons and Malow (2012) examined 
parental sleep concerns in ASD across childhood and adolescents (aged 3 to 18). 
Sleep problems were evident across all age groups However, factors contributing 
to sleep disturbance varied across the age groups, with younger children 
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experiencing difficulty with anxiety, parasomnias, night waking and higher levels 
of bedtime resistance. In contrast, older children and adolescents were observed to 
have increased difficulty with delayed sleep onset, shorter sleep duration and 
daytime drowsiness. 
Sleep difficulties in children with an ASD have been found to cause 
significant distress to both the caregiver and the child (Doo & Wing, 2000; 
Polimeni et al., 2005). In parents of children with ASD, stress levels are higher in 
those whose child has sleep difficulties (Doo & Wing, 2000). Children with an 
ASD who are regarded as having a regular sleep routine have been found as 
happier, calmer and less irritable (Gordon, 2000). These findings highlight the 
importance of sleep when it comes to influencing the child and caregiver’s 
functioning. 
A study by Taylor, Schreck and Mulick (2012) examined sleep 
disturbance as a correlate to cognitive and adaptive behaviour in children with an 
ASD. Findings suggested that children who slept fewer hours per night had lower 
verbal skills, adaptive functioning, daily living skills, socialisation skills, motor 
development and overall intelligence (Taylor et al., 2012). In addition, children 
who slept fewer hours at night, with more night awakenings, were found to have 
increased communication problems. This may suggest that sleep quality is likely 
to be closely related to overall functioning in a child with ASD. 
Moreover, sleep difficulties have been found to persist through 
adolescence, with adolescents more likely to have difficulty with delayed sleep 
onset, shorter sleep duration and daytime sleepiness (Goldman et al., 2011). 
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Studies have also suggested that adults with Asperger’s disorder are more likely 
to report subjective sleep difficulties than their neurotypical counterparts (Tani et 
al., 2004). 
1.6.9 Aetiology of sleep difficulties. 
Various studies have attempted to explain the higher incidence of poor 
sleep in those with an ASD. Theories regarding the development of sleep 
difficulties include hyperarousal, anxiety, poor social understanding, brain 
pathology and inadequate regulation of melatonin (Richdale, 1999; Wright, Sims, 
Smart, Alwazeer, Alderson-Day et al., 2011). The theory of inadequate melatonin 
regulation has received increasing attention in the literature (Brzezinski et al., 
2005; Leu, Beyderman, Botzolakis, Surdyka, Wang & Malow, 2011; Melke et al., 
2008). Melatonin is a naturally occurring chemical, which is most known for its 
function of regulating circadian and seasonal rhythms (Leu et al., 2011). Children 
with autism who have sleep disturbances have decreased melatonin levels, 
compared to matched controls (Brzezinski et al., 2005, Melke et al., 2008). 
Leading researchers in this area currently postulate that abnormalities in 
melatonin metabolism partly explain higher rates of sleep disturbance in those 
with an ASD (e.g.,Tordjman et al. 2005). 
In summary, both children and adults with an ASD report more sleep 
difficulties than their neurotypical counterparts. Sleep difficulties are associated 
with poorer academic function and increased behavioural difficulties. 
Consequently, sleep difficulties are a key variable to consider when assessing 
individuals with an ASD. 
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Currently in Australia, there are standardised multidisciplinary approaches 
to the diagnosis of ASD (O’Reily & Wicks, 2013). A variety of health 
professionals have expertise in ASD, including general practitioners, 
paediatricians, neurologists, psychologists, occupational therapists and speech 
pathologists and thus may be involved in the diagnostic process (O’Reily & 
Wicks, 2013). Although protocols for the assessment and diagnosis of ASD have 
been developed, a uniform approach to intervention and treatment of this disorder 
has not yet been established (O’Reily & Wicks, 2013). 
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Chapter 2: Autism Spectrum Disorders and Intervention 
Approaches 
There are a myriad of intervention approaches available for individuals 
with ASD and their caregivers to consider. Two of the most common include the 
medical approach, whereby pharmacology (medication) is used to treat associated 
symptoms of ASD (Erikson, Stigler, Posey & McDougle, 2007); and the 
psychosocial approach, where a wide range of services and strategies are 
employed to change behaviour and increase skills for the individual and their 
caregivers (Harris, 2007). The primary aim of these treatment approaches is to 
maximise the person’s functional capacity, such that they have an improved 
quality of life and are able to meet their ultimate developmental potential (Myers 
& Johnson, 2007). 
The medical model of intervention is applied to most mental health 
conditions and disabilities in Australia, including ASD (McDougle et al., 2006). 
When a diagnosis is made, a medical practitioner will commonly consider 
prescribing medication to alleviate any distressing symptoms of the disorder 
(McDougle et al., 2006). While the medical model of intervention is often applied 
to ASD, there is currently no medication that targets the core components 
(McPheeters et al., 2011; O’Reily & Wicks, 2013; Williamson et al., 2012). 
Despite this, pharmacological treatments are still widely used as a form of 
intervention for those with an ASD, principally targeting the behavioural and 
mental health symptoms/comorbidities associated with the disorder. 
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 Psychosocial interventions provide an alternative to pharmacology for the 
treatment of behavioural and psychiatric symptoms associated with ASD. While 
medication benefits some people with an ASD, there is growing evidence that 
psychosocial approaches are equally beneficial and improve the quality of life in 
people with an ASD (Krebs-Seida et al., 2009). Psychosocial interventions, such 
as programmes to promote communication and adaptive behaviours require 
careful assessment and analysis of factors that predict, maintain and interact with 
problem behaviours and psychiatric symptoms (Carr, et al., 1999; Schwartz, 
Boulware, McBride & Sandall, 2001). These psychological approaches are 
accepted best practice and form the foundation for early intervention programmes 
for ASD within Australia (O'Reily & Wicks, 2013).  
The behavioural approach is a further psychosocial intervention has been 
successfully implemented in the treatment, education and management of 
individuals with ASD (Brereton & Tonge, 2002). Most recently, this has involved 
the positive approach which focuses on understanding the meanings and purposes 
of behaviour from the individual with ASD’s point of view, rather than on 
extinguishing unwanted behaviours. For example, operant conditioning has been 
shown to be efficacious in increasing desirable behaviours in individuals with 
ASD by pairing a positive reinforcement with a desired behaviour (Zachor et al., 
2006).  
Although psychosocial interventions have been found to improve the 
quality of life of individuals with an ASD (Rogers & Ozonoff, 2006), there are 
some important limitations to this therapeutic approach. For instance, 
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psychosocial interventions are often difficult to access and require a significant 
amount of time and often financial investment by the individual and/or their 
caregivers. As a result, many people with an ASD may be precluded from access 
to psychosocial resources. Conversely, pharmacological options are often less 
expensive for individuals and their caregivers, are more readily available and 
require less time investment, compared to psychosocial interventions. Further, in 
some cases, individuals with ASD have distressing symptoms that do not readily 
respond to psychosocial interventions and a pharmacological approach is 
considered necessary (O'Reily & Wicks, 2013). 
Autism Spectrum Disorders and Psychotropic Medications 
Psychotropic medications refer to psychiatric medications prescribed for 
the purpose of altering emotions and behaviours of a person with an ASD 
(Weeden et al., 2011). The use of psychotropic medication for people with 
disabilities has been controversial, and has been much debated in the literature. 
Lipman (1970) was an early researcher to comment on this, indicating that rates 
of prescribing psychotropic medications in this population were unusually high. 
While the prescription of medication to people with disabilities has continued, the 
research surrounding its efficacy in this population has remained equivocal. It has 
been suggested there is an association between the presence of ASD and the 
prescribing of psychotropic medication (e.g., Aman et al., 2002, 2003, 2005; 
Gralton et al., 1998; Webber, McVilly & Chan, 2011). 
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Most of the research conducted in this area has addressed the use of 
psychotropic medications in the treatment of challenging behaviours and 
comorbid psychiatric conditions in people with intellectual disabilities (e.g., 
Brylewski & Duggan, 2004; McGillivray & McCabe, 2004). However, there is 
now a growing body of literature exploring the use of psychotropic medications in 
individuals with ASD (e.g., Aman et al., 2002, 2003, 2005; Esbensen Greenberg, 
Seltzer & Aman, 2009; Mandell et al., 2008; McPheeters, 2011). While no 
medications are known to treat the core elements of ASD (Mandell et al., 2008), 
they are often prescribed to address challenging behaviours commonly associated 
with the disorder (e.g., aggression & self-injurious behaviour), sleep difficulties 
or comorbid conditions (e.g., ADHD, depression, anxiety; Hollander, Phillips & 
Yeh, 2003; McDougle et al., 2000; Volkmar, Lord, Bailey, Schultz & Klin, 2004). 
2.1.1 Prevalence of psychotropic medications. 
Psychotropic medication is a common form of intervention in those with 
an ASD (Aman et al., 2002, Esbensen, Greenberg, Seltzer & Aman, 2009; 
Schubart, Camacho & Leslie, 2013). Attempts have been made over the previous 
two decades to establish the prevalence rates of psychotropic medication among 
ASD populations. Studies have found varying results, with estimates ranging 
from 30 to 81 per cent (Aman et al., 2005; Esbensen et al.,2009, Green et al., 
2006; Mandell et al., 2008; Martin Scahill, Klin & Volkmar, 1999; Memarie et 
al., 2012; Mire, Nowell, Kibiszyn & Goin-Kochel, 2013; Oswald & Sonenklar, 
2007; Rosenberg, Mandell, Farmer, Law, Marvin & Law, 2010; Schubart et al., 
2013; Whitwer & Lecavalier, 2005 ). 
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An influential American study by Aman, Van Bourgondien, Wolford and 
Saphare (1995) explored participants with mild to severe forms of an ASD and 
found that 31 per cent were taking psychotropic medication, 11.5% anti-epileptic 
medication; five per cent were taking other over the counter autism supplements. 
Aman et al. (1995) reported that 39 per cent of participants were taking both 
psychotropic medication and anti-epileptic medication. In addition, the study 
found that increasing age and living out of home were associated with greater use 
of psychotropic medications. 
A previous study by Aman, Lam and Collier-Crespin (2003) investigated 
the level of reported psychotropic medication in 417 families registered with the 
Autism Society of Ohio, America. The findings indicated that 46 per cent of 
participants (age range two to 46) were taking psychotropic medication. Similar 
to Aman et al.’s (1995) earlier study, greater age, and living outside of the family 
home were related to increased medication use. In addition, those who were male, 
had an intellectual disability, and had a more severe form of autism were more 
likely to be taking psychotropic medication (Aman et al., 2003). One important 
limitation of Aman et al.’s (1995, 2003) studies was they did not collate classes of 
medication, or the reasons for medication use. Further, these studies most likely 
included professionals responding on behalf of families, thus limiting their 
applicability to the wider community. 
Recent studies have begun to investigate the use of psychotropic 
medication among people with an ASD in more detail (e.g., Mandell et al., 2008; 
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Rosenberg, et al., 2010). A large-scale American study of 5,181 children with an 
ASD, who were registered on an internet- research database, found that 35 per 
cent were currently taking at least one psychotropic medication (Rosenberg et al., 
2010). The most common medications were stimulants, neuroleptics and/or anti- 
depressants. In another large-scale American study (n = 60,641) of the use of 
psychotropic medication among Medicaid enrolled children with an ASD (aged 4 
to 21 years) a much higher percentage of psychotropic medication use was found 
(Mandell et al., 2008). Specifically, 56 per cent of respondents reported taking at 
least one psychotropic medication. Mandell and colleagues (2008) also found the 
presence of autistic disorder, intellectual disability, and increasing age positively 
correlated with psychotropic medication use. Moreover, the findings suggested 
that psychotropic medication use was unexpectedly common among young 
children with an ASD (18% of 0 to 2 year olds, and 32% of 3 to 5 year olds). 
These startling findings influenced the authors to conclude that ‘there is an urgent 
need to assess the risks, benefits and costs of medication use’ (Mandell et al., 
2008, p. 441). The data used in this study was collected from Medicaid (a health 
programme for low income families in the United States of America (USA) and 
as such, no information on symptoms or severity of ASD  or comorbid conditions 
was available. 
An international internet study of parent reported treatments for ASD 
indicated that 52 per cent of parents reported using medication as a form of 
treatment for their child with an ASD (Green et al., 2006). The authors found 
parental reporting of higher levels of ASD impairment was associated with 
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increased medication use, as was increasing age. Medication use, according to 
any further demographic variables beyond, age, sex and severity of impairment, 
was not examined. Thus, the number of participants with comorbid intellectual 
disability is unknown. 
A study of psychotropic medication use in those with an ASD who do not 
have an associated intellectual disability (e.g., IQ of greater than 70) was 
undertaken by Martin et al., (1999). The findings revealed that 55 per cent of 
participants were taking at least one psychotropic medication, with 23 per cent 
taking two, and six per cent taking three or four psychotropic medications. This 
was similar to the findings of Mandell et al. (2008) and Green et al (2006), 
mentioned above, incorporating those with an intellectual disability. The most 
commonly observed psychotropic medication in the sample was anti-depressants 
(32%), followed by stimulants (20%). Therefore, it appears that psychotropic 
medications were widely used in individuals with an ASD with and without a 
comorbid intellectual disability. 
While most research on the prevalence of psychotropic medication use has 
been conducted in America, the highest noted prevalence of psychotropic 
medication use (81% of 345 children and adolescents attending ASD specific 
schools) was reported in an Iranian study (Memari et al., 2012). Anti-psychotic 
medications were the most commonly reported (57.4%), with a small number of 
individuals taking anti-depressants (8.7%). This study found no relationship 
between demographic variables (e.g., age & gender) and medication use. While 
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this study provided useful information, it did not differentiate between 
medications prescribed for epilepsy or other medical conditions. Moreover, it did 
not provide any information surrounding the reason for prescription, representing 
an important limitation of the findings. 
Longitudinal research indicates that the prevalence rate of psychotropic 
medication use is increasing (Aman et al., 2005; Esbensen et al., 2009; Schubart 
et al., 2013). A study by Aman and colleagues (2005) investigated patterns in 
psychotropic medication across an eight year period in Ohio and North Carolina, 
USA. The findings indicated there was a significant increase in the use of anti- 
depressants, anti-psychotics and stimulants with greater age, degree of 
impairment, and accommodation setting being associated with several classes of 
medications. A further longitudinal study conducted by Esbensen et al. (2009) 
examined psychotropic and non-psychotropic medication use among 286 
adolescents and young adults with an ASD (mean age = 21.1). The rates of 
psychotropic medication use increased from 57 to 64 per cent over a four year 
period, with those who commenced psychotropic medications likely to continue 
taking them. While these studies provided some important initial findings on the 
use of medication by those with an ASD, there was limited information regarding 
the differences between those who had an intellectual disability and those with 
comorbid conditions. Moreover, the majority of research conducted on the 
prevalence of psychotropic medication use has occurred in America, with limited 
research elsewhere. It is currently unknown if the trends noted above can be 
 Psychotropic Medication and ASD
   
 
 
43 
 
applied to an Australian sample, or whether there are differences in the use of 
psychotropic medications across cultures.  
A significant limitation of the research available to date is that the primary 
purpose of medication is often not explicitly stated. It is therefore, difficult to 
determine whether reported high levels of psychotropic medication use is for the 
treatment of co-morbid medical conditions such as epilepsy, or for emotions or 
behaviours. For example, sodium valproate may be used to primarily manage 
epilepsy or be used to stabilise mood.  
In summary, psychotropic medication use appears to be a common 
intervention for individuals with an ASD. Research has primarily been conducted 
in the USA thus limiting its generalisability to Australia, with differing 
demographic variables being identified as relation to psychotropic medication 
use. Further research on the prevalence and characteristics of psychotropic 
medication use, as well as on those individuals who are prescribed it, is needed. 
This is particularly the case with respect to Australians with an ASD, since there 
is currently limited local data on the use of psychotropic medication in this 
population. 
2.1.2 Issues related to psychotropic medications. 
Despite the high prevalence of psychotropic medication use among 
individuals with ASD, a number of concerns have been highlighted around its use 
in this population. These include, but are not limited to, off-label prescription, 
side effects, a failure to reduce or review medication once commenced, and the 
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cost- effectiveness of such interventions (Witwer & Lecavalier, 2005). Several 
professional organisations and a host of researchers have provided comment on 
these important issues. 
There has been extensive research over the past five decades into the short 
and long term, positive and negative impact of medication. This work well is well 
explored by Whitaker (2005), Ross and Read (2004), Weinman, Read &  
Aderhold (2009).  In particular, these authors present a case that the long term 
health outcomes of anti-psychotics needs to be carefully considered when making 
the decision to use these medications.  
Currently, the American Food and Drug Administration (AFDA) have 
only approved two medications to treat symptoms associated with ASD: these 
medications include risperidone and aripiprazole (both anti-psychotic 
medications) (Williamson & Martin, 2010). In Australia, only risperidone is 
currently approved for the treatment of associated behavioural disturbances in 
people with ASD (Australian Government, 2007). According to the 
Pharmaceutical Benefits Scheme (PBS) advisory committee (Australian 
Government, 2007), risperidone should be prescribed under the supervision of a 
paediatrician or psychiatrist for people with ASD. Despite this direct PBS 
recommendation, research indicates that a number of medications are often used 
in an ‘off-label’ capacity for a condition or age group, which has not been 
approved by the PBS (Williamson & Martin, 2010). 
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Off-label prescription of psychotropic medications to individuals with an 
ASD appears to be increasingly common (e.g., Williams, Woods, Stevenson, 
Davis, Radmacher & Smith, 2012). These psychotropic mediations include 
various anti-depressants, stimulants, anti-psychotics, and anti-convulsants (Aman 
et al., 2003; Oswald & Sonenklar, 2007; Rosenberg et al., 2010). They are 
commonly given to treat comorbid symptoms of ASD, such as irritability, 
aggression, self-injurious behaviours, attention deficits, anxiety or obsessive 
compulsive behaviours (Esbensen et al., 2009; Valdovinos, Caruso, Roberts, Kim, 
& Kennedy, 2005; Witwer & Lecavalier, 2005). This is particularly concerning 
given the lack of randomised controlled trials or meta-analyses ascertaining the 
effectiveness of these medications in this population. 
Both on-label and off-label psychotropic medications have been 
associated with adverse side effects and with some, the negative impacts for 
individuals are substantial (Williams et al., 2012). Noted adverse effects in people 
with ASD include weight gain, rashes, nausea, elevated blood sugar levels, 
suicidal ideation, sleep disturbance, sedation, increased salivation and tardive 
dyskinesia (Williams et al., 2012). The array of potential negative consequences 
arising from psychotropic medication use in people with ASD has prompted an 
increasing volume of research into outcomes. 
Valdovinos et al. (2005) investigated the incidence of medical and 
behavioural symptoms that could result as side effects of psychotropic 
medications in 30 adults with intellectual disabilities. Participants were selected 
on the basis that they were receiving psychotropic medication through a 
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psychopharmacological review panel. Each participant reported having at least 
one side effect, with the majority affecting behaviour (e.g., increased aggression), 
mood or sleep (Valdovinos et al., 2005). Further, when side effects were reported 
by participants, a change in medication was likely to occur; yet in most cases, the 
change involved an increase in the psychotropic regime. One important limitation 
of Valdovinos et al.’s study is the retrospective nature of data collection and the 
challenge often associated with accurate reporting of side effects. It is unclear 
what result these side effects have on the wellbeing and quality of life of people 
with ASD. 
Despite concerns being raised about the side effects of psychotropic 
medication on children and adults with an ASD, it appears that once an individual 
commences medication, it is likely to continue being prescribed (Esbensen et al., 
2009). Some studies have investigated the impact of withdrawal from medications 
to address concerns regarding side effects and to determine an accurate 
prevalence of psychiatric comorbidity (e.g., Branford 1994, 1996). Branford 
(1994) investigated the withdrawal of anti-psychotic medication in 198 people 
with intellectual disabilities. Of the 198 people reviewed, 123 were deemed 
suitable to have their medication reduced or withdrawn. Findings indicated that 
twelve months after the initial reduction in dose, 25 per cent remained free of 
anti-psychotic drugs and 32 per cent had a dose reduction. Although 42 per cent 
of individuals suffered from deteriorating behaviour after dose reduction or 
complete withdrawal, this study suggested that significant numbers of individuals 
with an intellectual disability might be unnecessarily medicated. 
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In a further linked study, Branford (1996) reported on the factors 
associated with the outcome (successful, unsuccessful) of withdrawing anti- 
psychotic medication. A history of epilepsy, a lower initial dose and the 
prescription of thioridazine were associated with successful withdrawal from anti-
psychotic medication. Minimal psychopathology, low levels of hyperactivity, 
aggression and stereotypy all significantly related to successful withdrawal from 
medication. A significant relationship was identified between autism symptoms 
and poor withdrawal from medication. However, caution is needed when 
interpreting this result, as further investigation of behaviours and traits of autism 
have not supported this finding (Branford, 1996). Nonetheless, the association 
between ASD and poor withdrawal from medication suggests the importance of 
further research to examine its use in this population and factors related to its use. 
Recently, the cost-effectiveness of psychotropic medication has also come 
under scrutiny with some estimating that ASD-related therapeutics have an 
approximate global market value of $2.2 to $3.5 billion dollars (King & Bostic, 
2006). An analysis of the cost-effectiveness of treating challenging behaviour in 
86 people with intellectual disabilities was conducted by Romeo and colleagues 
(2006). A randomised controlled trial was used to compare the cost-effectiveness 
of risperidone, haloperidol and a placebo from a societal perspective (unpaid 
caregiver inputs and service effects) using a double-blind trial with outcomes 
being measured in terms of aggression and quality of life. After 26 weeks, 
individuals allocated to the placebo group had the lowest costs compared to the 
haloperidol and risperidone groups. Quality of life was found to be highest among 
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people receiving risperidone, with the lowest found among the haloperidol group. 
In contrast, aggression rates were highest among individuals in the risperidone 
group and lowest for people receiving haloperidol. However, a large proportion of 
participants (25%) were lost to follow-up data collection. This affected the overall 
power of the study to draw meaningful conclusions. While this study explored the 
quality of life of people with an intellectual disability, the generalisability of these 
results to people with ASD are currently unknown. 
In summary, despite the high prevalence of psychotropic medication in 
individuals with an ASD, there are many concerns around its use. In particular, 
many of these medications are being prescribed off-label without a significant 
evidence base for their use. Moreover, the use of these medications, particularly 
anti-psychotics are associated with concerning side effects, and the cost-
effectiveness of this intervention has been questioned. At this time, relatively little 
is known about the use of psychotropic medication among people with ASD in 
Australia. Further research is thus warranted to ascertain the current use of 
psychotropic medications in Australians with ASD. 
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Chapter 3: Psychotropic Medication, Mental Health, 
Challenging Behaviour, and Sleep Difficulties 
Despite an increasing body of research attempting to establish prevalence 
rates of psychotropic medication in people with an ASD, there has been less focus 
on the reasons for prescription. Psychotropic medication recommendations in the 
ASD population are typically based on open-label trials, extrapolation from 
studies and expert opinions (Myers & Johnson, 2007). However, in clinical 
practice, people with an ASD are often prescribed medications for comorbid 
problems, with limited evidence to support effectiveness in this population. This 
chapter examines the relationship between psychotropic medication use and 
challenging behaviours, comorbid mental health conditions and sleep difficulties. 
These problems are likely to account for a large proportion of the use of 
psychotropic medication among people with ASD. Given the limited research 
examining psychotropic medication use, according to these variables for people 
with ASD, the following section includes research conducted on people with 
other types of disabilities, such as intellectual disability. 
3.1 Mental Health and Psychotropic Medication 
An extensive body of research exists suggesting that psychotropic 
medications are an effective treatment for many mental health conditions. Limited 
research has investigated the relationship between comorbid mental health 
conditions and the use of medication in people with ASD. Estimates of the 
prevalence of comorbid psychiatric conditions among those taking psychotropic 
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medication vary widely, from 60 to 100 per cent (e.g., Mandell et al., 2008; 
Memari et al., 2012; Morgan et al., 2003). For example, a study by Morgan and 
colleagues (2003) investigated the prevalence rates of psychiatric illnesses and 
use of medication in 164 adults with an ASD and intellectual disability. Results 
indicated that 35 per cent of individuals had a comorbid psychiatric illness, all of 
whom were on some form of psychotropic medication. Not surprisingly, Morgan 
et al. found that anti-depressants were the most common medication administered 
for the treatment of depression. In addition, of the 52 per cent of the sample 
treated with anti-psychotics, a large proportion (40%) had no identified comorbid 
mental health condition. A strength of Morgan et al.’s study was the 
heterogeneous nature of the sample, which made the results more representative 
for this complex population. Conversely, Morgan et al. only examined 
participants who were in full-time residential care, and only included individuals 
who had both an ASD and an intellectual disability. As such, the prevalence of 
medication use among individuals without an intellectual disability, across 
different residential settings was not established in this study.  
Two recent studies have explored the relationship between comorbid 
mental health conditions and psychotropic medication use in children with an 
ASD (Mandell et al., 2008; Memari et al., 2012). Memari and colleagues (2012) 
found a significant relationship between psychiatric comorbidity and use of 
psychotropic medications, with 91 per cent of all people with a comorbid mental 
health condition taking medication. Participants with a psychiatric comorbidity 
were most likely to be taking anti-psychotics (67%). The study did not find a 
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significant relationship between psychiatric comorbidity and higher levels of 
medication use. Despite these findings, the study failed to conduct more detailed 
analyses on specific comorbid conditions and did not include children with more 
severe forms of ASD, thus limiting generalisability. 
While research has started to examine the relationship between comorbid 
mental health conditions and psychotropic medication use among individuals with 
an ASD, further research is needed, given the high prevalence of psychotropic 
drug use in this population. Moreover, it would be beneficial to have data on 
comorbid mental health conditions and medication use in adults with an ASD 
who are living independently, as well as children of varying levels of impairment. 
Currently no such research exists on these ASD sub-groups. 
3.2 Challenging Behaviour and Psychotropic Medication 
While psychotropic medication for the treatment of comorbid mental 
health conditions is accepted as a standard level of care (Barlow & Durand, 
2004), the use of medication to manage challenging behaviours is more 
controversial, particularly in individuals with an ASD. Research examining the 
benefits of such medication has yielded conflicting findings, and vigorous debate 
surrounds the efficacy of this treatment approach in those with an ASD (e.g., 
Dove et al., 2012; Siegel & Beaulieu, 2012; Webber et al., 2010; Weeden et al., 
2011). 
In the state of Victoria, Australia, psychotropic medication used for the 
primary purpose of restricting a person’s behaviour is seen as a form of ‘chemical 
restraint’ (Victorian Government, 2007). This method of intervention is only 
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permitted within specialised disability service settings if it is necessary ‘to prevent 
the person from causing physical harm to themselves or other person’, or ‘to 
prevent the person from destroying property where to do so could involve the risk 
of harm to themselves or any other person’ (Victorian Government, 2007, p 142). 
At the outset, disability service providers employing restrictive interventions must 
apply to the Office of the Senior Practitioner for approval and must provide 
ongoing monthly reports of any restrictive intervention employed. In addition, 
any restraints must be the least restrictive form of intervention in the given 
circumstances (Victorian Government, 2007). Further, no individual is permitted 
to be subject to restraint unless the restraint is specified in that person’s individual 
management plan, or is in an emergency situation (Victorian Government, 2007). 
For example, a person may be administered prescribed medication on a daily 
basis to reduce the likelihood of them engaging in self-injurious behaviour (e.g., 
head banging). Such practice has been widely referred to as a form of ‘chemical 
restraint’ (Aman, Van Bourgondien, Wolford & Sarphare, 1995; Branford, 
Collacott & Thorp, 1995; McGillivray & McCabe, 2006). 
Chemical restraint is defined under the Disability Act (2006) as any form 
of medication given primarily for the purpose of behavioural control, but does not 
include the use of chemical substances specifically prescribed for the treatment of 
a psychiatric condition or physical illness (Victorian Government, 2009). Under 
this definition, these circumstances are not required to be reported to the Office of 
the Senior Practitioner, although it has been acknowledged there may be cases 
where medication is used for both treatment and restraint (Victorian Government, 
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2009). However, no data is available on how many people receive medication as a 
sole treatment. In addition, the numbers of people with disabilities who receive 
medication for treatment or restraint purposes, and who do not receive services 
through registered disability service providers, are unknown. Similarly, it is 
unknown how many individuals do not receive medication administered by staff 
while receiving such services and thus are not reported. 
An analysis of the 2007–2008 data collected by the Office of the Senior 
Practitioner on chemical restraint found that those with an ASD were over-
represented compared to the relative proportions of these people in registered 
disability services (Webber et al., 2010). It was reported that those subject to 
restrictive interventions were more likely to be young males with multiple 
disabilities, mainly autism. Similarly, the broader intellectual disability literature 
has identified that an ASD diagnosis is a risk factor for proportionally higher 
psychotropic medication use (e.g., Gralton et al., 1998; Robertson et al., 2005). 
Gralton and colleagues (1998) investigated the use of anti- psychotic 
medication and psychiatric diagnosis in children with an intellectual disability. 
The study was a 12-year longitudinal follow up that reviewed the relationship 
between anti-psychotic drug use and diagnosis. Case notes of 235 people with an 
intellectual disability were examined to extract information about the type and 
duration of medication prescribed, behavioural and psychiatric symptoms, and 
any comorbid mental health conditions. Findings revealed that children with 
challenging behaviours were significantly more likely to receive anti-psychotic 
medication (Gralton et al., 1998). Further, the more types of challenging 
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behaviour displayed, the more likely they were to receive anti- psychotic 
medication. The single factor that differentiated those children with challenging 
behaviours who received anti-psychotic medication from those who did not, was a 
diagnosis of ASD. However, this study did not further explore the link between 
ASD and anti-psychotic medication. Consequently, it was unclear whether ASD 
was associated with more significant challenging behaviour, or that ASD results 
in the challenging behaviour, having a larger impact on caregivers’ management 
abilities. A further limitation of their study was that it failed to examine the use of 
other psychotropic medication, including hypnotics and anxiolytics. It is therefore 
unclear whether these medications also had a significant relationship with an ASD 
diagnosis. 
Robertson and colleagues (2005) conducted a further study investigating 
comorbid conditions and the use of psychotropic medication in 500 people with 
intellectual disabilities. One of their important findings showed a significant 
relationship between ASD diagnosis and the use of psychotropic medication. This 
suggested that people with an ASD and intellectual disability may be more likely 
to be prescribed psychotropic medication than people with only an intellectual 
disability. Robertson et al. highlighted that these results should be interpreted 
tentatively, due to several methodological limitations, such as sole reliance on 
self-report data for analyses. With this in mind, Robertson et al.’s study provides 
additional preliminary evidence that having an ASD may increase the likelihood 
of being treated with psychotropic medications. While more research focusing on 
intellectual disability has identified ASD as a risk factor for psychotropic 
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medication use for managing challenging behaviour, there has also been some 
research specifically investigating the relationship between ASD, challenging 
behaviour and psychotropic medication use. 
Challenging behaviours have been identified as a predictor of medication 
use in adults with ASD. A study by Tsakanikos, Costello, Holt, Sturmey and 
Bouras (2007) investigated behaviour management problems as predictors of 
psychotropic medication in 66 adults with autistic disorder and an intellectual 
disability, compared to 99 matched controls in age, gender, level of intellectual 
disability. It was found that adults with autism had higher rates of behaviour 
problems and more frequent use of anti-psychotic medications than the control 
group. Tsakanikos et al. reported that the generalisability of the findings was 
limited because other client factors were not included in the analyses, such as 
housing, services and carer attitudes. These factors may also affect the 
relationship between challenging behaviours and medication use; consequently, 
further research needs to examine these factors among people with ASD. 
A systematic review of medical treatments for children aged 12 years and 
under was conducted by McPheeters and colleagues (2011). The review identified 
18 studies examining medical interventions, 10 being randomised controlled 
trials. Findings only indicated evidence to support the benefits of anti-psychotic 
medications (risperidone and aripiprazole) for challenging and repetitive 
behaviours in children with an ASD. McPheeters et al. also found these 
medications had significant adverse effects, leaving the authors to conclude that 
‘although many children with ASD are currently treated with medical 
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interventions, strikingly little evidence exists to support clear benefit for most 
medications’ (McPheeters et al., 2011, p. 1,318). 
Siegel and Beaulieu (2012) conducted a more recent review and synthesis 
of psychotropic medications in children aged 0 to 18 years with ASD. Thirty- 
three randomised controlled studies were identified, with the authors noting that 
the quality and distribution of studies had improved over the last 10 years. The 
review stated that the only medications to have established evidence were the 
following anti-psychotics: aripiprazole for the treatment of irritability, 
hyperactivity and stereotypy; haloperidol for behavioural symptoms; and 
risperidone for irritability and hyperactivity. Siegel and Beaulieu suggested that 
none of the other medications had sufficient evidence. The review noted the trials 
had taken place across heterogeneous samples, making it difficult to determine 
the ‘true effect’ of the medications. In addition, 70 per cent of the trials 
emphasised positive results and minimised adverse effects, suggesting a positive 
results publication bias (Siegel & Beaulieu, 2012). 
A further systematic review examined psychotropic medication as a form 
of treatment for adolescents and young adults (aged 13 to 30) with an ASD (Dove 
et al., 2012). Of the eight studies identified, five were randomised controlled 
trials. The findings indicated there was currently insufficient evidence to 
determine the effectiveness of psychotropic medication in this population. 
However, there was some indication that risperidone assisted in the reduction of 
challenging behaviours. Dove et al. recommended an urgent need for further 
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studies investigating psychotropic medication use in adolescents and young adults 
with an ASD to inform clinical practice. 
The growing controversy surrounding the use of medication in individuals 
with ASD has generated separate Cochrane reviews on the use of risperidone, 
aripiprazole, and anti-depressant selective serotonin reuptake inhibitors (SSRIs). 
A Cochrane review by Jesner et al. (2009) specifically investigated the efficacy 
and safety of risperidone (also known as risperdal) in individuals with an ASD. 
The review analysed all randomised controlled trials of risperidone versus a 
placebo in individuals with an ASD. The studies included in the review were 
required to have a standardised outcome measure that was clearly administered to 
treatment and control groups. Only three studies were found that met the review 
criteria. The review identified some evidence that supported the benefits of using 
risperidone in treating irritability, repetition, and social withdrawal. However, the 
authors suggested that adverse side effects associated with use (in particular, 
weight gain) should be considered when evaluating the advantages and 
disadvantages, prior to prescribing this medication. 
Another Cochrane review has been conducted into the safety and efficacy 
of aripiprazole in individuals with an ASD (Ching & Pringsheim, 2012). Two 
randomised controlled trials were identified, each with similar methodology and 
occurring over eight weeks. The authors suggested there was some evidence to 
support the benefit of aripiprazole in treating irritability and hyperactivity in 
children and adolescents with an ASD. Several side effects were also found: most 
notably weight gain, sedation, excessive saliva and tremors. The authors 
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concluded there was a need for further research investigating the efficacy of 
psychotropic medications among individuals with ASD, as well as the long term 
effects on these individuals. 
A third Cochrane review examined the efficacy of anti-depressant SSRIs 
in those with an ASD (Williams, Brignell, Randall, Silove & Hazell, 2013). Nine 
randomised controlled trials were identified, examining the outcome of four 
different SSRIs. The review noted that many studies had different components of 
outcome measures, which meant these studies were unsuitable for meta-analysis. 
The review found no evidence suggesting SSRIs were beneficial to children with 
an ASD, in terms of addressing challenging behaviours; with some evidence 
indicating its use potentially may cause harm (Williams et al., 2013). There was a 
small amount of evidence in the review suggesting that SSRIs may be beneficial 
to adults with an ASD to treat comorbid depression (Williams et al., 2013). It was 
concluded that caution should be taken when prescribing these medications to this 
population. 
While there are a range of medications that may be prescribed to 
individuals with ASD, it is important to note that similar medications are 
commonly prescribed to individuals, regardless of the reason (challenging 
behaviour or psychiatric illness) for prescription (Holden & Glisten, 2009). 
Although the use of pharmacology to manage behaviour or treat a psychiatrically 
comorbid condition may be warranted on some occasions (McGillivray & 
McCabe, 2004), it is important that research continues to explore the reasons for 
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the use and efficacy of the pharmacological intervention of the targeted 
symptoms. 
In summary, psychotropic medication is a commonly used management 
strategy for challenging behaviours in those with ASD. There is some sparse 
evidence to suggest that aripiprazole and risperidone may be beneficial in 
reducing irritability and hyperactivity in those with an ASD. However, there are 
significant limitation to the research base, including largely heterogeneous 
groups, limited longitudinal data collection, a variety of different outcome 
measures. In addition, there is currently limited support for other classes of 
medications. 
3.3 Sleep and Psychotropic Medication 
Psychotropic medications have been used to treat comorbid sleep 
problems among people with an ASD; however, there has been limited research 
evaluating the best methods to address sleep problems in this population (Bramble 
& Feehan, 2005; Myers & Johnson, 2007). One recent open-label trial 
investigated the effects of donepezil for rapid eye movement (REM) sleep 
problems in five children (aged 2 to 6 years) with an ASD (Buckley, Sassower, 
Rodriguez, Jennison, Wignert, Buckley, Thurm, Sato & Swedo, 2011). Findings 
suggested that REM sleep as a percentage of total sleep time improved and REM 
latency decreased significantly. Although these results provided a positive case 
study analysis for the use of donepezil in treating five young children with a 
specific sleep problem, no strong conclusions could be made from such a study. 
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The majority of studies evaluating treatments for sleep problems in people 
with an ASD have involved the used melatonin (e.g., Guenole, Godbout, Nicolas, 
Franco, Clasutrat & Balyete, 2011). This may be due to the availability of studies 
showing positive results from the use of melatonin in treating sleep disorders in 
typically developing children (Smits et al., 2001, 2003). As Melatonin is naturally 
produced in the brain, arguably there are less ethical objections to its use in 
children. 
There have been three open-label trials of melatonin in individuals with an 
ASD published to date. A study of 25 children with autistic disorder who had 
sleep difficulties indicated that controlled-release melatonin improved sleep and 
improvements were maintained at one and two year follow ups (Giannotti, 
Cortesi, Cerquiglini & Bernabei, 2006). A second study of 15 children and 
adolescents with Asperger’s disorder found a significant improvement in sleep 
latency during treatment with melatonin; however, these improvements weren’t 
maintained at follow-up (Paavonen et al., 2003). The most recent trial examined 
melatonin in 24 children with ASD over a 14-week intervention period. Again, 
melatonin was found to be effective in improving latent sleep length (Malow, 
Adkins, McGrew, Wang, Goldman, Fawkes & Burnett, 2012). Despite these 
preliminary results supporting the use of melatonin for sleep difficulties, each 
study had the limitations based on study design of open-label trials. The true 
efficacy of melatonin is thus currently unclear. 
Wright et al. (2010) conducted a randomised controlled crossover trial 
investigating the effectiveness of melatonin versus a placebo in 22 children with 
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an ASD, with severe sleep problems who had not responded to behaviour 
management strategies. The findings indicated that melatonin significantly 
improved sleep latency and total sleep time compared to the placebo, but not the 
number of night awakenings. Despite these promising findings, the long term 
safety of this medication is unknown and needs to be formally addressed, given 
that children may receive this treatment for several years or even indefinitely 
(Guenole & Baleyte, 2011). A systematic review of the use of melatonin in 
individuals with an ASD found that while there was a small amount of literature 
supporting the benefits of melatonin to treat sleep disturbances, these conclusions 
were preliminary and not yet approved by professional medical institutions 
(Guenole et al., 2011). Further research is required to determine the prevalence of 
melatonin prescriptions and to determine its effectiveness in assisting sleep 
difficulties. 
In summary, there is a small amount of research suggesting that melatonin 
use may be beneficial in assisting selected sleep difficulties in those with an ASD. 
The long term outcomes of this treatment modality are largely unknown. Further, 
there is a gap in the knowledge regarding the perspectives of individuals with 
ASD and caregivers about the effectiveness of this medication. 
3.4 Experiences of Individuals and Caregivers 
A considerable amount of research has focused on the views and 
experiences of individuals and caregivers regarding ASD (e.g., Gray, 2003; 
Hastings & Brown, 2002; Myers & Johnson, 2007). However, to date there has 
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been little investigation into the views and experiences of medication as a form of 
intervention from the perspective of recipients with ASD and their caregivers. 
The limited research that does exist within this domain has primarily 
addressed caregivers’ views of compliance with medication prescription (Moore 
& Symons, 2009; Morton-Cooper, 2004). From a medical approach, adherence 
with medication should be a straightforward process. This seemingly simple step 
fails to take into account other factors that may influence an individual’s (or a 
caregiver’s) decision to take or administer medication (Morton-Cooper, 2004). 
These factors could include knowledge or understanding of the medication, 
potential side effects, the ability of the medication to adequately treat people with 
an ASD, and the individual’s choice to accept or decline taking the medication 
(Morton-Cooper, 2004). 
In a study by Moore and Symons (2009), the adherence of caregivers of 
children with ASD in accurately administering medication regimes was 
investigated. Two hundred and twenty parents were surveyed regarding the 
implementation of pharmacological treatments to children living in home-based 
care environments. The study identified two significant predictors of adherence to 
medication regimes: a diagnosis of autistic disorder over Asperger’s disorder, and 
the caregiver being married. While this provides information as to caregivers’ 
administrative adherence, ASD individuals’ adherence with medication regimes 
and their perspectives on this has yet to be investigated. 
A further consideration is the extent to which individuals with ASD and 
their caregivers understand and agree with the decision to use pharmacological 
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interventions. It is currently unclear whether people with ASD and their 
caregivers make an informed choice about the use of medication for challenging 
behaviour and comorbid psychiatric conditions, or whether they are fully 
informed about alternative psychosocial intervention options. Further, as a 
consequence of their disability, people with ASD may be vulnerable to the 
decisions made by those around them regarding medication use (Schall, 2002). 
While caregivers may report an increase in challenging behaviour or symptoms of 
comorbid mental illness, it is also plausible that this may indicate the caregiver is 
frustrated or not coping (Schall, 2002). Consequently, an increase in a person’s 
medication may occur when the caregiver simply requires more support services 
(Schall, 2002). Given that a large proportion of people with an ASD receive 
psychotropic intervention for challenging behaviour, comorbid mental illness and 
sleep difficulties, it is of particular importance that the perspectives of the 
individuals concerned are researched and understood. To date, research has failed 
to explore both the individuals with ASD and their caregivers’ perspectives of 
why pharmacological interventions have been selected, and their attitudes towards 
this treatment approach. 
In summary, there is a paucity of research into the experiences of 
medication use from the perspective of caregivers and individuals with ASD. 
Further, there has been little exploration of ASD-affected people’s understanding 
of the reasons they receive medication and whether their views concord with 
those of their caregiver. 
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Chapter 4: The Present Research 
Given that there is relatively little research into the use of psychotropic 
medications in people with an ASD within Australia, further research is 
warranted. The majority of studies conducted in Australia have focused on 
individuals who access state funded accommodation services (Webber, McVilly, 
Stevenson & Chan, 2010), with limited research exploring the use of 
pharmacology in individuals with an ASD residing independently or in family 
based care. This research seeks to broaden the knowledge base available of 
psychotropic medication use by including individuals who reside independently, 
or with caregivers. Caregivers of children and dependent adults have been 
included to provide information on this population. The terms ‘caregivers’ and 
‘informants’ are used interchangeably to refer to those reporting on behalf of 
children and dependent adults. 
In addition, there has been little exploration of issues related to the use of 
pharmacology from the perspective of people with ASD and the caregivers of 
children and dependent adults with ASD. Specifically, there is a paucity of 
research into the understanding of people with ASDs, and their caregivers, 
regarding the reasons they receive medication, their experiences with medication, 
and the attitudes they have regarding medication. These gaps in the research 
literature signal a need for further exploration of the medication experiences of 
people with ASD and their caregivers. 
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The current series of studies will provide pivotal information regarding the 
use of medication in a broad sample of people with an ASD in Australia. Findings 
will promote a greater understanding of prescribing practices in this population. 
This research may ultimately provide individuals, caregivers and 
practitioners with the information to enable informed choices regarding the use of 
medication (and possible psychosocial alternatives) in the treatment of psychiatric 
conditions and challenging behaviour. 
4.1 Aims and Hypotheses 
The principal goal of this thesis is to better understand psychotropic 
medication use in people with an ASD in Australia, from the perspectives of 
individuals and caregivers. This will be examined through three studies. The first 
study explores psychotropic medication use in children and dependent adults with 
an ASD, with their caregivers serving as informants. The second study explores 
psychotropic medication use in self-reporting adults with an ASD. The third study 
is a qualitative study of caregivers’ (3a) and individual’s (3b) perspectives of 
psychotropic medication use. 
4.1.1 Study 1: Aim and hypotheses. 
The overall aim of Study 1 was to provide a detailed description and 
analysis of the use of psychotropic medication in children and dependent adults 
with an ASD in Australia. With consideration given to three key variables: 
challenging behaviour, comorbid psychiatric conditions and sleep difficulties. In 
addition, Study 1 aimed to contribute understanding to overall knowledge of 
psychotropic medication use in this through ascertaining the perspectives of 
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caregivers regarding the use of psychotropic medication in children and 
dependent adults with an ASD. On the basis of the current literature, the 
following hypotheses1 were explored: 
a. Male children/dependent adults are more likely to be in receipt of 
psychotropic medication than their female counterparts. 
b. Psychotropic medication use will increase with age in children/dependent 
adults. 
c. Children/dependent adults reported as having challenging behaviours are 
more likely to be in receipt of psychotropic medication than those without 
challenging behaviours. 
d. Children/dependent adults with comorbid mental health conditions are 
more likely to be in receipt of psychotropic medication than those without. 
e. Children/dependent adults with reported sleep difficulties are more likely 
to be in receipt of psychotropic medication than those without. 
Study 1 aimed to examine informants’ attitudes and perspectives on the 
use of psychotropic medication for the reduction of ‘challenging behaviour’, for 
the treatment of comorbid psychiatric conditions or sleep difficulties in children 
and dependent adults with an ASD. Given the lack of research exploring this, key 
questions were postulated, rather than specific hypotheses. Given the literature to 
date, the following key questions were asked from the caregivers perspectives: 
                                                          
1 Although these hypotheses are akin to audit standards and are largely self-evident, a decision 
was made to include them in this way in order to enhance the systematic examination of findings 
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a. What are the reasons for psychotropic medication use in a child/dependent 
adult? 
b. To what extent do caregivers perceive psychotropic medication as helpful 
for the child/dependent adult with an ASD? 
c. Do caregivers view psychotropic medication as a form of restraint? 
d. What are caregivers’ attitudes towards the administration of psychotropic 
medication to people with ASD? 
4.1.2 Study 2: Aim and hypotheses 
The aim of Study 2 was to examine the use of psychotropic medication to 
manage emotions or behaviours associated with an ASD from the perspective of 
adults with an ASD. The study aims to explore those who currently use 
medication, who have previously used it and who have never used it. This study 
will explore the differences variability in the extent of medication use, in addition 
to examining factors associated with medication use; in particular challenging 
behaviours, comorbid mental health conditions and sleep difficulties. On the basis 
of the current literature, the following hypotheses2 were posed: 
a. Males are more likely to be in receipt of psychotropic medication than 
females. 
b. Psychotropic medication use will decrease with age. 
                                                          
2 Although these hypotheses are akin to audit standards and are largely self-evident, a decision 
was made to include them in this way in order to enhance the systematic examination of findings 
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c. Individuals with comorbid mental health conditions are more likely to be 
prescribed psychotropic medications than those without. 
d. Individuals who reported challenging behaviour are more likely to be 
prescribed psychotropic medications than those without. 
e. Individuals with reported sleep difficulties are more likely to report 
psychotropic medication use than those without. 
A second aim was to examine the perspective of adults with an ASD 
regarding medication as an option for reducing challenging behaviour, or for the 
treatment of comorbid psychiatric conditions. Based on the literature the 
following key questions were asked: 
a. Is psychotropic medication perceived as helpful by adults with an 
ASD? 
b. Do adults with an ASD view psychotropic medication as a form of 
restraint? 
c. What do adults with an ASD state as their reason for using 
psychotropic medication? 
d. What are the attitudes of adults with an ASD towards the 
administration of psychotropic medication to people with ASD? 
 
4.1.3 Study 3: Aims. 
The primary goal of the last study was to explore caregivers’ and 
individuals’ attitudes and perspectives towards the use of psychotropic medication 
in an ASD population, through qualitative methodology. This approach aimed to 
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allow participants to provide personal perspectives in relaying their thoughts 
about psychotropic medication use. There were three main objectives: 1) to 
provide further insight into the topics covered; 2) to capture the viewpoints of 
informants and individuals and generate common themes; and 3) to inform future 
practice in this area. 
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Chapter 5: Method 
5.1 Participants 
A total sample of 308 individuals (240 males, 58 females) with an ASD, 
aged between three and 74 years of age (M = 18.13, SD = 14.75) participated in 
these studies. This sample comprised two groups of participants across three 
studies. Table 5.1 below presents the demographic material for each study.  
Table 5.1  
Demographic Material for Study 1, 2 and 3 (N = 308) 
Study No of. 
Participant  
Males Age Range M  SD  
1 245 198 3-69  12.91 9.65 
2 63 42 18-74  38.44 13.57 
3a 173 138 3-45 10.17 9.45 
3b 46 30 18-63  37.85 14.23 
 
Studies 1 and 3a included 245 children and dependent persons survey 
information (240 online, 5 paper versions) was provided by parents/caregivers 
who acted as informants on behalf of the child/dependent adult. Studies 2 and 3b 
included 63 adults (42 males, 21 females) with an ASD who independently 
completed an anonymous questionnaire (54 online, 10 paper versions).. 
5.2 Materials 
Two questionnaires were developed for this study. The first was designed 
for completion by caregivers of a child/dependent adult with an ASD; the second 
was designed for completion by adults with an ASD. The first part of the 
questionnaire was designed to collect information regarding characteristics of the 
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individual with an ASD, and their use of psychotropic medication. Topics 
included the extent of any sleep problems, any past or current use of medications, 
the reasons for and effect of, any such use. For these topics, caregiver informants 
were asked to provide information with respect to the person with an ASD. In 
addition, attitudes towards medication were sought from participants with an 
ASD; informants were asked to report their own attitudes. A ‘free text area’ was 
included throughout the questionnaire for respondents to provide comments about 
any medications prescribed to treat emotions or behaviours associated with ASDs, 
or to provide feedback about the survey. The questionnaire took approximately 20 
minutes to complete for both self-reporting adults with an ASD and informant 
caregivers. 
5.2.1 Demographic information. 
Demographic information was collected on participants with an ASD, 
including age, country of residence, and postcode. Respondents were also asked 
to confirm that they, or the person they cared for, had a diagnosis of an ASD and 
to indicate: the subtype of ASD (i.e. Autistic disorder, Asperger's disorder, PDD), 
the type of professional who diagnosed the disorder (no supporting 
documentation required), the age of the individual at diagnosis, the extent to 
which autism affected their functioning, the presence of any associated 
intellectual disability, and the presence of any communication impairment or any 
other medical conditions (e.g., epilepsy or diabetes). 
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5.2.2 Mental health and challenging behaviour. 
Participants were asked to report whether they (or in the case of the 
informant, the person they cared for) experienced any mental ill health. If so, they 
were asked to indicate whether this, or these, had been formally diagnosed 
(yes/no), by which type of professional, or if they believed a diagnosis should 
have been made (yes/no). Participants were also asked to indicate 
(yes/no/sometimes) if they (or in the case of the informant, the person they cared 
for) had difficulty managing their behaviour (e.g., obsessions, anger, self-
stimulation, impulse control). If yes, respondents with an ASD were asked to 
describe the behaviour they found difficult to manage, how often it presented, 
what management strategies they used and who assisted in developing these 
strategies. Caregiver informants were asked if they had difficulty managing the 
behaviours of the person with an ASD. If yes, they were asked to describe the 
behaviours that were difficult to manage, how often they presented, what 
management strategies they used and who assisted in developing these strategies. 
5.2.3 Extent of medication use. 
Participants were required to report if they (or in the case of the informant, 
the person they cared for) currently took and/or have previously taken medication 
to assist with emotions and behaviours associated with their ASD. If they 
indicated yes, they were then asked to complete a series of questions about each 
medication. The range of items relating to medication use, the response format, 
and extent of opportunity for other responses and/or comments can be found in 
Appendix A). 
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5.3 Sleep Characteristics 
5.3.1 Self-reporting adults with an Autism spectrum disorder. 
Four items from the Insomnia Severity Index (ISI; Morin, 1993) were 
administered to participants who reported they had difficulties with sleep. Self- 
reporting adults with an ASD were asked to report how severe their sleep 
problems were, across three domains (difficulty falling asleep, difficulty staying 
asleep and problem waking too early), as well as to report overall sleep 
satisfaction on a five point Likert scale (1 = none to 5 = very severe). Total 
possible scores ranged from four to 20, with higher scores representing more 
severe levels of insomnia. Participants were further required to report if they used 
medication to assist with sleep. The ISI is an established measure with sound 
psychometric properties. It has been found to have acceptable internal consistency 
(α =.90 -.91), convergent validity and acceptable correlations between individual 
items and overall scores (r =.73, r =.71) in both clinical and community samples 
(Morin et al., 2011). This current study found the items a relatively reliable 
measure of sleep difficulties (self-report α =.67). 
5.3.2 Caregivers of children/dependent adults with an Autism 
Spectrum Disorder. 
Four items from the ISI (ISI; Morin, 1993) were administered to informant 
participants, who reported the person they cared for had sleep difficulties. 
Informants were asked to report how severe they perceived the sleep problems 
were, across three domains (difficulty falling asleep, difficulty staying asleep and 
problem waking too early), as well as reporting their overall satisfaction with the 
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child’s/dependent adult’s sleep on a five point Likert scale (1 = none to 5 = very 
severe). Total possible scores ranged from four to 20, with higher scores 
representing more severe levels of insomnia. Informants were further required to 
report if the person they cared for used medication to assist with sleep (informants 
α =.71). 
5.4 Attitudes Towards Medication 
5.4.1 Self-Reporting adults with an Autism Spectrum Disorder. 
The Drug Attitude Inventory (DAI 30; Hogan, Awad & Eastwood, 1983) 
was administered to participants with an ASD who currently took medication or 
had previously taken medication. This 30-item self-report inventory focuses on 
attitudes towards medication use, as well as values concerning illness and health. 
The DAI-30 has primarily been used for people with schizophrenia to determine 
factors that may affect medication compliance. 
The DAI-30 has been found to have excellent internal consistency (α =.93; 
Hogan, Awad & Eastwood, 1983); high test-retest reliability (r =.82; Awad, 
1993); and a high correlation with medication compliance and treatment outcome 
in people with schizophrenia and depression (Brook, van Hout, Nieuwenhuyse & 
Heerdink, 2003; Gervin et al., 1999; Hogan et al., 1983; Pae et al., 2004; Rossi, 
Arduini, Stratta & Pallanti, 2000; Kampman et al., 2000; Sajatovic, Davies & 
Hrouda, 2004). 
In addition, a shortened version of the DAI was administered to 
individuals with an ASD who had never taken medication to manage emotions 
and behaviours associated with the disorder. This version removed all items  
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relating to how medication affected the individual and reflected only attitudes 
towards medication use. The adapted version of this questionnaire was found to 
have acceptable internal consistency (self-report α =.82). 
5.4.2 Caregivers of people with an Autism Spectrum Disorder. 
The DAI-30 was adapted for completion by parents/caregivers. This 
questionnaire was shortened to 16 items, focusing on understanding the 
informants’ values around medication and how they think medication affects the 
person they cared for. This adapted version of the DAI was found to have 
acceptable internal consistency (α =.87). 
In addition, a shortened version of the DAI was administered to caregivers 
who reported that the person they cared for had never taken medication to manage 
emotions and behaviours associated with ASD. This version removed all items 
relating to how medication affected the child/dependent adult and reflected only 
values relating to medication use. The adapted version of this questionnaire was 
found to have acceptable consistency (α =.72). 
The entire questionnaire is available to any interested reader by contacting 
the author or her supervisor, Associate Professor Jane McGillivray, contact details 
in Appendix C.  
5.5 Procedure 
Ethics approval for this study was obtained from the Human Research 
Ethics Committee at Deakin University. Participants were required to have a 
minimum age of 18 years, and to either have an ASD or be the caregiver of a 
child/dependent adult with an ASD. The individuals who took part in this study 
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were recruited from five sources over a 12 month period. First, through 
advertisements of the study in ASD and disability services newsletters; second, 
via announcements about the study and distribution of flyers to support groups for  
people with an ASD; third, via direct emails to caregivers who had self-identified 
through a research website as wanting to participate in research that focused on 
people with an ASD; fourth, posting brief information and/or the flyer about the 
project on ASD specific webpages and Facebook groups; fifth, advertisements 
were placed on search engines (e.g., Google), where the advertisement was 
displayed when key words were searched. For instance, if the words ‘autism and 
medication’ were entered into the search engine, a brief advertisement of the 
study may have appeared in the corner of the browser. Advertisements provided 
researchers contact details for further information or to access a paper copy of the 
questionnaire and/or directed potential volunteers to the webpage for access to the 
questionnaire. The advertisement (Appendix B) provided brief information about 
requirements for participation. 
The proportion of participants sourced from each recruitment method is 
unknown, as participation was anonymous. However, a large proportion of 
participants specified their location as Victoria, and any overseas participants 
were not included. The majority of participants (95.1%) elected to complete the 
online version of the questionnaire. Respondents were invited to email the 
researchers separately if they wished to receive a copy of group findings. 
Participation was voluntary and anonymous, and no financial or other 
inducements were offered. A Plain Language Statement was provided, which 
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contained information regarding informed consent (Appendix C). Participants 
were told that they could withdraw from the study at any time up until the 
questionnaire was submitted. Once the questionnaire was submitted, participants 
were not able to be identified; thus it was not possible to withdraw post- 
submission. In the event of any stress associated with completion of the survey, 
participants were encouraged to seek assistance from their local ASD association, 
crisis support service or attend their local general practitioner for support if 
necessary. 
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Chapter 6: Results Study 1 
This study involved a detailed description and analysis of 245 children and 
dependent adults with an ASD whose caregivers acted as informants. The 
caregivers will be referred to as ‘informants’ throughout this section of the results. 
A power analysis was conducted using the G-Power 3.1 Program (Faul, Erdfelder, 
Buchner & Lang, 2009), with anticipated moderate effect sizes. The power 
analysis indicated that the study required approximately 110 participants, and 
therefore was deemed to have sufficient power for analysis. Non-parametric 
approaches to analysis was taken as the data was not normally distributed. 
In the first section of this chapter, the demographic details of the sample 
are presented, including the frequencies of children and dependent adults 
according to age, gender, communication ability, intellectual ability, type of ASD 
and source of information. In the second section of this chapter, the characteristics 
of the children and dependent adults who are currently using psychotropic 
medication to assist the management of behaviours and emotions concomitant 
with the disorder are explored and compared with those who previously used 
medication, and those who have never used medication. The number and types of 
drugs are described for those who are prescribed medication. Further, the 
perspectives of informants regarding the use of psychotropic medication in the 
management of mental health, undesirable emotions and behaviours in the person 
with an ASD are reported. This is followed by a description and analysis of any 
relationship with psychotropic medication use in those who reported challenging 
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behaviour, those who reported comorbid mental health conditions, and finally, 
those who reported sleep problems. 
6.1 Overview of the Sample of Children and Dependent Adults 
with an ASD 
6.1.1 Sample characteristics. 
The 245 children and dependent adults with an ASD (80.8% males) who 
were subject to report in this study ranged in age from three to 69 years, with a 
mean age of 12.92 years (SD = 9.56, Median =10, Mode = 10). A Chi-Square 
Test for Independence determined that age and gender of this sample were not 
significantly related (χ2 (N = 245, df = 4) = 4.27, p =.37, phi =.13). As shown in 
Table 6.1.1, the majority were males aged between three and 11 years, with no 
females over 30 years; only 13.9% of the sample were aged 19 years or over. 
Three age groups were consequently determined for comparison: children (those 
aged 3 to 11 years), teenagers (those aged 12 to 18 years) and adults (19 + years). 
 
Table 6.1.1 
Frequency and Percentage of Age Distribution by Gender (N = 245) 
 Male Female Total 
Age 
Range Freq. % Freq. % Freq. % 
3 to11 112 56.6 28 59.6 140 57.1 
12 to 18 55 27.8 16 34.0 71 29.0 
19 to 29 16 8.1 3  6.4 19  7.8 
30 to 55 13 6.6 - - 13  5.3 
56 to 69 2 1.0 - - 2  0.8 
Total 198 100.0 47 100.0 245 100.0 
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Most informants were parents of children and dependent adults with ASD. 
A small proportion of other caregivers completed the survey, including foster 
carers, siblings and partners. As shown in Table 6.1.2, the majority of informants 
were mothers who resided with the child or dependent person with an ASD. A 
small proportion of informants did not live with the child/dependent person with 
an ASD (2.9%), or only did so occasionally (2.5%). 
 
Table 6.1.2 
Informant Relationship to Dependent Person with ASD and Living Status (N=245) 
  Resides with 
informant 
Does not reside 
with informant  
Occasionally 
resides with 
informant  
Total  
Informant relationship 
to person with ASD 
Freq. 
 
% Freq. % Freq. % Freq. 
 
Mother 204  87.9 3  42.9 4  66.7 211 
Father 14  6.0 2  28.6 - - 16 
Other 14  6.0 2  28.6 2  33.3 18 
Total  232 100.0 7 100.0 6 100.0 245 
 
Informants for dependent adults were asked if they thought the individual 
with an ASD would also complete the survey, with most indicating ‘no’ (94.0%); 
a small percentage indicated ‘yes’ (1.7%) or unsure (4.3%). 
 
 
 
 
 
 Psychotropic Medication and ASD
   
 
 
81 
 
Table 6.1.3 
Frequency and Percentage of ASD Type and Severity of Impairment (N = 245) 
 Autistic disorder Asperger’s 
disorder 
PDD–NOS Total 
Severity of 
impairment. 
Freq. % Freq. % Freq. %  
Mild  17  26.1 37  30.8 4  28.6 58 
Moderate 59  63.6 76  63.3 6  42.9 141 
Severe 34  20.3 7  5.8 4  28.6 45 
Total 110 100.0 120 100.0 14 100.0 245 
 
Table 6.1.3 shows the frequency and percentage of participants according 
to ASD type and ratings of severity of impairment. According to informants, the 
majority of dependent children and adults with an ASD had received a diagnosis 
of Asperger’s disorder and autistic disorder, with a small proportion being 
diagnosed with PDD–NOS. A Chi-Square Test of Independence determined a 
significant relationship between ASD subtype and severity (χ2 (n = 244, df = 4) = 
27.76, p <.001). More people were found to be in the mild level of impairment 
range with Asperger’s disorder, and a greater number of participants who had 
autistic disorder were in the severe level of impairment category. 
Frequency of intellectual disability in the sample according to ASD 
diagnosis is presented in Table 6.1.4. Most children and dependent adults were 
diagnosed with Asperger’s disorder without intellectual disability. Of those with a 
reported intellectual disability, the significant majority were diagnosed with a 
moderate intellectual disability and autistic disorder (χ2 (n = 243, df = 2) = 64.62, 
p <.001, phi =.52). 
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Table 6.1.4 
Frequency of Intellectual Disability According to ASD Diagnosis (n = 243) 
Intellectual 
Disability 
 Asperger’s 
disorder 
Autistic 
disorder 
PDD–NOS  
  Freq. % Freq. % Freq. % Total.  
Yes Mild 13 11.0 25 22.5 5  35.7  43 
 Moderate  3  2.6 28 25.2 3  21.4  34 
 Severe  - - 18 16.2 1    7.1  19 
 Total 16 13.6  71  63.0 9  64.3  96 
         
No    102  86.4  40  36.0 5   35.7 147 
Total  120 100.0 111 100.0 14 100.0 243 
 
In summary, significant relationships were identified between type of 
ASD and severity of impairment; those with Autistic disorder were more likely to 
be reported as having a severe impairment, along with an intellectual disability. 
6.2 Use of Psychotropic Medication 
This section presents a comparison of children and dependent adults with 
an ASD who were currently prescribed psychotropic medication, with those who 
had previously taken medication and those who had never done so. Medication 
use is described according to demographic variables, as well as the reasons for 
use and caregiver views on its effectiveness, whether it was restrictive, and 
overall attitudes regarding use. 
6.2.1 Psychotropic medication. 
Of the 245 child/dependent adult participants, 149 (60.8%) were reported 
to be currently taking medication to assist with emotions or behaviours. A further 
16 (6.6 %) had used medication in the past to assist with emotions and 
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behaviours, but were not currently using medication, and 81 (33.0%) had never 
used medication for this purpose. This group of 81 will be referred to as non-
users. Results for each group of participants are provided in Table 6.2.1.1. 
 
Table 6.2.1.1 
Demographic Details According to Medication Status (N = 245) 
 Total Male Female Age No. of challenging behaviours 
n = 198 n = 47 M SD M SD 
Non-user  81  61 20 11.79 10.35 2.53 2.01 
Previous 
user  15  13 3 12.60 7.20 2.13 1.84 
Current 
user 149 124 24 13.55 9.46 3.20 1.98 
 
Chi-Square Tests of Independence were conducted to determine whether 
medication status (non-user, previous user, current user) related to gender, type of 
ASD diagnosis, level of impairment or communication ability. The results 
indicated no significant relationships between medication status and gender (p 
=.29), ASD diagnosis (p =.26), level of impairment (p =.26) or intellectual ability 
(p =.62). 
Informants indicated that the child/dependent adult with an ASD used 
between 0 and 5 different psychotropic medications. A total of 241 medications, 
with an average of 1.65 medications (SD =.88, Median =1, Mode =1) per person, 
were reported for the 149 individuals currently prescribed psychotropic 
medication. Routine use of medication was reported for 143 individuals, and pro 
re nata (PRN; ‘as required’) medication was reported for six individuals. A 
further seven informants (and thus 13 overall) indicated that the person they cared 
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for used both routine and PRN medication. Of note, 17 informants (7%) reported 
use of complementary and alternative medications (e.g., St Johns Wort, fish oil) 
to assist the child/dependent adult with their emotions or behaviours. This 
medication use was excluded from the analyses, as the focus of the study was on 
prescribed psychotropic medication, however it is plausible the use of these 
medications may have affected responses in terms of perceived effectiveness. 
Medications that were reported for primary treatment of diagnosed medical 
conditions were also excluded from the analysis (e.g., sodium valproate for 
epilepsy, diabex for diabetes). Where informants reported medication was used 
for a dual purpose (e.g., behavioural control and epilepsy), the medication use 
was included in the analysis. 
The reported psychotropic medications were coded according to their 
primary MIMS classifications (MIMS online, 2012): anti-depressant, anti- 
psychotic, anti-anxiety, anti-convulsant, hypnotic sedatives, central nervous 
system stimulants (CNS stimulants), or other. The coding of each medication 
according to type can be found in Appendix D. Table 6.2.1.2 presents the 
frequencies of psychotropic medication reported. As can be seen, risperidone was 
the most commonly reported medication, followed by methylphenidate and 
fluoxetine. 
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Table 6.2.1.2 
Frequency of Medications Reported by Name and Type (n of medication = 241) 
Type of Medication Name of Medication 
Number of Children/Dependent 
Adults 
  Freq. 
Anti-depressant Fluoxetine 33 
 Fluvoxamine 7 
 Escitalopram 4 
 Sertraline 4 
 Talohexal 4 
 Duloxetine 3 
 Venlafaxine 2 
 Amitriptyline 2 
 Desvenlafaxine 1 
 Total 60 
Anti-psychotic Risperidone 54 
 Olanzapine 6 
 Queitiapine 3 
 Haloperidol  2 
 Lithium 2 
 Pericyazine 1 
 Ziprasidone 1 
 Total 69 
CNS stimulant Methylphenidate 38 
 Atomoxetine 5 
 Total 43 
Anti-convulsant Sodium Valproate 10 
 Carbamazepine 1 
 Lamotrigine 2 
 Clonazapam 1 
 Total 14 
Hypnotic Sedative Melatonin 17 
 Dexamphetamine 4 
 Chloral Hydrate 1 
 Total 22 
Anti-Anxiety Diazepam 2 
 Total 2 
Other Clonidine 19 
 Depo Provera 1 
 Benzhexol 1 
 Total 21 
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6.2.2 Psychotropic medication and gender. 
In this section, the reported use of psychotropic medications taken by 
children and dependent adults to manage emotions and behaviours associated 
with an ASD are examined according to age and gender. Frequencies related to 
the concurrent use of medications are also presented, to determine the extent of 
polypharmacy (multiple medications) among the sample. 
The frequencies and percentages of medication use according to gender 
are illustrated in Table 6.2.2.1. The majority of female and male 
children/dependent adults took one medication. A small number of male 
children/dependent adults (1.6%) were reported to be taking five medications to 
manage emotions and behaviours associated with the disorder. The mean number 
of medications used by male and female children and dependent adults was 1.61 
and 1.83, respectively. 
 
Table 6.2.2.1 
Number and Percentage of Medication in Current Users used Routinely by Gender ( n = 
125) 
  Male  Female  Total  
No. of 
Medications 
Freq. % Freq. % Freq. % 
1 68 54.4 13 54.2 81  54.4 
2 43 34.4 5 20.8 48  32.2 
3 10  8.0 3 12.5 13  8.7 
4 2  1.6 3 12.5  5  3.4 
5 2  1.6 - -  2  1.3 
Mean No. of 
Medication  1.61   1.83   1.65  
Total  125 100.0 24 100.0 149 100.0 
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Further analyses revealed that 68 (45.6%) of children/dependent adults 
who were taking psychotropic medication were prescribed two or more 
medications, with seven (4.6%) being prescribed four or more medications to 
manage emotions or behaviours associated with an ASD. A Mann-Whitney U 
Test revealed no significant difference in the number of medications prescribed 
for males (Md = 1, n = 125) and females (Md = 1, n = 24), U = 1396, z = -.60, p 
=.55, r =.05. 
As shown in Table 6.2.2.2, of the children/dependent adults who were 
described as currently taking medication, the majority (42.3%) were reported to 
be taking one or more anti-depressant medications, with 40.9% taking anti-
psychotic drugs. The most commonly reported medication types were the same 
for males and females (anti-depressant and anti-psychotic medication). A smaller 
proportion of males (11.2%) were taking anti-convulsant drugs; however, no 
females were reported as taking these. 
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Table 6.2.2.2 
Gender Comparison According to Type and Number of Medications (n = 149) 
   Male (n = 125) Female (n = 24) Total 
Medication Type No. of 
Medications Freq % Freq % 
 
Anti-depressant  1 49 39.2 11 45.8 60 
 2 3  2.4 - - 3 
Anti-psychotic  1 49 39.2 5 20.8 54 
 2 3  2.4 3 12.5 6 
 3 - - 1  4.2 1 
Anti-anxiety 1 2  1.6  - - 2 
Anti-convulsant 1 12  9.6 - - 12 
 2 2  1.6 - - 2 
Hypnotic sedative 1 17 13.6 5 20.8 22 
CNS stimulant 1 32 25.6 7 29.2 39 
 2 2  1.6 - - 2 
Other  1 16 12.8 4 16.7 20 
 2 - - 1  4.2 1 
Total medications  197  44  241 
  
 
6.2.3 Psychotropic medication and age. 
Table 6.2.3.1 presents results of medication status (current user, previous 
user, non-users) across age groups (3–11 years, 12–18 years, 19–69 years). Most 
participants in each age group were reported as currently taking medication 
(55.7% of 3–11 yrs; 69.0% of 12–18 yrs; 64.7% of 19–69 yrs). There was no 
significant relationship between medication status and age group, χ2 (N = 245, df 
= 4) = 6.13, p =.19. 
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Table 6.2.3.1  
Medication Status According to Age Group (N = 243) 
 Current user Previous user Non-user Total  
Age 
Range. 
Freq. % Freq. % Freq. % Freq. % 
3 to 11 78 55.7 7  5.0 55 39.3 140 100.0 
12 to 18 49 69.0 5 7.0 17 23.9 71 100.0 
19 to 69 22 64.7 3 8.8 9 26.5 34 100.0 
Total 149  15  81  245  
 
Table 6.2.3.2 presents the frequencies and percentages of medication use 
according to age group. The majority of participants in the three to 11 year old 
and the 12 to 18 year old groups were reported to be taking one medication, 
whereas the majority of participants in the 19 to 69 years age group were reported 
to be taking two medications. Children aged three to 11 years used a mean 
number of 1.44 medications, with those aged 12 to 18 using 1.84 medications on 
average. Those above 19 years old were taking a mean number of 2.00 
medications. A Kruskal-Wallis Test revealed a significant difference in the 
number of medications between the three age groups, with more medications 
being prescribed in the 19 to 60 year old group (χ2 (N = 245, df = 2) = 11.04, p 
=.003). 
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Table 6.2.3.2 
Frequency and Percentage of Medications used Routinely by Age Group (N = 245) 
  Age Group   
  3 to 11 years 12 to 18 years 19 to 69 years Total  
No. of 
Medications. 
Freq. % Freq. % Freq. % Freq. % 
1 51 65.4 23 46.9 7 31.8 81 54.4 
2 22 45.8 17 34.7 9 40.9 48 32.2 
3  4  5.1  4  8.2 5 22.7 13  8.7 
4 - -  4  8.2 1  4.5  5  3.4 
5  1  1.3  1  2.0 -  -  2  1.3 
Mean No. of 
Medication 1.44  1.84  2.00    
 
Table 6.2.3.4. indicates the frequency of children and dependent adults 
using at least one of the five medication types according to age group. The most 
frequently reported medication type in the three to 11 year old group was anti-
psychotic medication. In contrast, anti-depressant medication was most 
commonly reported for 12 to 18 year olds and those aged over 19 years. 
Table 6.2.3.4 
Type of Psychotropic Medication by Age Group (n = 149) 
  Age Group  
 
Medication Type 
3 to 11 years 12 to 18 years 19 to 69 years Total 
Freq. % Freq. % Freq. % Freq. % 
Anti-depressant 23 29.5 23 46.9 17 77.3 63 42.3 
Anti-psychotic 32 41.0 20 40.8 9 40.9 61 40.9 
CNS stimulant 22 28.2 19 38.2 - - 41 27.5 
Anti-convulsant 3 3.8 6 12.2 5 22.7 12 9.4 
Hypnotic 
sedative 14 17.9 6 12.2 2 9.2 22 14.8 
Anti-anxiety 1 1.3 1 2.0 - - 2 1.3 
Other 12 15.4 8 16.3 1 4.5 21 14.1 
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6.2.4 Reasons for psychotropic medication use. 
The majority of the sample (75.4%) stated that medication was prescribed 
for a single purpose. The reasons for medication use were coded into the 
categories of mental health conditions, challenging behaviour, sleep difficulties 
and other. Table 6.2.4.1 presents the frequencies of reasons for each medication 
reported. The most commonly reported primary purpose was a mental health 
condition (103 participants, 42.7%) and challenging behaviour (85 participants, 
35.3%). Sleep difficulties were reported as the primary reason by 19.5% (45 
participants). The other category (6 participants, 2.5%) included stress, as well as 
prescription of medication to assist with the side effects of another medication. 
The primary reason provided by informants for psychotropic medication 
use was further analysed by type of medication (see Table 6.2.4.1). The majority 
of informants reported that anti-depressant and CNS stimulants were used 
primarily for a mental health condition, whereas anti-psychotic and anti-
convulsant drugs were predominantly reported for the management of challenging 
behaviours. Hypnotic sedatives were most commonly used for management of 
sleep disturbance. 
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Table 6.2.4.1 
Frequency of Primary Reason for Medication Use According to Medication Type  in 
Current Users (n = 149) 
 
 
Medication Type 
Freq.  Mental 
Health 
Challenging 
Behaviour 
Sleep 
Disturbance 
Other No 
Reason 
Provided 
Anti-depressant 66 48 9 8 - - 
Anti-psychotic 69 19 45 1 2 2 
CNS stimulant 41 27 14 - - - 
Anti-convulsant 12 3 8 - - 1 
Hypnotic sedative 22 4 1 17 - - 
Anti-anxiety  2 1 1 - - - 
Other 21 - 8 11 4 - 
Total 233 103 85 37 6 3 
 
 
 
 
6.2.5 Restraint. 
The majority of informants reported they did not believe their medication 
was a form of restraint (69.9%), with less than one third (27.1%) indicating that 
the medication was restrictive; a small proportion were not specific (3%). 
Responses are presented below in Table 6.2.5.1, according to medication type. 
Table 6.2.5.1 
Frequency and Percentage of Informants Indicating Medication as Restraint by 
Medication Type (n of medication  = 233) 
Medication Type N Yes No Unspecified 
Anti-depressant 66 15 49 2 
Anti-psychotic 69 26 40 3 
CNS stimulant 41 7 34 - 
Anti-convulsant 12 6 6 - 
Hypnotic sedative 22 1 21 - 
Anti-anxiety 2 2 - - 
Other 21 6 15 2 
Total 233 63 165 7 
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A Chi-Square Test of Independence revealed a significant relationship 
between the reason for medication use and views on restraint (p<.001), with more 
informants reporting they did not believe the medication was restrictive, in those 
who reported medication use for sleep disturbance (see Table 6.2.5.2). 
 
Table 6.2.5.2 
Reason for Medication Use According to Belief about Restraint (n = 236) 
 
 
 
n Mental 
Health 
Challenging 
Behaviour 
Sleep 
Disturbance 
Other No Reason 
Provided 
Restrictive 64 29 27 - 1 - 
Not Restrictive 165 73 54 35 1 2 
Unspecified 7 1 3 2 1 - 
Total 236 103 85 45 6 3 
 
6.2.6 Perceived helpfulness of psychotropic medication. 
Informants were asked to report whether they felt the medication assisted 
them to manage the behaviours or emotions of the person with an ASD. 
Informants were also asked whether they believed the medication helped the child 
or dependent adult to manage their own emotions and behaviours. The vast 
majority (89.9%) of informants indicated that the medication assisted them to 
manage the behaviours or emotions in the person with an ASD. Similarly, a large 
number of informants (88.8%) also reported they felt that medication assisted the 
person they cared for, while a smaller percentage remained undecided (8.8%), and 
a small number (2.4%) stated they did not believe the medication helped the 
person they cared for. Perceived helpfulness was examined according to reason 
for medication use, as well as according to type of medication (see Table 6.2.6.). 
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Table 6.2.6 
Frequency of Primary Reason for Medication Use According to Medication Type (n = 
149) 
 
 
Medication Type 
n  Mental 
Health  
Challenging 
Behaviour 
Sleep 
Disturbance 
Other  No 
Reason 
Provided 
Anti-depressant 66 48 9 10 - - 
Anti-psychotic 69 19 45 1 2 2 
CNS stimulant 41 27 14 - - - 
Anti-convulsant 12 3 8 - - 1 
Hypnotic sedative 22 4 1 19 - - 
Anti-anxiety 2 1 1 - - - 
Other 21 - 8 15 4 - 
Total  103 85 45 6 3 
 
Informants were further requested to report on a 10-point Likert scale how 
satisfied they were with the child/dependent adult taking the medication, from 0 
(totally dislike) to 10 (totally like) (M = 7.69, SD = 2.88). Kruskall-Wallis Tests 
established no significant relationship in satisfaction according to the reported 
reason for medication use, (p =.058), and no significant relationship in 
satisfaction according to type of medication, (p =.68). 
6.2.7 Caregiver attitudes towards psychotropic medication. 
Table 6.2.7.1 presents overall frequencies of responses (by informants 
who reported that the child/dependent adult was currently taking psychotropic 
medication) to each item of the modified DAI scale. The most strongly endorsed 
items (94.6%) were, ‘For the person I care for, the good things about medication 
outweigh the bad’ as well as the item, ‘Medications make the person I care for 
more relaxed’ (93.2%). The least endorsed item (10.7%) overall was, ‘The person 
I care for only needs to take medication when they feel ill’. The majority of 
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participants endorsed the items, ‘By staying on medication I can prevent the 
person I care for having difficult behaviour’ (72.3%). Almost half of the sample 
endorsed the item ‘Taking medications will do no harm to the person I care for.’ 
Table 6.2.7.1 
Frequency of Informant Responses on the Modified DAI (n = 149) 
Item True False 
 Freq. % Freq. % 
For the person I care for, the good things about 
medication outweigh the bad 140 94.6 7  4.7 
Medications make the person I care for more relaxed 137 93.2 9  6.8 
The person I care for is more relaxed on medication 135 91.2 11  7.4 
The person I care for is happier on medication 131 88.5 15 10.1 
The person I care for gets along better with people 
when on medication 125 85.1 21 14.2 
The person I care for is on medication to control their 
behaviour 111 75.0 34 23.0 
By staying on medication I can prevent the person I 
care for having difficult behaviour  107 72.3 37 25.0 
The person I care for should keep taking medication 
even when they are well  105 70.9 39 26.4 
It is up to the doctor to decide when the person I care 
for should stop taking their medication 86 58.1 60 40.5 
Taking medications will do no harm to the person I 
care for  71 48.0 64 43.2  
The person I care for experiences unpleasant effects 
of medication  34 23.0 112 75.7 
Medications make the person I care for tired and 
sluggish 26 17.6 120 81.8 
The person I care for is only on medication because 
of pressure from other people 19 12.8 128 86.5 
Medications are slow acting poisons 13  8.8 129 87.2 
The person I care for is no different on or off 
medication 8  5.4 138 93.2 
The person I care for only needs to take medication 
when they feel ill  5  3.4 139 93.9 
 
 
 
In summary, psychotropic medication was reported being administered to 
60.8% of children and dependent adults with an ASD. A key finding included that 
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the age group significantly related to the number of prescribed medications, with 
those aged over 19 years more likely to receive multiple medications. Informants 
predominantly viewed medication as helping the child or dependent adult, and did 
not view the medication as a form of restraint. 
6.3 Challenging Behaviour and Psychotropic Medication 
Following an overview of the nature and extent of any challenging 
behaviours, and with respect to demographic variables, this section of the study 
examines any relationships between challenging behaviours and psychotropic 
medication status (current use, previous use and non-users). Finally, differences 
among those who currently take psychotropic medication and have challenging 
behaviour are examined. 
All informants were required to report whether the child/dependent adult 
with an ASD had behaviours that they or the individual with ASD found 
challenging (yes, no, sometimes). The majority of informants (57.6%) reported 
the person with an ASD regularly had difficulty with their behaviour, with almost 
a third reported sometimes having difficulty (30.2%); only a small proportion 
reported no difficulties (12.2%). The number of reported challenging behaviours 
ranged from 0 to 10 (M = 2.91, SD = 2.01), and the majority of the sample 
(87.5%) reported that the child/dependent adult with an ASD had difficulty with 
at least one challenging behaviour. Table 6.3.1.1 presents the numbers of 
behaviours reported. A Mann-Whitney U Test revealed no significant difference 
in the number of challenging behaviours reported by males (Md = 3, n = 198) and 
females (Md = 3, n = 47), U = 4594, z = -.14, p =.89, r =.009. 
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Table 6.3.1.1 
Numbers of Challenging Behaviour Reported by Informants (N = 245) 
No. of Behaviours 
 
Males Females Total 
Participants n = 198 n = 47 
 Freq. % Freq. % Freq. % 
0 27 13.6 3  6.4 30 12.2 
1 25 12.6 9 19.1 34 13.9 
2 34 17.2 8 17.0 42 17.1 
3 38 19.2 15 31.9 53 21.7 
4 39 19.7 3  6.4 42 17.1 
5 13  6.6 3  6.4 16 6.5 
6 13  6.6 3  6.4 16 6.5 
7 7  3.5 1  2.1 8 3.3 
8 -  - 1  2.1 1 0.4 
9 -  - 1  2.1 1 0.4 
10 2  1.0 - - 2 0.9 
Mean No. Of 
Behaviours   2.91   2.95   2.91  
Total 198 100.0 47 100.0  100.0 
 
Table 6.3.1.2 presents informants’ reports of the presence of challenging 
behaviour (regular, sometimes, no), according to age group. Similar rates of 
behaviours across age groups were reported by informants. Chi-Square Tests of 
Independence demonstrated no significant relationships between the presence of 
challenging behaviour and gender (p =.39), cognitive ability (p =.31), age group 
(p =.92), ASD diagnosis (p =.63), or level of impairment (p =.20). 
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Table 6.3.1.2 
Difficulty Managing Behaviour by Age Group 
 Yes Sometimes No Total  
Age 
Range 
Freq. % Freq. % Freq. % Freq. % 
3 to11 85 60.7 40 28.6 15 10.7 140 100.0 
12 to 18 38 53.5 25 35.2  8 11.3  71 100.0 
19 to 29 10 52.6  4 21.1  5 26.3  19 100.0 
30 to 55  7 53.8  4 30.8  2 15.4  11 100.0 
56 to 69  1 50.0  1 50.0 - -  2 100.0 
Note: Freq. = Frequency 
 
Informant responses to ‘Describe the behaviour you have difficulty managing’ 
were coded into five categories of behaviours: aggressive, stereotyped/self-
injurious, emotion-related, impulse control or other disruptive behaviours. 
Aggressive behaviours included verbal and physical aggression towards other 
people, as well as property destruction. Stereotyped/self-injurious behaviours 
included repetitive routines, obsessions and self-harming behaviours (e.g., biting 
self, hitting head). Emotion-related behaviours of concern included reports of 
anxiety, depression and psychosis. Other disruptive behaviours included 
absconding and smearing faeces. Difficulty with impulse control was coded as its 
own category, due to a large number of informants reporting this behaviour. The 
majority of informants reported that the dependent child/ adult had difficulty with 
at least one aggressive behaviour (59.0%), with a large number also reporting 
difficulty with at least one other disruptive behaviour (56.6%), and emotion-
related behaviour (51.4%). 
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Chi-Square Tests (with Yates Continuity Correction reported as required 
(to prevent overestimation of statistical significance for small samples)) were 
conducted to determine if the type of challenging behaviour related to 
demographic variables (age gender, ASD diagnosis, intellectual disability, level 
of impairment). Bonferroni adjustments (Tabachnik & Fidell, 2007) were made to 
safeguard against type-one error, reducing the significance level to p <.001. As 
illustrated in Table 6.3.1.3, a significant relationship was found between reporting 
stereotyped/self-injurious behaviour and level of impairment, with more children 
and dependent adults who reported stereotyped/self-injurious behaviour also 
reporting a severe level of impairment. While not significant, there was a trend for 
a relationship between emotion-related behaviours and ASD diagnosis, with more 
children/dependent adults with Asperger’s disorder reporting emotion-related 
behaviours. Similarly, there was a trend for relationships between 
stereotyped/self-injurious behaviour and gender, with boys more likely to exhibit 
stereotyped behaviours; ASD diagnosis, those with autistic disorder were more 
likely to report stereotyped/self-injurious behaviours; and those with an 
intellectual disability were more likely to have stereotyped/self-injurious 
behaviours. 
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Table 6.3.1.4 
Relationship between Type of Challenging Behaviour and Demographics (N = 245) 
 df χ2 p phi 
Aggression     
 Gender 1 1.28 .20 -.08 
 Age group 2 0.84 .66 .06 
 ASD diagnosis 2 0.63 .73 .05 
 Intellectual disability  1 0.47 .49 .04 
 Level of impairment 2 3.24 .20 .12 
Emotion-Related      
 Gender 1 2.25 .13 .11 
 Age group 2 2.35 .31 .10 
 ASD diagnosis 2 6.35 .04 .16 
 Intellectual disability  1 2.32 .13 .11 
 Level of impairment 2 2.96 .23 .11 
Stereotyped/Self-injurious     
 Gender 1 5.27 .02 .16 
 Age group 2 2.42 .30 .10 
 ASD diagnosis 2 7.71 .02 .18 
 Intellectual disability  1 4.19 .04 .14 
 Level of impairment 2 17.43 .00*** .27 
Impulse Control Difficulty     
 Gender 1 0.10 .76 -.03 
 Age group 2 5.11 .07 .14 
 ASD diagnosis 2 1.28 .53 .07 
 Intellectual disability  1 0.00 .83 .01 
 Level of impairment 2 1.19 .55 .07 
Other Disruptive     
 Gender 1 1.70 .19 -.08 
 Age group 2 5.52 .06 .15 
 ASD diagnosis 2 5.57 .06 .15 
 Intellectual disability  1 1.17 .23 -.08 
 Level of impairment 2 2.19 .33 .10 
Note: *** significant at p <.001 
 
The relationship between medication status (current user, previous user, 
non-users) and difficulty managing behaviour was examined. A Chi-Square Test 
indicated a significant relationship between medication status and presence of 
challenging behaviour, χ2 (n = 245, df = 2) = 27.60, p <.001, Cramer’s V =.24. 
Findings indicated that those who reported the child/dependent adult had 
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challenging behaviour, or sometimes had challenging behaviour, were more likely 
to report current medication use than those who did not. 
A Kruskal-Wallis Test was conducted to determine if there were 
significant differences between the numbers of challenging behaviour across the 
three medication status groups (current user, previous user, non-user). A 
significant difference between the number of challenging behaviours was 
observed across the three groups, χ2 (n = 245, df = 2) = 8.40, p =.015. This 
indicated a greater number of reported challenging behaviours among those who 
used medication, compared to those who did not. 
A Mann-Whitney U Test was conducted to determine if the presence of 
challenging behaviours related to the number of reported medications. A 
significant difference in the mean number of medications was found between 
those who reported challenging behaviours (Md = 1, n = 215) and those who did 
not. (Md = 0, n = 30), U = 2326, z = -2.617, p <.009, r =.17. That is, those with 
reported challenging behaviours were more likely to take one or more 
medications. 
Informants were requested to report specifically whether the 
child/dependent adult experienced aggression and/or impulse difficulties. Chi-
Square Tests of Independence were conducted to examine if aggression or 
impulse control related to medication status. A Bonferonni correction (Tabachnik 
& Fidell, 2007) was used; thus the alpha level was adjusted to p =.025. 
Aggression was not found to relate significantly to medication status, χ2 (n = 245, 
df = 2) = 5.23, p =.073, phi = .15. Impulse control difficulties were found to relate 
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significantly to medication status χ2 (n = 245, df = 2) = 7.55, p =.023, phi =.18. 
That is, according to informants, children and dependent adults who were 
currently using medication were more likely to experience impulse control 
difficulties than expected by chance. 
The frequency and percentage of children and dependent adults using each 
type of medication was examined according to the type of challenging behaviour 
(see Table 6.3.1.5.). Individuals who reported multiple challenging behaviours 
were allocated to more than one category of behaviour. Those children and 
dependent adults who reported using at least one anti-depressant medication were 
most commonly reported as experiencing emotion-related behavioural difficulties 
(59.1%). Alternatively, those taking at least one anti-psychotic medication were 
reported to experience at least one type of aggressive behaviour (53.6%). 
Individuals who were taking CNS stimulants were most likely to have other 
disruptive behaviours reported (58.5%), while those on hypnotic sedatives and 
anti-convulsants were most commonly reported to experience aggressive 
behaviour. 
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Table 6.3.1.5 
Frequency of Type of Challenging Behaviour According to Medication Type (n of 
medication =236) 
Medication Type 
 
n  Aggression Emotion-
Related 
Stereotyped 
Self-injury 
Other 
Disruptive 
Impulse 
Control 
Anti-depressant 66 33 39 27 32 17 
Anti-psychotic 69 37 29 31 29 17 
CNS stimulant 41 23 17 13 24 22 
Anti-convulsant 12 9 6 6 7 4 
Hypnotic sedative 22 13 9 6 22 10 
Anti-anxiety 2 2 1 2 2 1 
 
In summary, the majority of children and dependent adults were reported 
to exhibit at least one challenging behaviour. The presence of challenging 
behaviours was found to relate to the use of psychotropic medication; those with 
challenging behaviours were more likely to report current use and number of 
types of medication. Those who were taking anti-psychotic drugs had more 
reports of aggressive-type behaviours, whereas those on anti-depressants had 
more reports of emotion-related behaviours. 
6.4 Mental Health and Psychotropic Medication 
The relationship between comorbid mental health conditions and 
psychotropic medication is examined in this section of the study. First, data on 
comorbid mental health conditions across the sample is presented and explored, 
with respect to demographic variables. The relationship between medication 
status (current user, previous user, and non-users) and comorbid mental health  
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conditions is then presented, followed by any differences between those currently 
taking psychotropic medications with comorbid mental health, with those who did 
not have a diagnosis. 
Informants were requested to report whether the person with an ASD 
currently experienced any mental health difficulties, and if so, had they received a 
formal diagnosis for this condition. Approximately two thirds (66.5%) indicated 
that the child/dependent adult with an ASD had at least one diagnosed mental 
health condition. The type of mental health conditions are presented in Table 
6.4.1.1. Children and dependent adults with an ASD were most commonly 
reported to have a diagnosed anxiety disorder. A large proportion of informants 
also reported that the child/dependent adult experienced attention deficit disorder 
(ADD) or ADHD and depression, with a smaller number reporting obsessive 
compulsive disorder (OCD), oppositional defiance disorder (ODD) or bipolar 
disorder. 
Table 6.4.1.1 
Mental Health Conditions Present in Sample as Reported by Informants (N = 245) 
Mental Health Condition Presence of Condition Formally Diagnosed 
 Freq. % Freq. % 
Anxiety   185 64.5 127 51.9 
ADHD   69 28.2  60 24.5 
Depression  53 21.6  39 15.9 
OCD  7  2.9  7 2.9 
ODD  7  2.9  7 2.9 
Bipolar  3  1.2  3 1.2 
Note: ADHD = Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder, 
OCD = Obsessive Compulsive Disorder, ODD = Oppositional Defiance Disorder 
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Of note, a quarter of the sample (24.5%) reported two formal mental 
health diagnoses, and a small number (7.5%) stated the child/dependent adult had 
received three or more such diagnoses. Specifically, 15.5% of informants 
indicated the child/dependent adult had a formal diagnosis of depression and 
anxiety, 13.8% of all participants indicated a diagnosis of anxiety and ADHD, 
with a further 4.5% indicating a diagnosis of depression and ADHD. 
Chi-Square Tests of Independence were conducted to determine if the 
presence of a diagnosed mental health condition related to age group, gender, 
ASD diagnosis or level of impairment. Findings indicated that the presence of a 
mental health condition (formally diagnosed) did not significantly relate to age 
group (p =.30), gender (p =.35), or level of impairment (p =.26). A significant 
relationship was found between the presence of a mental health condition and 
ASD diagnosis, χ2 (N = 245, df = 2) = 10.85, p =.004, phi =.21. That is, higher 
numbers of children and dependent adults were found to report a comorbid mental 
health condition than expected by chance. 
Table 6.4.1.2 presents the Chi-Square results (Yates Continuity Correction 
reported as required) for the type of mental health condition and demographic 
characteristics. Bonferroni adjustments (Tabachnik & Fidell, 2007) were 
conducted to safeguard against type-one error, reducing the significance level to p 
<.01. As can be seen in Table 6.4.1.2, significant relationships were found 
between anxiety and age group, with younger age being associated with 
diagnosis; depression and age group, with those aged 19 years and over more  
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likely to be diagnosed with depression; and between depression and type of ASD, 
with more children and dependent adults with a diagnosis of Asperger’s disorder 
being diagnosed with depression. 
Table 6.4.1.2 
Relationship between Diagnosed Mental Health Conditions and Demographics (N = 
245) 
 Df χ2 p phi 
Anxiety (n =127)     
 Gender 1  2.20 .14 .11 
 Age group 4 11.16     .00** .21 
 Type of ASD  2  7.02 .03 .17 
 Intellectual disability  1  0.65 .42 -.06 
 Level of impairment 2  6.32 .04 .16 
Depression (n = 39)     
 Gender 1  1.05  .30 -.08 
 Age group 4 41.36       .00*** .41 
 Type of ASD  2 12.41     .00** .23 
 Intellectual disability  1  3.99 .05 -.14 
 Level of impairment 2  6.14 .05 .16 
ADHD (n = 60)     
 Gender 1 1.75 .19 -.09 
 Age group 4 2.33 .32 .10 
 Type of ASD  2 2.80 .25 .11 
 Intellectual disability  1 0.01 .99 .01 
 Level of impairment 1 0.94 .63 .06 
Note: *** significant at p <.001, ** significant at p <.01 
 
The relationship between medication status (current user, previous user, 
non-user) and comorbid mental health diagnosis was examined. A Chi-Square 
Test of Independence indicated a significant association between medication 
status and the presence of a diagnosed mental health condition, χ2 (n = 245, df = 
2) = 37.32, p <.001, phi =.39. This indicated that children/dependent adults who 
were reported as having a formally diagnosed comorbid mental health condition 
were more likely to be currently taking medication. 
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Further Chi-Square analyses (Yates Continuity Correction) were 
conducted to determine if there was a significant relationship between medication 
status with the three most commonly reported mental health diagnoses (anxiety, 
ADHD, depression). Bonferonni adjustments (Tabachnik & Fidell, 2007) were 
conducted, reducing the significance levels to p <.017. As shown in Table 6.4.1.3, 
medication status related significantly to a diagnosis of anxiety and ADHD, but 
not to a diagnosis of depression. This indicates that people with a reported formal 
diagnosis of anxiety and/or ADHD were more likely to be taking medication than 
those without these diagnoses. 
 
Table 6.4.1.3 
The Relationship between Medication Status and Comorbid Depression, Anxiety and 
ADHD  
 Df χ2 p phi 
Anxiety 2 10.06 .01** .20 
Depression  2  4.59      .10 .14 
ADHD 2 28.29   .00*** .34 
Note: *** significant at p <.001, ** significant at p <.01 
 
A Mann-Whitney U Test was conducted to determine if there was a 
significant difference in the mean number of medications prescribed to those who 
had a mental health diagnosis and those who did not. A significant difference was 
found in the number of medications prescribed for those who had mental health 
diagnoses (Md = 0, n =82) and those who did not (Md = 1, n =163), U = 5389, z = 
-6.25., p <.001, r =.40. That is, those with a comorbid mental health diagnosis 
were prescribed more medication than those without such a diagnosis. 
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Additional Mann-Whitney U tests were conducted to determine if there 
was a significant difference in the number of medications prescribed for children 
and dependent adults for whom there was a reported formal diagnosis of 
depression, anxiety or ADHD, compared to those without these diagnoses. 
Bonferroni adjustments (Tabachnik & Fidell, 2007) were made, reducing the 
significance level to p <.017. A significant difference was found in the number of 
medications prescribed for those who reported a diagnosis of anxiety (Md = 1, n = 
130) and those who did not (Md = 0, n = 115), U = 5238, z = -4.27, p <.001, r 
=.27, as well as in those who reported a diagnosis of ADHD. A significant 
difference was not observed in the number of medications prescribed for those 
who reported a diagnosis of depression (Md = 1, n = 41) and those who did not 
(Md = 1, n =204) U = 3262, z = -2.34, p =.019, r =.15. Significant differences 
were also observed in the number of medications prescribed for those with a 
reported diagnosis of ADHD (Md = 1.5, n = 60) and those without (Md = 1, n = 
185), U = 3205, z = -5.19, p <.001, r =.33. These results indicated that children 
and dependent adults who had a diagnosis of anxiety or ADHD were more likely 
to report taking medication. 
In summary, a large proportion of children and dependent adults with 
ASD were reported to have at least one comorbid mental health condition. 
Current use of psychotropic medication was found to relate to the presence of a 
comorbid mental health condition. Most particularly, those who reported a 
diagnosis of anxiety were more likely to be taking a greater number of 
psychotropic medications than those without anxiety. 
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6.5 Sleep and Psychotropic Medication 
This final section of Study 1 focuses on the relationship between 
psychotropic medication use and sleep. Data for sleep difficulties across the 
sample is presented, as well as any relationships between sleep difficulties and 
demographic variables. This is followed by an examination of any relationships 
between medication status (current user, previous user, non-users) and sleep 
difficulties. Finally, differences in sleep are explored in those who were currently 
taking psychotropic medication. 
6.5.1 Sleep and psychotropic medication. 
The majority of informants (69.8%) reported that the child/dependent 
adult experienced some difficulty with sleep, with 31.2% indicating the person 
had been formally diagnosed with a sleep disorder. Chi-Square Tests (Yates 
Continuity Correction) were conducted to determine if sleep difficulties related to 
gender, age group, type of ASD or intellectual disability. Bonferroni adjustments 
(Tabachnik & Fidell, 2007) were conducted, reducing the significance level to p 
<.013. As displayed in Table 6.5.1.1, no significant relationships were observed 
between sleep difficulties and demographic variables. 
Table 6.5.1.1 
Relationship between Overall Reported Sleep Difficulties and Demographic 
Characteristics (N = 245) 
 Df χ2 p phi 
Gender 2 0.36 .48 -.05 
Age group 4 1.29 .86 .07 
Type of ASD  2 3.35 .19  -.12 
Intellectual disability  1 1.48 .22 .09 
Level of impairment 2 8.52 .01 .19 
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Informants who reported the child/dependent adult with an ASD 
experienced sleep difficulties were requested to rate whether these difficulties 
occurred in the domains of falling asleep, staying asleep, or early wakening over 
the previous two weeks. Of the total children/dependent adults in the study, 
19.2% of the sample indicated sleep difficulty in at least one domain, with 20.0% 
indicating sleep difficulties in two domains, and 31.2% of the sample indicating 
difficulty in all three domains. The majority of informants who reported their 
child/dependent adult had sleep difficulties reported that the child/dependent adult 
experienced difficulty falling asleep (83.0%), with the majority (85.3%) 
indicating they had experienced moderate levels of difficulties across the three 
domains. Table 6.5.1.2 illustrates the range of reported sleep difficulties 
according to severity. 
 
Table 6.5.1.2 
Sleep Difficulties in Dependent Children/Adults According to Severity as Reported by 
Informants (n of those reporting sleep difficulties = 177) 
Sleep Difficulty 
Mild Moderate Severe Very Severe 
Total 
Freq. % Freq. % Freq
. 
% Freq. % Freq 
Falling asleep 42 23.7 59 33.3 34 19.2 12 8.2 147 
Staying asleep 49 27.6 44 24.9 19 10.7 5 2.8 117 
Waking too early  33 18.6 48 27.0 19 10.7 12 6.8 112 
Total  124  151  72  29   
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6.5.2 Mental health and sleep. 
A Chi-Square Test (Yates Continuity Correction) revealed that diagnosis 
of a mental health condition was significantly related to overall reported sleep 
difficulties, χ2 (N = 245, df = 1) = 6.63, p =.01. Further Chi-Square Tests (Yates 
Correction Continuity) were conducted to determine if there was a significant 
association between sleep difficulties and diagnosis of anxiety, depression or 
ADHD (see Table 6.5.2.1). Bonferroni adjustments (Tabachnik & Fidell, 2007) 
reduced the significance level to p <.017. A significant relationship was found 
between reported sleep problems in children and dependent adults, and diagnosis 
of an anxiety disorder. The findings indicated that children and dependent adults 
with an ASD who were reported to have sleep difficulties were also more likely to 
have a reported diagnosis of anxiety, than those who did not have sleep 
difficulties. 
 
Table 6.5.2.1 
Relationship Between Overall Reported Sleep Difficulties and Mental Health Conditions 
in Children and Dependent Adults (N = 245) 
 
 df χ2 p phi 
Anxiety 1 12.67 <.001*** -.24 
Depression 1 4.80         .028 -.15 
ADHD 1 0.00        1.00 -.00 
Note: *** significant at p <.001 
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6.5.3 Psychotropic medication for sleep. 
Sixty-nine informants reported that their child/dependent adult took 
medication to assist specifically with sleep difficulties. Fifty-nine male 
participants (47.2%) and 10 female participants (41.6%) were reported to take 
medication to assist with sleep. The medications reported as being taken by 
children and dependent adults can be seen in Table 6.5.3.1. The majority (47.8%) 
were prescribed melatonin to assist with sleep difficulties, followed closely by 
clonidine. A small number reported taking amitriptyline, and quetiapine for sleep 
purposes. Other medications reported to assist with sleep included paracetamol, 
valerian, fluvoxamine, clobazam, ziprasadone, and diazepam.  
Table 6.5.3.1 
Medications Prescribed for Sleep Difficulties According to Gender (n = 69) 
Medications Male  Female  Total  
 Freq. % Freq. % Freq. % 
Melatonin 27  45.9 6  60.0 33  47.8 
Clonidine 22  37.3 3  30.0 25  36.3 
Amitriptyline 3  5.1 - - 3  4.3 
Quetiapine 1  1.4 1  10.0 2  2.9 
Other 6  10.3 - - 6  8.7 
Total  59 100.0 10 100.0 69 100.0 
Note: Freq. = Frequency 
 
A Chi-Square Test was conducted to determine if gender related to the use 
of medication to assist with sleep. No significant difference was found, χ2 (n = 63, 
df = 2) =.51, p =.47, phi = -.13. 
A further Chi-Square Test examined the relationship between overall 
reported sleep difficulties and medication status (current user, previous user, non-
user). A significant relationship was found, with those currently using medication 
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more likely to have informant-reported sleep difficulties than those without χ2 (n 
= 245, df = 2) = 8.10, p =.017, phi =.18. A Mann-Whitney U Test was conducted 
to determine if the presence of sleep difficulties related to the number of 
psychotropic medications that a child/dependent adult was taking. A significant 
difference in the mean number of medications was found between those with 
reported sleep difficulties (Md = 1, n =171) and those without (Md = 0, n = 74), U 
= 4988, z = -2.78, p =.005, r =.18. The children/dependent adults with reported 
sleep difficulties were thus more likely to be taking a higher number of 
psychotropic medications than those without reported sleep difficulties. 
In summary, it was found that most children and dependent adults were 
reported to have difficulties with sleep. Sleep difficulties were more commonly 
observed in those with a reported diagnosis of anxiety. In addition, those with 
reported sleep difficulties were more likely to be currently using psychotropic 
medication, and a greater number of medications, than those without sleep 
difficulties. 
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Chapter 7: Study 1 Discussion 
The purpose of Study 1 was to gain a comprehensive understanding of the use 
of psychotropic medication in an Australian sample of children and dependent adults 
with an ASD, from the perspective of caregivers. Psychotropic medication use 
according to gender, age, ASD diagnosis and intellectual disability was examined, 
with a particular focus on those who reported challenging behaviours, comorbid 
mental health conditions and sleep difficulties. There is now a considerable amount 
of international literature on psychotropic medication use in people with disabilities 
(e.g., Brylewski & Duggan, 2004; McGillivray & McCabe, 2004), including some 
specifically focused on people with ASD (e.g., Aman et al., 2003, 2005; Jesner et al., 
2007; Morgan et al., 2003). However, these studies predominantly involve 
administrative or clinical samples and there is less knowledge about community-
based individuals and relatively little understanding from the caregivers’ 
perspectives. This study is an attempt to address this gap. 
While previous research has examined the use of psychotropic medications in 
Australians with disabilities (e.g., McGillivray & McCabe, 2004; Webber et al., 
2010), the first study is now quite dated; in both studies, samples were drawn from 
administratively collected data on individuals who resided in or accessed state funded 
accommodation or other services. Further, both the cohorts included all disability 
types, who were reported on the basis of medication used for behaviour management. 
In contrast, Study 1 attempted to capture evidence for psychotropic medication use in 
children and dependent adults, who are primarily living in family based care in 
Australia, were likely to have been overlooked by previous research, and who had an 
 Psychotropic Medication and ASD
   
 
 
115 
 
ASD. By increasing knowledge of psychotropic medication use in children and  
dependent adults with an ASD in this population, the capacity to tailor clinical and 
research investigations to meet the needs of these individuals and their caregivers will 
be improved. 
In this chapter, the findings of Study 1 are systematically explored and 
discussed in the context of previous research. The characteristics of psychotropic 
medication use are discussed in the context of the sample. Consideration is then given 
to caregivers’ views on medication and the difference in psychotropic medication use 
among those who have a comorbid mental illness, challenging behaviour and sleep 
problems. The discussion includes acknowledgement of the limitations of this 
research, recommendations for future research, as well as suggestions for clinical 
practice. 
7.1 Sample Characteristics 
Since there is a dearth of Australian research exploring psychotropic 
medication use in children/dependent adults with an ASD, it was imperative to 
provide an accurate description of the sample in terms of demographic 
characteristics. The sample of individuals with an ASD, subject to informant 
report, was comprised of similar proportions of individuals diagnosed with 
autistic and Asperger’s disorder, with few diagnosed with PDD–NOS. 
Specifically, there were slightly more reports on individuals with Asperger’s 
disorder than autistic disorder, a pattern that is inconsistent with previous 
research, indicating a higher rate of autistic disorder compared to those with 
Asperger’s disorder (e.g., Fombonne et al., 2006, Williams et al., 2008; Lazoff et 
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al., 2010). A recent meta-analysis by French and colleagues (2013) concluded that 
epidemiological data comparing rates of Asperger’s disorder and autistic disorder 
were questionable, due to the recent use of the term ‘high functioning ASD’, and 
issues surrounding the diagnosis of Asperger’s disorder as separate from this 
(French et al., 2013). It is therefore plausible that the rates of autistic disorder to 
Asperger’s disorder observed in this study reflect this trend. The lower level of 
participants with PDD–NOS observed in this study is consistent with previous 
research, suggesting this disorder has a lower prevalence rate than autistic 
disorder and Asperger’s disorder (Fombonne et al., 2005; Williams, 2005). 
The gender comparison of participants in this study was observed at a rate 
of four males per one female. This finding is consistent with previous research 
suggesting a 4:1 ratio of male to females diagnosed with an ASD (Holtmann, 
Bōlte & Poustka, 2007; Fombonne, 2005; Morgan et al., 2002), and thus appear 
representative. Of note, the study did not include any female participants over the 
age of 30. This may be due to the historical nature of ASD being considered more 
prevalent among males (Baron-Cohen, Lombardo, Auyeung, Ashwin, Chakrabarti 
et al., 2011). It is therefore possible that the findings discussed below may not be 
representative of trends in adult females diagnosed with an ASD and the 
generalisability of results beyond this subgroup are thus limited. 
The focus of this study was on capturing data from individuals who 
resided in home-based care situations. Consistent with this aim, the overwhelming 
majority of caregivers who provided data for this study resided full time with the 
child/dependent adult, on behalf of whom they completed the questionnaire. The 
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majority of individuals subject to report were aged between three and 18 years, 
with only a small number aged over 19 years. This may be a reflection of care 
giving years being predominantly associated with children; with older individuals 
more likely to have entered alternative living arrangements. The predominantly 
younger age group observed is likely to have resulted from the focus being on 
those who resided in home-based care situations. 
A high rate of comorbid intellectual disability was evident in those who 
had a diagnosis of autistic disorder, with a relatively low level of comorbid 
intellectual disability in those with Asperger’s disorder. This finding is consistent 
with previous research showing similar rates of comorbidities between autistic 
disorder and intellectual disability (Deb & Prasad, 1994; Fombonne, 2003b; 
Morgan et al., 2002). This finding has likely been to have been confounded on the 
basis of what psychometric instruments were used to diagnose intellectual 
disability. That is, those with an intellectual disability may have been more likely 
to have lower expressive language capacity and therefore more likely to have 
received a diagnosis of autism as opposed to Asperger’s disorder. This situation is 
likely to be rectified by the consolidation of the three disorders and the new 
criteria of the DSM-V (APA, 2014). 
7.2 Prevalence 
Although limited by the self-selecting nature of the sample, the data 
obtained provides some indication of medication use extent in community-based 
children and dependent adults with ASD. The majority of children and dependent 
adults with an ASD, who were subject to report, were taking at least one 
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psychotropic medication. The rate of psychotropic medication use observed in 
this study was comparable to that in America (Aman et al., 2002, 2005); however 
it was less than the rate recently observed in Iran (Memari et al., 2012). This may 
be a result of differences in prescriptions across developing as opposed to 
developed countries, or different sampling procedures. 
Only a small proportion of children/dependent adults in this study were 
reported as having previously used psychotropic medication. Again, this may 
reflect a sampling bias (e.g., carers of people who have previously taken 
medication may be less inclined to participate in a study on medication). 
Alternatively, this may reflect a situation whereby individuals who receive 
psychotropic medication predominantly stay medicated over time. In a 
longitudinal study, Esbensen and colleagues (2009) reported an increase in the 
number of adolescent and adults with ASD taking psychotropic medication over 
time, as well as an increase in the number of medications they were taking. This 
may be a result of prescribers/caregivers having more concerns (medical and 
ethical) about prescription of psychotropic medication to younger children, given 
a lack of data on effectiveness and long term side effects in children. The findings 
also concur with those of Esbensen et al. (2009) and who concluded that once an 
adolescent/adult commenced psychotropic medication, it was highly unlikely the 
medication would be discontinued  
In the current study, the most commonly reported type of medication was 
anti-depressants, followed closely by anti-psychotics. Previous research has 
identified an increase in the use of anti-depressants in people with ASD (Aman et 
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al., 2005; Esbensen et al., 2009) and an increasing trend to treat anxiety symptoms 
in this population with SSRIs. There are suggestions that anti-depressants reduce 
‘autistic behaviour’ (Aman et al., 1999; Esbensen et al., 2009). This is consistent 
with the low use of anti-anxiety medication observed in this study, despite a large 
majority of participants having a diagnosed anxiety disorder. This is consistent 
with the use of anti-depressants to treat anxiety disorders in the general 
population (Barlow & Durand, 2005). In addition, common anxiolytics, such as 
benzodiazepine, are recognized as having an addictive potential and so are 
unlikely to be used to treat pervasive anxiety (Barlow & Durand, 2005). It thus 
appears unlikely that these medications would be prescribed to young children in 
other than an isolated situation. 
Children and dependent adults were commonly reported to take anti- 
psychotic medication. This finding is consistent with previous research in which 
increasing levels of anti-psychotic use (particularly atypical anti-psychotics) in 
this population, when compared to other psychotropic medications, are reported 
(Aman, 2002; Aman et al., 2005; Esbensen, 2009). The findings are consistent 
with other research indicating these medications are used to treat irritability and 
challenging behaviours in individuals with an ASD (Aman & Madrid, 1999; 
Esbensen et al., 2009; McDougle et al., 2000). 
In this study, the most commonly reported psychotropic medication was 
Risperidone, which is on the PBS in Australia, as a recognised treatment for 
severe behavioural disturbance in children and adolescents with autism 
(Australian Government, 2007). A Cochrane Review, conducted by Jesner et al 
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(2009), identified some benefits of using Risperidone in treating irritability, 
repetition and social withdrawal in people with an ASD. However, it is also 
noteworthy that the authors cautioned a decision to use this medication demanded 
consideration of the balance between the advantages and disadvantages, 
particularly the adverse side effects associated with its use (e.g., weight gain). 
Given the high level of participants reporting taking anti-psychotic medication, 
there is a clear need for further randomised controlled trials into the effectiveness 
of different anti-psychotic drugs, as well as longitudinal studies focusing on any 
long term side effects in this population. 
CNS stimulants were the next most commonly reported psychotropic 
medication in this study. Over a quarter of those reported as taking medication 
were taking a CNS stimulant, with the majority indicating methylphenidate. This 
appeared to be higher than reported in previous studies (e.g., Esbensen et al., 
2009) and may reflect different diagnostic trends, related to the high number of 
participants diagnosed with comorbid ADHD, or to the predominantly younger 
age of this current sample. The use of stimulant medication among those with 
ASD appears controversial; with research indicating that stimulants are not as 
effective in individuals with ASD compared to those in the general population 
(Aman, 1996; Aman & Langworthy, 2000) and with it being hypothesised that 
stimulants may exacerbate anxiety in those with an ASD. However, three recent 
studies have indicated positive effects on ADHD symptoms from administration 
of a non-stimulant, atomoxetine, and with claims that adverse events were no 
worse in children with ASD than neurotypical children (Aman et al., 2008). 
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Despite the conflicting evidence, many Australian children and dependent adults 
with an ASD appear to be using CNS stimulants. This finding highlights a need 
for further examination of the evidence base to support CNS stimulant use in this 
population. 
In the present study, a large number of children and dependent adults were 
reported as receiving more than one different psychotropic medication; either 
from the same type of medication (e.g., anti-psychotics) or from different types 
(e.g., anti-psychotic and anti-depressant). The rates of polypharmacy were higher 
than those reported in previous research in Ohio, USA (Aman et al., 2003). This 
may reflect a general trend for increasing rates of prescribing psychotropic 
medications to individuals with ASD (Aman et al., 2005; Esbensen et al., 2009). 
It may also be explained by the trend for the ongoing use of medication 
once initiated, with additional medications added to address further symptoms and 
behaviours as they arise (Aman et al., 2005; Esbensen et al., 2009). The need for 
further education concerning the benefits of each type of medication, as well as 
examination of the interactions between medications prior to their prescription is 
clearly needed to determine if it results in increased side effect profiles or reduced 
tolerances (Williamson & Martin, 2012). 
No relationship was found between psychotropic medication use and 
levels of cognitive impairment or severity of ASD in the present study. This is 
inconsistent with previous research, which indicated that more severe ASD 
impairment and cognitive impairment were related to increased rates of 
psychotropic medication use (Aman, Lam & Collier-Crespin, 2003; Aman, Lam 
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& Bourdegion, 2005). Although this may result from differing sampling 
procedures (community versus clinical populations), it may also reflect a 
difference in patterns of prescribing across countries, or may indicate a change in 
prescription trends. Regardless, it was evident that in this Australian community 
sample, more severe impairment and/or more impaired cognitive functioning did 
not make it more likely that children/dependent adults would be prescribed 
psychotropic medication. More sophisticated measures of impairment would be 
required to determine this, which was beyond the scope of this study. In addition  
to gaining some understanding of the characteristics and extent of psychotropic 
medication use among this population, it was important to explore the role of 
gender and age in medication use. 
7.3 Gender and Age 
The hypothesis that males would be more likely to be receiving 
psychotropic medication than females was not supported by the current study. 
Males and females were reported as equally likely to be taking psychotropic 
medication. This supports similar research conducted by Memari et al. (2012), 
whereby no differences in psychotropic drug use were identified according to 
gender. However, these findings contrast with previous research by Aman et al. 
(2002, 2005), who suggested that males were more likely to take psychotropic 
medication than females. The lack of gender distinction in the current study may 
be a result of the small number of female participants; alternatively, it may reflect 
different prescribing practices in Australia, or be a consequence of changes in 
prescription or diagnostic trends. It is possible, for example, that increases in 
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recognising girls with ASD is resulting in more of those with concomitant mental 
health issues being identified: such that females and males are equally likely to be 
prescribed medications. While the mean number of medications taken by male 
and females was similar, it was important to note the trend for a slightly higher 
number of medications being reported in female participants. This highlights the 
need for further examination of psychotropic medication prescription patterns 
regarding females.  
Although trends in the type of psychotropic medication appeared to be 
similar across genders, with anti-depressant and anti-psychotic medication being 
the most commonly prescribed medications for both females and males, it is 
noteworthy that only males took anti-convulsant medication (except for the stated 
treatment of epilepsy). This differs from research by Memari and colleagues 
(2012) who found that more females than males were prescribed anti-convulsants 
in Iran. However, Memari et al.’s findings included the use of anti-convulsants 
used primarily for epilepsy. The findings of the present study may therefore 
reflect the exclusion of those who used this medication for treating epilepsy. 
However, it is also plausible that prescription practices differ across countries. 
In addition to examining the relationship between gender and medication 
use, the relationship between age and medication use was explored in Study 1. On 
the basis of the literature (e.g., Aman et al., 2003, 2005), it was hypothesised that 
the use of psychotropic medication would increase with age. This was examined 
by comparing current medication status and the extent of use in those who were 
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currently in receipt of medication. The hypothesis was partially supported, with a 
higher number of psychotropic medications associated with increasing age. 
However, the findings did not indicate any difference in the age of those 
who currently used, had previously used or had never used. The relationship 
between age and the number of medications could be explained thus: once 
psychotropic medication was commenced it was accepted as an ongoing treatment 
modality and more medications were added, rather than removed or changed 
(Esbensen et al., 2009). Alternatively, the relationship may be due to increased 
difficulty in managing a person with an ASD as they developed in size and 
strength, possibly increasing risks to self and others. This highlights the 
importance of regularly reviewing the rationale for each medication as the person 
ages. 
Prior research has established differences in types of psychotropic 
medication prescribed across age groups (Memari et al., 2012). In the present 
study, children aged three to 11 were most commonly prescribed anti-psychotics, 
whereas those aged 12 to 18 years and <19 years were most commonly prescribed 
anti-depressant medications. This indicates prescribing differences in Australia 
according to age. This may be a result of the PBS introduction in 2008 of 
risperidone as a treatment modality for behaviours in those with an ASD 
(Australian Government, 2008); older children may have already commenced 
alternative medication prior to this change. However, this may also reflect 
differences in prescription practices across age groups by different professionals. 
The results indicated that a growing number of children were being prescribed 
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anti-psychotic medication in Australia. It is unclear at what age these children 
commence psychotropic medication, and the effect this may have on their 
development is not known. The high level of psychotropic medication use (57%) 
in children aged three to 11 is a concerning finding, given there are no 
randomised controlled trials evaluating medication in children with ASD who are 
this young. Given the adverse side effects that have been identified and the 
possibility that the effect these may have (specifically on children), there is a need 
for careful consideration prior to deciding to use medication in children and 
adolescents (Jesner et al., 2009).  The present findings highlight the need for 
prospective follow up by prescribers of established metabolic and physical 
parameters to determine if the medications are adversely affecting the child. 
7.4 Attitudes and Perceptions of Caregivers 
A key aim of this study was to explore caregivers’ perceptions of why 
their child/dependent adult was taking psychotropic medication, and their 
attitudes towards its use. The predominant reason stated for medication was the 
existence of a comorbid mental health condition (42.7%), followed closely by the 
presence of challenging behaviour (35.3%). This suggests that a considerable 
proportion of children and dependent adults with ASD in Australia, primarily 
residing in the care of their parents, receive psychotropic medication for the 
primary purpose of behavioural management (according to their carers). 
However, the two categories (behaviour management and mental health) are not 
mutually exclusive and the findings may reflect the understanding of the caregiver 
of these terms or alternatively the capacity of the mental health clinician to 
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accurately diagnose a mental health condition in this population. This can be 
particularly difficult with children/dependent adults with a co-morbid intellectual 
disability. Further, large numbers of this population were reported to have a 
diagnosed comorbid mental health condition that was being treated with 
psychotropic medication. 
Although the debate regarding the use of these drugs for children and 
adults with ASD continues, their use appears widespread. As previously stated, 
this highlights a significant need for further controlled evaluations of these 
medications in children and dependent adults. Moreover, ongoing education is 
required for caregivers surrounding the various interventions available and their 
potential side effects and relative efficacy. 
In addition to determining the reasons for psychotropic medication use, 
another aim of this study was to explore how caregivers perceived medication in 
terms of managing ‘challenging behaviour’, or the treatment of comorbid 
psychiatric conditions in children and dependent adults with an ASD. The 
overwhelming majority of caregivers reported they felt the medication was both 
helpful for themselves, in managing their child’s emotions or behaviours, as well 
as helpful to the person for whom they cared. The majority of caregivers endorsed 
the items ‘Medications make the person I care for more relaxed’, and ‘The person 
I care for is happier on medication’. Despite this overall positive view expressed 
by caregivers, the literature remains conflicted over the helpfulness of 
psychotropic medication in those with an ASD: many argue there is little clinical 
evidence of efficacy in treating core symptoms of ASD (e.g., Antonacci, Manuel 
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& Davis, 2008; Brylewski & Duggan, 1999; Gralton, James & Lindsey, 1998). Of 
course, the current findings may reflect the sampling methodology, whereby 
perhaps those caregivers with more positive views are more interested in 
participating in the research; or it may result from a tendency for caregivers to 
validate their use of medication. However, it could also reflect a situation 
whereby the medications are effective in the management of challenging 
behaviours or concomitant symptoms of mental ill health. There is clearly a need 
for further controlled research to explore the equivocal findings regarding clinical 
benefits, against those largely positive views expressed by caregivers. 
As previously mentioned, concerns have been raised about the side effects 
of psychotropic medication on individuals with an ASD (e.g., Jesner et al., 2007; 
Valdovinos et al., 2005). For example, Jesner et al. cautioned that the adverse side 
effects associated with Risperidone use (in particular, weight gain) should be 
considered when evaluating the advantages and disadvantages, prior to deciding 
to use this medication. Nonetheless, the large majority of caregivers in this study 
endorsed the item ‘For the person I care for, the good things about medication 
outweigh the bad.’ It is unclear whether the side effects are truly minimal in 
comparison to the benefits of the medication. The impact of negative side effects 
may be negated by caregivers in light of the perceived gains for the individual, or 
in terms of the caregiver’s capacity to care for them. 
Approximately half the caregivers endorsed the item ‘I feel it is up to the 
doctor to decide when the person I care for should stop taking their medication.’ 
This indicated deferred decision making to the prescribing professional highlights 
 Psychotropic Medication and ASD
   
 
 
128 
 
the need for medical professionals to undertake frequent reviews of the purpose 
and effectiveness of medication, in consultation with caregivers. 
Medication that is primarily given for the purpose of ‘behavioural control’ 
in a person with a disability is widely regarded in the literature as restrictive (e.g., 
Finn & Sturmey, 2009; Palley, 2006; Victorian Government, 2009). In the present 
study, most of the caregivers did not believe that the medication their 
child/dependent adult took restricted behaviour. This was consistent for all types 
of medications. Similarly, when analysed according to the reason for medication 
use, the majority of caregivers reported they did not perceive the medication as 
restrictive for the child/dependent adult. Despite this view, the large majority of 
caregivers endorsed the following: ‘The person I care for is on medication to 
control their behaviour.’ Therefore, there appears to be a disparity between 
caregiver perceptions and what the literature considers as restrictive. This may 
reflect different population samples (residential, community, institutional). This 
potentially highlights the need for caregiver education and discussion around 
medication use, and what constitutes restrictive practices. In addition to 
establishing the attitudes and perceptions of caregivers regarding the use of 
psychotropic medication, it was important to determine if gender or age related to 
medication use. 
7.5 Challenging Behaviour and Psychotropic Medication 
Another important aim of Study 1 was to explore the relationship between 
the presence of challenging behaviours and the use of psychotropic medication. 
According to the caregiver respondents, approximately half of the children and 
 Psychotropic Medication and ASD
   
 
 
129 
 
dependent adults exhibited some form of challenging behaviour. This was 
consistent with previous estimates of challenging behaviour in those with an ASD 
(e.g., Emerson, et al., 2001; Kerth, Progar & Morales, 2009; Murphy, Macdonald, 
Hall & Oliver, 2000; Myers & Johnson, 2007). 
It was hypothesised that individuals demonstrating challenging behaviours 
were more likely to be prescribed medications than those without challenging 
behaviours. This hypothesis was supported, with psychotropic medication use 
associated with the presence of challenging behaviours. In addition, those who 
were currently taking medication had a higher number of reported challenging 
behaviours, compared with those who had previously used or had never used 
medications. These findings are consistent with previous research demonstrating a 
link between psychotropic medication use and the presence of challenging 
behaviour in those with an ASD (Witwer & Lecavalier, 2005). This is likely 
because children/dependent adults with challenging behaviour are by definition 
more difficult to manage; as such, their caregivers may have sought assistance 
from medical professionals. 
Interestingly, while aggressive behaviours were the most commonly 
reported type of challenging behaviour in the current sample, those who currently 
used psychotropic medication were not more likely to report aggressive 
behaviours than those who had never used or had previously used medication. 
While aggressive behaviours were not found to relate to overall 
psychotropic medication status, it was found that those who were currently taking 
anti- psychotic medication were more likely to exhibit aggressive behaviours than 
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those who were not. This finding was consistent with research investigating those 
with an intellectual disability, which found that patients exhibiting aggressive 
behaviours were more likely to be taking anti-psychotic medications (Allington-
Smith, 2006; McGillivray & McCabe, 2005). Individuals with aggressive 
behaviour were therefore not necessarily more likely to be taking medication than 
those without; however, if they were prescribed medication they were likely to be 
prescribed an anti-psychotic. 
In addition, those who were reported with impulse control difficulties 
were more likely to be currently taking psychotropic medication. Impulse control 
difficulties are not considered a core symptom of ASD; however they are 
commonly associated in those with the disorder (Kadesjo & Gillberg, 2011; 
Nazeer, 2011). Therefore, children/dependent adults who express impulse control 
difficulties may be more likely prescribed medication for these difficulties, given 
the evidence base supporting its effectiveness (Nazeer, 2011). This suggests that 
clinical interventions tailored to prevent or minimise psychotropic medication use 
may benefit from focusing on improving impulse control difficulties in children 
and dependent adults with an ASD with consideration to the effect size each 
produces.    
The findings discussed in this section, on the use of psychotropic 
medication in association with challenging behaviour, indicate that challenging 
behaviours were highly prevalent in this sample. Moreover, those who had 
challenging behaviours were more likely to be taking psychotropic medication. 
As such, thorough clinical assessments appear to be warranted when caregivers 
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present with their dependent child/adult for medication. This would assist in 
identifying the type of behaviours, and whether or not these stem from a 
comorbid condition. It appeared that some caregivers identified emotion-related 
difficulties as challenging behaviours; as such, it is important when conducting 
assessments that consideration is given to the presence of a mental illness in 
children/dependent adults with an ASD. The findings further illustrated the 
importance of education for caregivers around the difference between challenging 
behaviours and mental illness. This may enable caregivers to respond 
appropriately to different presentations and reframe the behaviour. 
7.6 Comorbid Mental Health Conditions and Psychotropic 
Medication 
An additional aim of Study 1 was to examine the level of comorbid mental 
health conditions among children and dependent adults with ASD, and to explore 
its relationship with psychotropic medication use. The majority of 
children/dependent adults were reported to have at least one comorbid mental 
health condition. This was higher than findings in previous research, focusing on 
adults with an ASD and an associated intellectual disability (Morgan et al. 2003), 
and those examining children and adolescents with an ASD (Ghazziuddin, 
Weidmer-Mikhail & Ghazziuddin, 1998). This finding may result from caregivers 
reporting conditions that have been diagnosed over a lifespan, not understanding 
diagnosis or increasing rates of the recognition of comorbid conditions in children 
and dependent adults with an ASD. Alternatively it may be harder to elicit the 
information required to make a diagnosis with confidence in those with a co-
 Psychotropic Medication and ASD
   
 
 
132 
 
morbid intellectual disability than in the current sample population. Regardless, 
the findings suggest a high level of reported comorbid conditions; as such, 
tailoring interventions (both medical and psychosocial) specifically for those with 
an ASD may prove beneficial. This is especially important, given that the 
presence of psychiatric symptoms predicts social and academic functioning 
(Gadow et al, 2008). 
The most commonly reported diagnosed comorbid mental health condition 
in the children and dependent adults involved in Study 1 was anxiety. Much 
debate has centred around whether anxiety is a symptom of ASD or is a separate 
comorbid condition (Matson & Nebel-Schwam, 2007). Nevertheless, many 
caregivers reported that their child/dependent adult had been diagnosed with an 
anxiety disorder. In this study, it was not possible to confirm the validity of the 
informant reports of a diagnosis. Their response may be based on 
acknowledgement of anxiety by professionals, either as a component of the ASD, 
or as a separate comorbid condition. This finding highlights the importance of 
clinical interventions targeting anxiety in this population. Clinically, the need for 
tailored intervention is likely to be similar regardless of whether an anxiety 
disorder is considered separate to, or a component of, the ASD.  
The study also found a high prevalence of reported ADHD, which was 
somewhat surprising, given the DSM-IV-TR (APA, 2000) stipulation that ADHD 
should not be diagnosed during the course of a PDD (this has since been 
addressed by the DSM-V (APA, 2014)). Despite this stipulation, ADHD has been 
identified as one of the most commonly diagnosed comorbid conditions 
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(Goldstein & Schwebach, 2004). Hyperactivity and impulsivity are regularly 
displayed by people with ASD (Kadesjō & Gillberg, 2001), although much debate 
has surfaced in the literate surrounding whether impulsivity and hyperactivity are 
core symptoms of ASD or separate disorders (Kadesjo & Gillberg, 2011; Nazeer, 
2011). Similarly, in the current study there appears to be a disparity between 
diagnostic criteria and diagnostic practice, in terms of comorbid ADHD in 
children and dependent adults with an ASD. 
Compared to previous research (e.g., Ghaziuddin, Weidmer-Mikhail & 
Ghaziuddin, 1998) examining depression rates in adolescents and adults with 
Asperger's disorder, lower rates of diagnosed depression were reported in this 
sample. This may reflect differences between the samples. In particular, previous 
research focused on psychopathology in adolescents and young adults, whereas 
the present study incorporated a large number of children. Further, the current 
sample was community-based, rather than clinical. The discrepancy may also 
arise from the high number of participants with an ASD and intellectual disability 
in the current sample. Depression may be more difficult to diagnose in this 
population, due to differential symptom presentation (Matson & Nebel-Schwalm, 
2007). Collectively, the findings indicated a high level of reported diagnosis of 
comorbid conditions in children and dependent adults with an ASD. Comorbid 
mental health conditions are clearly relevant to examining rates of psychotropic 
medication. 
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Consistent with previous research (e.g., Mandell et al., 2008; Memari et 
al., 2012; Morgan et al., 2003), children and dependent adults with a comorbid 
mental illness were more likely to be taking psychotropic medication than those 
without a diagnosis. Once a comorbid diagnosis was made, it appeared likely it 
would be treated pharmacologically. Specifically, those who were reported to 
have a diagnosis of anxiety or ADHD were more likely to be taking psychotropic 
medication (as well as a higher number of such medications) than those who did 
not have these diagnoses. However, a diagnosis of depression was not found to be 
related to psychotropic medication use. This may be attributed to the smaller 
number of participants (15.9%) having a diagnosis of depression. Conversely, it 
may reflect that those with depression were less likely to be treated with 
medication. Regardless, the finding was somewhat surprising, given the high level 
of anti-depressant medication use reported in this study. It is possible that 
medication is more likely to be sought and/or prescribed for ADHD and anxiety, 
due to the overt nature of the symptoms (Nazeer, 2011). In contrast, symptoms of 
depression (e.g., withdrawal, apathy) may be less apparent or challenging, 
resulting in less help-seeking among caregivers and/or less prescription by 
medical practitioners. 
7.7 Sleep and Psychotropic Medication 
Consistent with previous research (Richdale, 2001; Polimeni et al., 2005), 
the majority of children/dependent adults with an ASD were reported to 
experience sleep difficulties. The most commonly reported sleep difficulty was 
related to falling asleep, which was similar to that estimated in the literature 
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(Polimeni et al., 2005). In addition, it was found that one third of the sample with 
sleep difficulties had a diagnosed sleep disorder, as reported by their caregivers. 
The level of sleep disturbance observed in this sample is particularly pertinent, as 
sleep difficulties persist across the lifespan, and thus are likely to influence these 
individuals for many years (Goldman, Richdale, Clemons & Malow, 2012). Sleep 
difficulties have been associated with intensified symptoms of autism, higher 
levels of psychiatric comorbidities, and higher levels of challenging behaviour 
(Goldman et al, 2012; Malow et al., 2012; Schreck, Mulick & Smith, 2004; 
Taylor et al., 2012). 
A higher prevalence of comorbid mental health conditions was also found 
among those with sleep difficulties. In particular, children and dependent adults 
with an ASD who had a comorbid diagnosis of anxiety were more likely to have 
sleep difficulties reported than those without. This link is consistent with previous 
suggestions that sleep difficulties in those with an ASD are related to increased 
anxiety (Paavonene et al., 2003; Richdale, 1999). These findings highlight sleep 
disturbance and anxiety as significant issues in this population that warrant 
consideration when individuals with ASD present for treatment. 
Further, previous research has established that those with an ASD who 
have sleep difficulties are more likely to exhibit challenging behaviour and 
comorbid mental illnesses (Goldman et al, 2012; Malow et al., 2006; Schreck et 
al., 2004; Taylor et al., 2012). On the basis that challenging behaviour and 
comorbid mental illness are considered predictors for the use of psychotropic 
medication (Matson & Nebel-Shwalm, 2007; Morgan et al., 2003), it was 
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hypothesised that individuals with sleep difficulties would be more likely to be 
taking psychotropic medication, as well as a higher number of medications. This 
was supported, with those who reported sleep difficulties more likely to be taking 
psychotropic medication, and a higher number of medications than those without 
sleep difficulties. 
Approximately a third of those who reported sleep difficulties were taking 
a specific psychotropic medication for sleep, with the majority also reporting 
melatonin use. This is consistent with recent research in which melatonin has 
been found to be effective in improving sleep in children with an ASD, 
particularly sleep onset (Leu et al., 2011; Wright et al., 2011). Intervention for 
sleep difficulties in children and dependent adults with an ASD commonly 
appears to be pharmacologically based and may have contributed to the level of 
polypharmacy observed in this sample. 
7.8 Limitations and Directions for Future Research 
This study has provided an analysis of psychotropic medication in a 
community-based sample of children and dependent adults with an ASD from the 
perspective of caregivers. The findings must be viewed in light of several 
limitations. Foremost is the possibility that the sample may not be representative 
due to ascertainment bias. There are a number of factors that could have 
contributed to this possibility. First, respondents who elect to participate in an 
online survey would be more likely, for example, to be caregivers of individuals 
with ASD who are administered psychotropic drugs. Second, they may also be 
more likely to have a particular interest in, or strong views about, the topic. Third, 
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due to the significant skew in the age distribution of children and dependent 
adults towards younger people (≤18 years), it is likely that a large proportion of 
people with an ASD (>18) were not captured in this study. Although a positive 
feature of this study was its focus on individuals living in the community who 
may not have been included in previous studies, the methodology also means that 
older individuals with more severe impairment who reside in government run 
accommodation are unlikely to be included. It is not known if prescribing patterns 
differ in this population. 
In addition, the study utilised predominantly online methods for 
recruitment and completion of the questionnaire. This allowed for the anonymous 
collection of sensitive information across a broad population of children and 
dependent adults with an ASD and their caregiver’s, however, it also limited the 
generalisability of the study. Considering participants required computer and 
internet access in order to complete the questionnaire, this suggests that the 
current study may have recruited caregiver’s with higher education levels and 
socio-economic status than those who did not have access to computers or the 
internet. While a paper version of the questionnaire was available it was not 
readily accessed. It would be beneficial for further studies to clarify the 
association between education level and socio-economic status when 
investigating caregiver perspectives. 
The reliability of some of the findings may also be limited as the data 
provided by caregivers may not be accurate. No supporting documentation was 
requested in relation to diagnosis of ASD, comorbid mental health conditions, 
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psychotropic medication, sleep difficulties or challenging behaviours. While the 
focus of this study was on obtaining caregivers viewpoints, it is important to 
acknowledge that caregivers’ perspectives do not always reflect those of the 
individuals they are reporting for (Hope et al., 1999). It is suggested that future 
research would be strengthened by including data from multiple sources to cross- 
reference the accuracy of caregiver reporting and from exploring and comparing 
individual and caregiver viewpoints surrounding psychotropic medication use to 
determine if there are differences in views and attitudes. 
In addition, there were few caregivers who reported that their 
child/dependent adult had previously taken psychotropic medication. This may 
simply be because there are relatively few of these as noted in previous research 
(Esbensen et al., 2009). Alternatively, it may be because these individuals did not 
feel the study related to them and therefore chose not to participate. Further 
investigation of those who have previously used psychotropic medication and 
discontinued it would be valuable. This would allow for exploration of why this 
group ceased using medication and more extensive analysis of the differences 
between this group and those who continue with medication. 
A further limitation of the study was that caregivers' were reporting the 
behaviours of the child or dependent adult with ASD that they found personally 
challenging. The interpretation of behaviour as 'challenging’ is subjective, and 
thus possibly dependent on individual views as well as other factors, such as their 
parental efficacy, level of stress and mental state (Gray, 2003). The conclusions 
that can be drawn with relation to challenging behaviour are therefore limited to 
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subjective caregiver accounts. On the other hand, gaining personal caregiver 
experiences of challenging behaviour added valuable information to the literature. 
It would be of benefit to examine psychotropic medication use and challenging 
behaviours where an objective measure of behaviour was included such as the 
developmental behaviour checklist (Einfeld & Tonge, 1995). 
It is important to note that the majority of caregivers indicated that they 
used a range of different interventions (e.g., positive behaviour support, social 
stories, speech therapy, communication aids) in addition to psychotropic 
medication for behavioural management. This study's primary focus was on the 
use of psychotropic medication as a treatment rather than as a component of a 
treatment approach. There has been recent research indicating the benefits of 
psychotropic medication in combination with behaviour management programs 
when compared to medication alone in children with an ASD (Arnold et al., 
2012). Consequently, the findings of the present study need to be viewed in the 
context that there were likely to have been other interventions that impacted 
caregivers’ perspectives. It was beyond the scope of this study to compare those 
who used additional interventions as well as medication. Future research would 
benefit from exploring further the different treatment approaches caregivers use in 
addition to medication to assist in determining the perceived helpfulness of the 
different approaches. 
It was not possible in the present study to examine and compare the level 
of psychotropic medication use in terms of dosage. This was made particularly 
difficult by the manner in which the information was collated, but also levels can 
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be highly variable based on individual characteristics (e.g., height, weight). It 
would be helpful for future research to be able to compare and examine the 
different levels of psychotropic medication and caregivers perceptions of the 
effectiveness. 
It is possible that the findings relating to the DAI (Hogan & Awad, 1983) 
have some level of bias as the inventory was explicitly designed to help to 
increase compliance with psychotropic medication. It is likely that caregivers had 
viewpoints and attitudes that were not captured by the DAI. Consequently future 
research may benefit from exploring attitudes from a qualitative perspective, thus 
not limiting the scope of caregivers responses with relation to psychotropic 
medication use.  
The findings from Study 1 have been conducted with the current DSM-IV- 
TR (APA, 2000) criteria for ASD. As previously mentioned the proposed changes 
to DSM-V (due for release in 2013) would possibly alter the diagnosis of some 
participants in this study. Thus it is possible that some participants would not 
continue to meet the criteria for ASD. While the complexities of such changes are 
not able to be addressed in this Study (see Gensler, 2012; Kurita, 2012; Mandy, 
Charman & Skuse, 2012), it may impact the future generalisability of the findings 
to those who meet the new criteria. Despite the limitations of the study, it 
provided important information into the extent and characteristic prevalence of 
psychotropic medication use among a sample of community-based children and 
dependent adults with ASD in Australia. 
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7.9 Implications and Conclusions 
Study 1 has demonstrated the high prevalence of psychotropic medication 
use among a sample of children and dependent adults living with carers in the 
Australian community. The rate of reported psychotropic medication use suggests 
that psychotropic medication prescription is common practice among 
professionals treating children and dependent adults with ASD. This study 
provides further support for the suggestion that while there is evidence supporting 
the efficacy of some psychotropic medications in the management of emotions, 
behaviours and comorbid conditions occurring with ASD, others are being 
prescribed with minimal research support (Aman et al., 2003). This is of 
particular concern as it highlights the need for randomised controlled trials to 
determine the efficacy and appropriateness of the specific medications prescribed 
in this population and the importance of including caregivers in these studies. 
These trials need to not only focus on adolescents, but also include younger 
children, as it has been established in this study that psychotropic medication is 
being prescribed in Australia to young children with ASD. In addition, 
longitudinal research needs to be conducted to determine not only the long term 
outcomes of medication use in children and dependent adults, but also how likely 
it is that medication is ceased as a form of intervention. 
Despite the controversy surrounding the effectiveness of psychotropic 
medication in reducing challenging behaviours, this study demonstrates that 
caregivers perceive psychotropic medication as helpful to them in managing their 
child/dependent adult’s difficult behaviour or emotions. Further examination of 
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these perceptions needs to occur in order to determine the reasons for the disparity 
between caregivers’ perspectives and other sources of data. It is unclear from the 
current findings whether this relates to caregivers need to justify the use of 
psychotropic medication, a possible placebo effect, the focus of change not being 
identified or that it is actually effective for what prescribers are targeting.  
It was demonstrated that caregivers did not perceive psychotropic 
medications as restrictive, despite some using them as a way to manage 
challenging behaviours. This suggests a disparity between caregivers’ perceptions 
and current policy and practices within Australia (Victorian Government, 2009). 
For example, in the state of Victoria, medication that is prescribed to a child/adult 
who accesses disability funded care, with the primary intent of behavioural 
control is considered restrictive and reportable under the Disability Act (Victorian 
Government, 2009). This suggests that further work needs to occur in order to 
bring parental perceptions in line with current policies and what is considered best 
practice. 
In this study, the majority of children and dependent adults were reported 
as being administered psychotropic medication. It was also the case that the 
majority of these children and dependent adults were reported to have been 
diagnosed with a comorbid mental health condition. It is plausible, even likely 
that these two factors relate to each other. It is possible, for example, that those 
with an ASD had a significantly higher level of comorbid conditions for which 
treatment with psychotropic medication is considered an appropriate option. 
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Alternatively, diagnosis with a mental health condition (such as ADHD) may be 
sought and provided in order to enable access to pharmacological treatment.  
In conclusion, the use of psychotropic medication was common among 
children and dependent adults with ASD whose caregivers participated in an 
online questionnaire. Anti-depressants and anti-psychotics were the most 
commonly reported type of medications in use, with challenging behaviour, 
comorbid mental health conditions and sleep difficulties all relating to medication 
use. Overall, psychotropic medications were viewed positively and were 
perceived by caregivers as helpful to the child/dependent adult. This study 
contributes new knowledge regarding the extent and nature of psychotropic 
medication use among children and dependent adults with ASD residing in home-
based care in Australia. In particular, it highlights key variables relating to the 
administration of psychotropic medication, including the reasons for use and the 
extent to which it is perceived as helpful. 
. 
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Chapter 8: Results Study 2 
This study involved a detailed description and analysis of self-reported 
data from a sample of 63 adults with an ASD. A power analysis was conducted 
using the G-Power 3.1 program (Faul, Erdfelder, Buchner, & Lang, 2009) with 
anticipated moderate effect sizes. The power analysis indicated that the study 
required approximately 111 participants, the study does not therefore, have 
sufficient power and the results need to be interpreted with caution. Non-
parametric approaches to data analysis was taken as the data was not normally 
distributed. 
In the first section of this chapter, the demographic details of the sample 
are presented including: age, gender, communication ability, intellectual ability 
and type of ASD. The focus of the second section of this chapter is on any 
differences between participants who reported current use of psychotropic 
medication to assist with the management of maladaptive behaviours and 
emotions arising in association with their ASD, participants who had previously 
taken psychotropic medication, and those who had never taken psychotropic 
medication. It presents their perspectives and attitudes towards psychotropic 
medication and their views on its effectiveness. This section then details 
information relating to the number and types of medications prescribed, as well as 
an examination of any differences in reported mental health concerns, sleep 
difficulties and challenging behaviour across the samples. 
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8.1 Overview of Sample of Adults with ASD 
8.1.1 Participant characteristics. 
The 63 adults with ASD (66.6% males) all resided in Australia and ranged 
in age from 18 to 69 years, with a mean age of 38.44 years (SD = 13.58, Median 
= 37, Mode =39). See Table 8.1.1 for a distribution of ages. A Chi-Square Test 
for Independence was conducted to determine if the relationship between age and 
gender differed from expectations. Age and gender were not found to be 
significantly related (χ2 (n = 63, df = 5) = 5.56, p =.06, phi =.30). The majority of 
participants were aged between 30 to 55 years old, with no females aged over 56 
years. The majority of participants reported residing in their own home (87.2%), 
with a small percentage indicating that they were living with some support 
(12.8%). 
 
Table 8.1.1 
Frequency and Percentage of Age Distribution by Gender (N = 63) 
 Male Female Total 
Age Range Freq. % Freq. % Freq. % 
18 to 29 14 33.3 5 23.8 21 30.2 
30 to 55 21 50.0 16 72.2 37 58.7 
56 to 69 7 16.7 - - 7 11.1 
Total 42 100.0 21 100.0 63 100.0 
 
Table 8.1.2 presents the frequency and percentage of participants 
according to ASD type and reported severity of impairment. The majority of 
participants reported being diagnosed with Asperger’s disorder (84%), with few  
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reporting a diagnosis of PDD-NOS (Pervasive Developmental Disorder - Not 
Otherwise Specified). Most participants reported their levels of impairment in the 
mild to moderate range. 
 
Table 8.1.2 
Frequency and Percentage of ASD and Severity of Impairment (N = 63) 
 Autistic Disorder Asperger’s 
Disorder 
PDD-NOS Total 
 Freq. % Freq. % Freq. %  
Mild  6 75.0 25  47.2 1 50.0 32 
Moderate 2 25.0 23  42.4 1 50.0 26 
Severe - - 5  9.4 - - 5 
Total 8 100.0 53 100.0 2 100.0 63 
 
Frequencies relating to intellectual ability and communication ability of 
the sample are presented in Table 8.1.3. Most individuals reported no intellectual 
disability (90.5%), with 33 per cent of these participants reporting above average 
communication ability. 
 
Table 8.1.3 
Frequency of Intellectual Disability and Communication Ability (N = 63) 
 Communication Ability  
 Below average Average Above average Total 
 Freq. % Freq. % Freq. % Freq.  
No ID   8  72.7 30  90.9 19 100.0 57 
ID 3  27.3 3  9.1 - - 6 
Total 11 100.0 33 100.0 19 100.0 63 
Note: ID = Intellectual Disability 
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8.2  Use of Psychotropic Medication 
This section describes the participants who reported currently taking 
medication, in comparison to those who had previously taken medication and 
those who had never taken medication. Medication use is presented according to 
demographic variables, as well as reasons for use, perceived helpfulness of the 
medication, views on whether the medication is seen as restrictive and general 
attitudes pertaining to the use of psychotropic medication. 
8.2.1 Psychotropic medication. 
The 63 adults with ASD (66.6% males) all resided in Australia and ranged 
in age from 18 to 69 years, with a mean age of 38.44 years (SD = 13.58, Median = 
37, Mode = 39). See Table 8.1.1 for a distribution of ages. A Chi-Square Test for 
Independence was conducted to determine if the relationship between age and 
gender differed from expectations. Age and gender were not found to be 
significantly related (χ2 (n = 63, df = 5) = 5.56, p =.06, phi =.30). The majority of 
participants were aged between 30 to 55 years old, with no females aged over 56 
years. The majority of participants reported residing in their own home (87.2%), 
with a small percentage indicating that they were living with some support 
(12.8%). 
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Table 8.2.1.1 
Demographic Details According to Medication Status (N = 63) 
 
Medication 
status 
Total Male 
n = 42 
Female 
n = 21 
Mean 
Age 
(yrs) 
Mean Age 
Diagnosis 
(yrs) 
Mean No. 
Behaviours 
Non-user  22 14 8 41.4 28.6 2.05 
Previous user 8 6 2 32.1 24.0 3.00 
Current user 33 22 11 38.1 32.4 2.39 
 
Chi-Square Tests of Independence were conducted to determine if 
medication use related to gender, type of ASD diagnosis, levels of impairment or 
communication ability. The results indicated no significant relationship between 
medication status and gender (p =.84), ASD diagnosis (p =.98), level of 
impairment (p =.093), communication ability (p =.69), age (p =.55) or intellectual 
ability (p = .52). 
A total count of 33 participants reported using psychotropic medication, 
with nine taking two or more medications (M = 1.39, SD =.73, Median = 1, Mode 
=1). Nine participants (14.2%) were taking two or more medications, with four 
(6.3%) using three medications. Table 2.1.2 displays the number of medications 
according to gender. 
Of the 33 people reporting medication use, 30 reported routine use, and 
three reported only PRN use. A further seven individuals, (thus, 10 overall) 
reported they also used PRN medication to assist with managing their emotions or 
behaviours. Of note, 10 participants (16% of the total sample) reported using 
complementary and alternative medications (e.g., St Johns Wort, fish oil) to assist 
with their emotions or behaviours. This medication use was excluded from 
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analyses, due to the study’s focus on psychotropic medication. The reported 
medications were coded according to their primary MIMS classifications (MIMS 
online, 2012): anti-depressant, anti-psychotic, anti-anxiety, anti-convulsant, 
hypnotic sedatives, CNS stimulant or other. If there were two classifications 
listed, the first listed classification was used. The coding of each medication 
according to type can be found in Appendix E. 
 
8.2.2 Psychotropic medication and gender. 
In this section, the number of psychotropic medications routinely taken by 
individuals was examined according to the participant’s gender. The majority of 
male and female participants reported taking one such psychotropic medication 
(see Table 8.2.2.1). A Mann-Whitney U test revealed no significant difference in 
the number of medications prescribed for males (Md = 1, n = 42) and females (Md 
= 1, n = 21), U = 438, z = -.42, p =.96, r =.05. 
 
Table 8.2.2.1 
Number and Percentage of Medications Used Routinely by Gender (n = 33) 
  Male  Female  Total  
Number of 
Medications. 
Freq. % Freq. % Freq. % 
1 16  72.7  8  78.7 24 38.1 
2 4  18.2  1  9.0 5  7.9 
3 2  9.0 2  18.2 4  6.3 
Mean no. 
Medication 1.36  1.45  1.39  
Total  22 100.0 11 100.0 33 100.0 
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As shown in Table 8.2.2.2, of the 33 individuals who reported taking 
medication, the majority (60.6%) reported taking one or more anti-depressant 
medications. Anti-psychotic and anti-anxiety medications were the next most 
commonly reported. The overall pattern of medication use appeared to be similar 
in males and females, with the exception that females indicated greater use of 
anti-convulsants and no use of hypnotic sedatives or CNS stimulants. 
Table 8.2.2.2 
Gender Breakdown According to Type of Medication (n = 33) 
   Male (n = 22) Female (n = 11) Total 
Type of 
Medication.  
No. of 
Med. 
Freq. % Freq. % Freq. % 
Anti-depressant  1 11 50.0 7 50.0 18 39.1 
 2 1  4.5 1  9.5 2 4.3 
Anti-anxiety 1 4 18.2 2  18.2 6 13.0 
Anti-psychotic  1 6 15.8 1  9.1 7 15.2 
 2 - - 1  5.6 1 2.2 
Anti-convulsant 1 3 13.6 2  18.2 5 10.9 
Hypnotic 
sedative 1 2  4.5 - - 2 4.3 
CNS stimulant 1 2  4.5 - - 2 4.3 
Other  1 2  9.1 1  9.1 6 13.0 
Total   31  14  46  
Note: Med = Medications 
 
8.2.3 Psychotropic medication and age. 
The extent of medication use and number of medications was examined by 
participant age group (18 to 29 years, 30 to 55 years, or 56 and older; see Table 
8.2.3.1). The sample of 63 participants comprised 30.2% of individuals who were 
aged between 18 and 29, 58.7% who were between 30 and 55 years, and 11.1% who 
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were 56 years or over. Across all age groups, a substantial proportion of participants 
reported current use of medication. 
 
Table 8.2.3.1 
Medication Use According to Age (N = 63) 
Medication use N 18 - 29 yrs 30 - 55yrs  56+ yrs Freq. % Freq.  % Freq. % 
Never  22 6 31.6 13 35.2 3 42.9 
Previous  8 2 10.5 6 16.2 - - 
Current  33 11 57.9 18 48.6 4 57.1 
Total  63 19 100.0 37 100.0 7 100.0 
Table 8.2.3.2 displays the number and mean number of medications 
routinely administered according to age group. Individuals aged 30 to 55 years 
used the highest mean number of medications (M = 1.55), with those aged 18 to 
29 years using the lowest (M =1.18). 
 
Table 8.2.3.2 
Number and Percentage of Medication Used Routinely by Age Group (n = 33) 
 18-29 yrs 30-55 56+yrs 
Number of 
Medications. Freq. % Freq. % Freq. % 
1 10 90.9 11 61.1 3 75.0 
2 - - 4 22.2 1 25.0 
3 1 9.1 3 16.7 - - 
Mean No. of 
Medications  1.18  1.55  1.22 
Total  11  18  4  
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Table 8.2.3.3 displays the frequency of individuals using the five 
medication types according to age group. The most frequently reported 
medication type across 18 to 29 year olds and 30 to 55 year olds was anti-
depressant medication. 
Table 8.2.3.3 
Frequency of Participants Reporting Medication Type by Age Group (n = 33) 
  Age Group 
 
Type of 
medication 
18-29 yrs 30-55 yrs 56+ yrs Total 
Freq. % Freq. % Freq. % Freq. 
Anti-depressant  7 58.4 14 50.0 2 33.3 23 
Anti-anxiety 2 16.7 4 14.3 - - 6 
Anti-psychotic  1 8.3 5 17.8 2 33.3 8 
Anti-convulsant 1 8.3 4 14.3 - - 5 
Hypnotic sedative 1 8.3 - - - - 1 
CNS stimulant - - - - 1 16.7 1 
Other - - 1 3.6 1 16.7 2 
Total 12 100.0 28 100.0 6 100.0 46 
8.2.4 Reasons for psychotropic medication use. 
In this section, the reasons provided by participants for medication use 
were examined, according to medication type (see Appendix E for a full list of 
primary and secondary reasons provided for prescription). The majority of this 
adult sample (66.6%) provided a single reason for each medication, with the 
remainder providing two reasons. The most commonly reported primary reasons 
for medication were anxiety (30.7%) and depression (28.4%). Smaller numbers 
reported that medication was used for sleep disturbance (17.6%), mood  
 Psychotropic Medication and ASD
   
 
 
153 
 
stabilisation (13.3%) and obsessional thoughts (5.6%). Responses coded as 
‘other’ (4.4%) included use for agitation, and on the basis of a past history of 
codeine abuse. 
The primary reason for medication was further examined according to the 
type of medication (see Table 8.2.4.1). Of note, the five participants who reported 
anti-convulsant medication use reported their primary reason for using this 
medication was for mood stabilisation. 
Table 8.2.4.1 
Primary Reason for Medication Use According to Medication Type (no. of medication = 
46) 
Medication 
type 
n  Depression Anxiety Mood 
stabilisation 
Sleep 
disturbance 
Obsession 
thoughts 
Other  
Anti-
depressant 23 12 7 - 3 1 
- 
 
Anti-
anxiety 6 - 5 - 1 - - 
Anti-
psychotic 8 - 2 1 2 2 1 
Anti-
convulsant 4 - - 4 - - - 
Hypnotic 
sedative 1 - - - 1 - - 
CNS 
stimulant 1 - - - - - 1 
Other 3 1 - 1 1 - - 
 
Participants were asked whether they viewed the medication they were 
taking as a form of restraint. The majority (87.8%) responded that they did not 
believe the medication was restrictive, with a smaller number (12.2%) indicating  
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it was. This trend appeared consistent across medication types (see Table 8.2.4.2). 
Anti-depressant medication was viewed as restrictive by the largest proportion of 
respondents (26.1%). 
Table 8.2.4.2 
Frequency of Participants Indicating Medication as Restraint by Type (n of 
medication = 46) 
Medication Type N Restrictive Not Restrictive 
  Freq. % Freq. % 
Anti-depressant 23 6  26.1 17  73.9 
Anti-psychotic 8 1  12.5 7  87.5 
CNS stimulant 1 - - 1 100.0 
Anti-convulsant 4 - - 4 100.0 
Hypnotic sedative 1 - - 1 100.0 
Anti-anxiety 6 1  14.3 5  85.7 
Other 3 1  33.3 2  66.6 
Total 46 9 100.0 37 100.0 
 
The responses provided by adults with ASD to the question ‘Do you 
believe this medication is a form of restraint?’ was further analysed according to 
the reasons for medication use (see Table 8.2.4.3), with evidence of some 
endorsement across reasons. 
 
Table 8.2.4.3 
Reason for Medication According to Belief about Restraint (n of medication = 46) 
 
 
 
n  Depression Anxiety Mood 
stabilisation 
Sleep 
disturbance 
Obsessions Other 
Restrictive 9 3 3 1 1 1 - 
Not 
restrictive 37 10 11 5 7 2 2 
Total 46 13 14 6 8 3 2 
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8.2.5 Perceived helpfulness of psychotropic medication. 
Participants were asked to report the extent to which they found each 
medication helpful in assisting them to manage difficult emotions or behaviours, 
on a four point Likert scale from (1) not at all to (4) a lot (see Table 8.2.5.1). Most 
adults reported that medication helped a ‘moderate amount’ or ‘a lot.’ All 
recipients of anti-convulsant medication rated the medication as helping ‘a 
moderate amount’ or ‘a lot.’ Those taking anti-depressants and anti-psychotic 
most commonly indicated the helpfulness of the medication was ‘a lot.’ 
Participants were further requested to report on a 10 point Likert scale how 
satisfied they were with the medication from 0 (totally dislike) to 10 (totally like) 
(M = 6.52, SD = 2.95). The majority of participants rated the medication 
positively. 
Table 8.2.5.1 
Perceived Helpfulness of Medication According to Type of Medication in Managing 
Difficult Emotions & Behaviours (n of medication = 46) 
  Perceived Helpfulness 
Type of Medication Not at all A little bit A moderate amount A lot 
Anti-depressant 1 2 8 11 
Anti-psychotic - 2 1 5 
CNS stimulant 1 - - - 
Anti-convulsant - - 1 4 
Hypnotic sedative - - - 1 
Anti-anxiety - 2 4 - 
Other - 2 - 1 
Total 2 8 14 22 
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8.2.6 Attitudes towards psychotropic medication. 
A further aim was to examine the views of adults with an ASD towards 
medication use in participants who reported current medication use. Table 8.2.6.1 
presents the overall frequencies of responses by participants to each item of the 
DAI (Hogan et al., 1998; participants that did not provide a response were omitted 
from the table). The most strongly endorsed item overall was ‘I take medications 
of my own free will.’ The least endorsed items were, ‘I can’t relax on medication’ 
and ‘I would rather be ill than take medication.’ Twenty participants (60.6%) 
indicated they disagreed with the statement ‘Taking medications will do me no 
harm’, with 14 (42.4%) participants indicating that ‘Medications make me feel tired 
and sluggish’, and ten participants (30.3%) endorsing the item ‘I am given 
medication to control behaviour that other people (not myself) don’t like’.' 
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Table 8.2.6.1 
Frequency of Participant Responses on the DAI-30 (n = 33) 
Item True False 
 Freq. % Freq. % 
I take medications of my own free choice 31 93.9 2 6.1 
For me the good things about medication outweigh the bad 30 90.9 3 9.1 
Even when I am not in hospital I need medication regularly 27 81.8 6 18.2 
I am happier and feel better when I am taking medications 26 78.8 7 21.2 
I should keep taking medication even if I feel well 26 78.7 7 21.2 
I am in better control of myself when taking medication 25 75.8 8 24.2 
Medications make me feel more relaxed 24 72.7 8 24.2 
I get along better with people when I am on medication 24 72.7 8 24.2 
Taking medication will prevent me from having a breakdown 22 66.7 10 30.3 
By staying on medication I can prevent myself getting sick 22 66.7 10 30.3 
My thoughts are clearer on medication 22 66.7 11 78.8 
I feel more normal on medication 21 63.6 13 36.4 
It is up to the doctor to decide when I should stop taking 
medication 20 60.6 12 36.4 
I am more aware of what I am doing of what is going on 
around me when I am on medication 19 57.6 14 42.4 
It is unnatural for my mind and body to be controlled by 
medication 15 45.5 17 51.5 
Medications make me feel tired and sluggish 14 42.4 19 57.6 
Taking medications will do me no harm 12 36.4 20 60.6 
The unpleasant effects of medication are always present 12 36.4 20 60.6 
I am given medication to control behaviour that other people 
(not myself) don’t like 10 30.3 23 69.7 
I feel strange, doped up on medication 9 27.3 24 72.7 
I know better than the doctors when to stop taking medication 8 24.2 25 75.8 
I don’t need to take medication once I feel better 7 21.2 26 78.8 
Things that I could do easily are much more difficult when I 
am on medication 7 21.2 25 75.8 
Medications are slow acting poisons 6 18.2 25 75.8 
I can’t concentrate on anything when I am taking medication 5 15.2 28 84.8 
I am no different on or off medication 5 15.2 28 84.4 
I take medication only when I feel ill 3 9.1 30 90.9 
If I take medication, it's only because of pressure from other 
people 2 6.1 31 93.9 
I can’t relax on medication 1 3.0 32 97.0 
I would rather be ill than take medication 1 3.0 32 97.0 
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8.3 Challenging Behaviour and Psychotropic Medication 
This section of the study examines the relationship between self-reported 
challenging behaviour and psychotropic medication. Firstly, the data for 
challenging behaviour across the whole sample of adult respondents is described 
and the relationship between demographic variables and challenging behaviour is 
explored. Then, the relationship between challenging behaviour and medication 
status (current users, previous users, and non-users) is examined. The differences 
between individuals with challenging behaviour who currently take psychotropic 
medication and those who do not are then explored. 
In response to a question about difficulties in managing their behaviours, 
the majority of total adult respondents (79.4%) reported at least sometimes having 
difficulty, with 20.6% reporting regular difficulties. The number of reported 
challenging behaviours ranged from zero to seven (see Table 8.3.1) (M = 2.39, SD 
= 1.85), with the majority of participants (79.4%) indicating at least one 
challenging behaviour. A Mann-Whitney U test revealed no significant difference 
in the mean number of challenging behaviours reported by males (Md = 2, n = 42) 
and females (Md = 2, n = 21), U = 412.0, z = -.43, p =.67, r =.058. 
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Table 8.3.1 
Frequency and Percentage of Challenging Behaviour (N = 63) 
No. of 
Behaviours  
Males 
n = 42 
Females 
n = 21 
Total 
 Freq. % Freq. % Freq. % 
0 9 21.4 4 19.0 13 20.6 
1 7 16.7 2  9.5 9 14.3 
2 9 21.4 6 28.6 15 23.8 
3 6 14.3 3 14.3 9 14.3 
4 6 14.3 3 14.3 9 14.3 
5 2  4.8 1  4.8 3  4.8 
6 2  4.8 2  9.5 4  6.3 
7 1  2.4 1  4.8 1  1.6 
Mean  2.29  2.48  2.35  
Total 42 100.0 21 100.0 63 100.0 
 
Participant responses to ‘describe any behaviours you have difficulty 
managing’ were coded into four categories of behaviours: aggressive, 
stereotyped/self-injurious, emotion- related or other disruptive behaviours. 
Aggressive behaviours included verbal and physical aggression towards other 
people, as well as property destruction. Stereotyped/self-injurious behaviours 
included repetitive routines, obsessions and self-harming behaviours (e.g. cutting, 
hurting oneself). Emotion-related behaviours included anxiety, depression and 
psychosis. Other disruptive behaviours included sleep and social difficulties. 
Table 8.3.2 displays the frequency and percentage of individuals reporting 
one or more of these categories of behaviours. The majority (74.0%) identified at 
least one emotion-related challenging behaviour, with many (60.0%) also 
indicating they experienced difficulty with stereotyped/self-injurious behaviour. 
Chi-Square Tests for Independence indicated that the overall presence of 
challenging behaviour did not significantly relate to the type of ASD diagnosis (p 
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=.34), gender (p = 1.00), level of impairment (p =.47), cognitive ability (p =.58), 
age group (p =.22), communication ability (p =.20) or the reported presence of a 
mental health condition (p =.31). Chi-Square Tests of Independence examined 
whether the type of challenging behaviour related to gender. No significant 
differences were observed between the type of behaviour reported and gender. 
 
Table 8.3.2  
Frequency of Participants Reporting Types of Challenging Behaviour (n = 50) 
 Number of Behaviours Total Sample 
Type of Behaviour 1 ≥2   
 Freq. % Freq. % Freq. %  
Aggression 16 32.0 3  6.0 19 38.0 
Emotion-related 20 40.0 17 34.0 37 74.0 
Stereotyped/Self-
injurious 16 32.0 14 28.0 
30 60.0 
Other disruptive 9 16.5 1 2.0 10 18.5 
 
The relationship between reported medication use and reported difficulty 
in managing behaviour was examined. A Chi-Square Test of Independence 
indicated no significant relationship between medication status and presence of 
challenging behaviour, χ2 (n = 63, df = 2) = 5.091, p =.078, Cramer’s V =.28. A 
Kruskal-Wallis test was conducted to determine if there were significant 
differences between the numbers of challenging behaviours across the three 
sample groups. No significant differences were observed (current medication 
users, n = 33; previous users, n = 8; non-users, n = 19), χ2 (n = 63, df = 2) = 2.84, 
p =.24. 
 Psychotropic Medication and ASD
   
 
 
161 
 
Chi-Square Tests of Independence were also conducted to determine if 
there was a relationship between the type of challenging behaviour and 
medication status (Bonferroni adjustments reduced the significance level to p 
<.017) (see Table 8.3.3). There were no significant relationships observed 
between medication status and the type of concerning behaviour. 
Table 8.3.3 
The Relationship between Medication Status and Specified Type of Behaviour (N 
=63) 
Challenging Behaviour Df χ2 p Cramer's V 
Self-Injurious 2 5.65 .05  .30 
Emotion-Related 2 3.86 .15 .25 
Aggression 2 3.44 .18 .23 
Note: *** significant at p <.001, ** significant at p <.01, * significant at p <.05 
 
A Mann-Whitney U test was conducted to examine if the number of 
challenging behaviours differed between those who reported taking an anti-
depressant and those who did not. No significant difference was found between 
those who reported taking an anti-depressant (Md = 2, n = 20) and those who did 
not (Md = 2, n = 43), U = 376, z = -.81, p =.42. 
8.4 Mental Health and Psychotropic Medication 
This section of the study examines the relationship between comorbid 
mental health conditions and psychotropic medication. The data for comorbid 
mental health conditions is presented across the whole sample and demographic 
variables. The relationship between medication status (current use, previous use, 
and non-users) and comorbid mental health conditions is presented next. Lastly, 
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the differences between those with comorbid mental health conditions currently 
taking psychotropic medication are examined. 
Participants were requested to report whether they currently experienced 
any mental health difficulties and if so, whether they had received a formal 
diagnosis for this condition. The majority of adults reported experiencing at least 
one mental health difficulty (79.6%), while a significant proportion indicated 
experiencing two or more mental health conditions (61.6%). Table 8.4.1 displays 
the mental illnesses, as reported by participants. The majority of adults with an 
ASD reported difficulty with anxiety. Further, a large proportion of the sample 
reported experiencing depression, with almost all having been formally 
diagnosed. A formal diagnosis of both depression and anxiety was reported by 
35.6% of the sample. Chi-Square Tests for Independence indicated that the 
presence of an anxiety disorder (formally diagnosed) did not significantly relate to 
the type of ASD diagnosis (p =.84), gender (p =.38), level of impairment (p =.84), 
age group (p =.55) or communication ability (p =.08.). Similarly, a formal 
diagnosis of depression did not significantly relate to the type of ASD diagnosis 
(p =.29), gender (p =.93), level of impairment (p =.79), age group (p =.78) or 
communication ability (p =.66). A Chi-Square Test of Independence indicated a 
significant association between depression and anxiety (χ2 (n = 63, df = 1) = 
15.01, p <.001, phi =.50); that is those who reported experiencing depression 
were more likely to report anxiety than those who did not. 
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Table 8.4.1 
Frequency and Percentage of Mental Health Conditions Present in Sample (N = 
63) 
Mental Health Condition Presence of Condition Formally Diagnosed 
 Freq.      % Freq.           % 
Anxiety   45 71.4 34 54.0 
Depression 32 52.4 31 47.6 
ADHD 9 14.3 8 12.7 
Bipolar disorder 4  6.3 3  4.8 
Post-traumatic stress disorder 2  3.2 2  3.2 
Obsessive compulsive disorder 1  1.6 1  1.6 
Schizoaffective disorder 1  1.6 1  1.6 
 
The relationship between medication status (current user, previous user, or 
non-user) and comorbid mental health diagnosis was examined. A Chi-Square 
Test for Independence indicated a significant association between medication 
status and the presence of a mental health condition, χ2 (n = 63, df = 2) = 8.53, p 
=.014, Cramer’s V =.39. Further Chi-Square analyses were conducted to 
determine if there was a significant relationship between medication status 
(current users, past users and non-users), with the two most commonly reported 
mental health diagnoses (depression & anxiety) (see Table 8.4.2.). Bonferonni 
adjustments (Tabachnik & Fidell, 2007) were conducted to reduce Type I error, 
and as such, reduced significance levels for mental health diagnoses to p <.017. 
Medication status significantly related to a diagnosis of anxiety, but not 
depression. Follow-up analyses indicated that those who reported a diagnosis of 
anxiety were more likely to be currently taking medication. 
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Table 8.4.2 
The relationship between Medication Status (Current User, Previous User, Non-
User) and Comorbid Depression and Anxiety 
 df χ2 p phi 
Anxiety 2 9.83     .01** .40 
Depression  2 5.90 .05 .31 
Note: *** significant at p <.017, 
 
A Mann-Whitney U test revealed a significant mean difference in the  
number of medications prescribed for those with mental health diagnoses (Md = 
1, n =50) and those who did not (Md = 0, n = 13), U = 206, z = -2.21., p =.027, r 
=.28. That is, those who reported having a mental health diagnosis were more 
likely to report taking a higher number of medications than those who did not 
have a diagnosis. 
Additional Mann-Whitney U tests were conducted to determine if there 
was a significant difference between the number of medications prescribed for 
those who reported a formal diagnosis of depression, anxiety, or both depression 
and anxiety, and those who did not (Bonferroni adjustments reduced significance 
to p <.017). A significant difference was found in the number of medications 
prescribed for those who reported a diagnosis of anxiety (Md = 1, n = 34) and 
those who did not (Md = 0, n = 29), U = 318, z = -2.64, p =.008, r =.33. That is, 
those who reported a diagnosis of anxiety were more likely to report taking a 
higher number of medications than those who did not. A significant difference 
was found in the number of medications prescribed for those who reported a 
diagnosis of anxiety and depression (Md = 1, n = 23) and those who did not (Md = 
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0, n = 40), U = 284.5, z = -2.74, p =.006, r =.35. However, a significant difference 
was not observed in the number of medications prescribed for those who reported 
a diagnosis of depression alone (Md = 1, n = 33) and those who did not (Md = 0, n 
=30) U = 340, z = -2.34, p =.019, r =.30. 
8.5 Sleep and Psychotropic Medication 
The majority of participants (69.8%) reported experiencing some 
difficulty with sleep; a smaller number of participants (19.0%) indicated they had 
been formally diagnosed with a sleep disorder. Chi-Square Tests of Independence 
were conducted to determine if there was a relationship between reporting of 
sleep difficulties, gender, age group, type of ASD communication ability, or level 
of impairment. Table 8.5.1 presents the findings. Bonferroni adjustments 
(Tabachnik & Fidell, 2007) were conducted to safeguard against type-one error, 
reducing the significance level to p <.013. Age group related to sleep difficulties, 
with those aged 18–29 and 30–55 more likely to report sleep difficulties than 
those aged over 55. 
Table 8.5.1.1 
Relationship between Overall Reported Sleep Difficulties and Demographic 
Characteristics (N = 63) 
 df χ2 p phi 
Gender 1 1.14 .29 -.17 
Age group 2 11.69   .00* -.43 
Type of ASD  2 1.06 .59 .13 
Communication 
ability 2 0.06 .97 .03 
Level of impairment 2 0.88 .64 .12 
Note: significant at p <.013* 
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Participants were requested to report any specific difficulties they had 
experienced over the previous two weeks in the domains of falling asleep, staying 
asleep or early wakening, and to rate these in terms of severity. Table 8.5.1.2 
presents the frequency and percentage of participants reporting each sleep 
difficulty according to severity. Difficulty with falling asleep was reported by 
58.7% of the sample, with 57.1% reporting moderate levels of sleep difficulties 
across the three domains. The majority of participants (69.8%) reported difficulty 
in at least one sleep domain, with 27.0% indicating difficulties in two domains of 
sleep, while a smaller percentage of the overall sample (19.0%) reported difficulty 
in all three domains. 
Table 8.5.1.2 
Sleep Difficulties Reported by Participants According to Severity (N = 63) 
 Minor Moderate Severe 
Very 
Severe 
Total  
Freq. % Freq. % Freq. % Freq. % Freq. % 
Difficulty 
falling 
asleep 
15 23.8 12 19.0 7 11.0 3 4.8 37 58.7 
Difficulty 
staying 
asleep 
9 14.3 13 20.6 3  4.8 2 3.2 27 42.9 
Problem 
waking too 
early  
8 12.7 11 17.5 4  6.3 2 3.2 25 39.6 
Total  32  36  14  7  -  
 
 
 
 
8.5.1 Mental health and sleep. 
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Chi-Square Tests of Independence (Bonferroni adjustment; p <.017; 
Tabanack & Fiddell, 2007) were conducted to determine if there was a significant 
association between those who reported some form of sleep difficulty (from any 
domain or severity) and diagnosis of anxiety, depression or ADHD. As indicated 
in Table 8.5.1.3, there was no significant relationship observed with the reduced 
significance level. However, the relationship between the presence of an anxiety 
disorder and difficulties with sleep appears to approach significance. 
Table 8.5.1.3 
Relationship between Reported Sleep Difficulties and Mental Health Conditions 
(N = 63) 
 df χ2 p phi 
Anxiety 1 4.29 .04 .30 
Depression 1 2.29 .13 .23 
ADHD 1 0.31 .57 -.07 
Note: *** significant at p <.017* 
 
Sixteen participants reported using medication to assist with their sleep 
difficulties. Participants reported using the following medications to assist with 
sleep: sertaline, codeine, antihistamines, sodium valproate, fluvoxamine, 
melatonin, mirtazapine, quetiapine, zolpidem, temazapam and agomelatine. A 
Chi-Square Test of Independence indicated no significant difference (Yates 
Continuity Correction) between the gender of those taking medication to assist 
with sleep and those who were not (χ2 (n = 63, df = 2) =.51, p =.47, phi = -.13). 
A Chi-Square Test of Independence was conducted to determine if there 
was a relationship between medication status and reporting of overall sleep 
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difficulties. No significant association was found (χ2 (n = 63, df = 2) = 1.37, p 
=.50, phi =.15); that is, those who reported experiencing sleep difficulties were 
not more likely to be currently taking medication than those without. Neither was 
any significant relationship found between anti-depressant use and reported sleep 
difficulties (χ2 (n = 63, df = 2) =.098, p =.75, phi = -.077). 
The relationship between the three domains of sleep difficulties and anti-
depressant use was examined (Bonferroni adjustment; p <.017; Tabachnik & 
Fidell, 2007). Table 8.5.1.4 presents the findings. As can be seen, no significant 
relationships were found at this reduced significance level. 
 
Table 8.5.1.4 
Relationship between Anti-depressant Use and Sleep Difficulties (n =21) 
   Anti-depressant 
 U p Z R 
Difficulty falling asleep  362 .29 -1.05 .13 
Difficulty staying asleep 355 .22 -1.24 .16 
Early wakening  301 .03  -2.18 .35 
Note: *significant at p <.017, 
In summary, 63 adults independently completed the questionnaire; most 
had a diagnosis of Asperger’s disorder without an intellectual disability. Over two 
thirds of the sample reported having one mental health difficulty, with those 
having mental health difficulties also being more likely to report sleep difficulties. 
Thirty-three adults reported using medication to assist with management of 
emotions and behaviours associated with their ASD. The majority reported taking 
anti-depressant medication, with only a small proportion (20.5%) using multiple 
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medications. Participants who indicated they had a diagnosed mental health 
condition were more likely to be currently taking psychotropic medication. 
Further analysis revealed that participants who reported having a diagnosis of 
anxiety or anxiety with depression were more likely to report taking psychotropic 
medication than those who did not. The majority of participants indicated they did 
not believe the medication they were taking was restrictive, and rated the 
medication as being helpful. 
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Chapter 9: Discussion Study 2 
The purpose of Study 2 was to gain an understanding of the use of 
psychotropic medication, from the perspective of an Australian sample of adults 
with an ASD. Although previous research had captured findings regarding adults 
residing in state-based accommodation (e.g., Webber et al., 2010), the current 
study adds to the literature through its focus on medication use in community- 
based adults with ASD, who are able to self-report. In this chapter, the results of 
Study 2 are explored and the findings are discussed in the context of previous 
research. Individuals who reported psychotropic medication use were compared 
with those who had previously used medication and those who never had; and 
also according to gender, age, ASD diagnosis and the presence of intellectual 
disability. The views and experiences of adults were explored, and a particular 
focus was placed on describing medication use in those who presented with 
comorbid mental health conditions, challenging behaviour and sleep difficulties. 
The limitations of the study, recommendations for future research and the clinical 
implications of the findings are also discussed. 
9.1 Description of Sample 
The majority of participants indicated they were diagnosed with 
Asperger’s disorder, lived independently and had communication skills enabling 
them to articulate their views. This was expected, given that the study aimed to 
recruit independent adults who were able to provide self-report data on their 
current medication use. The gender ratio observed in the sample of one female to 
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three males indicated a higher number of females than the widely accepted one to 
four ratio (Fombonne, 2003). This may be attributed to a bias in females 
participating in this study or alternatively may be the result of a higher number of 
females diagnosed with Asperger’s disorder. 
9.2 Extent of Use 
The rates of psychotropic medication use observed in the sample of self- 
reporting adults in this study (52%) was somewhat lower than the rates of 57 to 
64 per cent reported in recent international research on adults residing in 
residential care (Esbensen et al., 2009). However, the rates in this study are well 
within those identified across the literature (30 to 81%) (Aman et al., 2005; 
Esbensen, Greenberg, Seltzer & Aman, 2009, Green et al., 2006; Mandell et al., 
2008; Memari et al., 2012; Oswald & Sonenklar, 2007; Whitwer & Lecavalier, 
2005). Lower rates may have arisen from the community-based nature of the 
sample, in comparison to the majority of research to date that has been conducted 
on adults living in residential care settings and who by virtue of this are likely to 
be more significantly impaired (Esbensen et al., 2009). Alternatively, this 
relatively lower rate in this study may arise from the small number of participants 
with a comorbid intellectual disability, given the reported high level of 
psychotropic drug prescription to people with intellectual disabilities (Aman et 
al., 2002). 
In this study, most participants reported current use, with only a small 
proportion reporting previous use. This is in keeping with findings from 
longitudinal research in those with an ASD and co-morbid intellectual disability 
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indicating that those who commence taking medication are unlikely to cease its 
use (e.g., Esbensen et al., 2009; Aman et al., 2005). It would be beneficial for 
future researchers to undertake a more in depth exploration of those who 
previously used psychotropic medication, the reasons for discontinuation and 
their views on medication. This would enable greater understanding of the 
variables that influence cessation. 
The findings did not support any relationship between the use of 
psychotropic medication and type of ASD. This result may simply reflect the high 
number of participants with Asperger’s disorder in the sample. 
9.3 Gender and Age 
A further aim of this study was to examine differences in the use of 
psychotropic medication across age and gender. The findings are in contrast with 
previous research on those with an ASD and an intellectual disability, which 
found that males were more likely to receive psychotropic medication (Aman et 
al., 2003). It is plausible that there may be no differences in the use of medication 
according to gender in self-reporting adults with ASD in Australia. However, 
these findings may also reflect a bias in the population who participated in this 
study. Overall, the type of medication use appeared to be similar across males and 
females, with anti-depressant medication being the most commonly taken 
psychotropic medication for both. However, more females reported using anti-
convulsants, none used hypnotic sedatives or CNS stimulants. Given the small 
number of overall participants reporting taking these medication types, it is 
impossible to know whether this is a result of a pattern in differences in 
 Psychotropic Medication and ASD
   
 
 
173 
 
prescription or a sampling error (due to the small sample size). A larger study 
investigating the use of medication in this population is clearly warranted. 
In addition to gender, age has been established in the literature as a 
variable relating to psychotropic medication use (e.g., Aman et al., 2003; Aman et 
al., 2005). In this study, however, age did not appear to affect either mean number 
or type of medication, irrespective of whether participants were previous, current 
or non-medication users. This contrasts with previous research on adults with 
intellectual disability, in which those who were younger appeared to receive 
higher levels of medication (Aman et al., 2003, 2005; Esbensen et al., 2009 
McGillivray &McCabe, 2004). The differences in findings may be attributed to an 
older mean age in the present study, or alternatively the higher proportion of 
participants in those with ASD without an intellectual disability. Further 
exploration of the relationship between psychotropic medication and age is 
indicated to address this question. 
9.4 Attitudes and Perceptions 
An additional key aim of this study was to explore the perspectives of self- 
reporting adults with an ASD on psychotropic medication as an option for 
reducing challenging behaviour or for the treatment of comorbid psychiatric 
conditions. This was explored in terms of the reason for medication use, 
perceived helpfulness, overall satisfaction with the medication and the extent to 
which they perceived the medication as restrictive. 
The most commonly reported reason for medication use was depression, 
followed by anxiety and mood stabilisation. These apparent emotional difficulties 
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are likely symptomatic of a mental illness. In contrast, only a small number of 
participants reported that medication was used to assist with the management of 
behaviours and stereotypies. In addition, it was found that anti-depressants were 
most commonly reported for treatment of anxiety and depression. This indicates 
that while many participants reported having difficulty with challenging 
behaviours (see Section 9.6), this was not the reported primary reason for using 
psychotropic medication. There could be a myriad of reasons why challenging 
behaviours were not reported as the primary reason; for example, the person may 
not feel that they have challenging behaviours, self-reporting adults may feel the 
need to justify their decision to use medication in the survey; alternatively they 
may have wanted to avoid the viewpoint that medication was used as a form of 
restraint. Conversely, practitioners may be prescribing medication based on 
comorbid mental health conditions. 
A possible explanation for why participants indicated mental health as the 
primary reason for taking medication is to avoid the perception of medication as a 
form of restraint. The study explicitly explored whether participants believed the 
psychotropic medication they were taking was restrictive. There have been 
significant questions raised in the literature as to the appropriateness of 
psychotropic medication for the management of behaviours, or the treatment of 
symptoms co-occurring with ASD (Aman et al., 2005; Matson et al., 2011; 
Webber et al., 2010). Consistent across types of medications, most participants 
did not view their psychotropic medication use as restrictive. For example, the 
majority of participants endorsed the item, ‘I take medications of my own free 
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will.’ This perception that medication was not restrictive may be a result of the 
large number of participants reporting primary use for mental health purposes. 
This explanation is consistent with literature and legislation endorsing the 
view that psychotropic medication use is not restrictive if it is used for the 
treatment of a comorbid mental health condition (Victorian Government, 2009; 
Webber et al., 2010). It is also possible these adults view themselves as being 
empowered in their decision making around medication use, and as such do not 
view it as restrictive. 
Research investigating the perspectives of adults with an ASD on the use 
of psychotropic medication is limited. In this study, most adults perceived 
psychotropic medication as helpful, with a trend for those taking anti-psychotics 
and anti-depressants to indicate these as particularly helpful. In addition, it was 
found that adults had a positive attitude towards taking their medication, with 
findings indicating that the majority accepted their medication. The 
overwhelming proportion of participants acknowledged, ‘For me the good things 
about medication outweigh the bad’ and ‘I am happier and feel better when I am 
taking medications.’ This indicates that in this sample of adults with ASD, the use 
of psychotropic medication was a predominantly positive experience. Given the 
above statement, this suggests there is a partial role for the use of psychotropic 
medication in this population. 
The findings of this study indicated that participants were concerned about 
the side effects of medications. A large number of participants indicated that 
medications ‘make me feel tired and sluggish’ and that medications ‘do harm.’ 
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This corresponds with a body of research indicating the presence of concerning 
side effects from many medications (e.g., Valdovinos et al., 2005, Williams et al., 
2012). 
9.5 Mental Health and Psychotropic Medication Use 
A further goal of the study was to examine whether mental health 
difficulties related to the use of psychotropic medication. Most participants 
(79.6%) reported experiencing at least one comorbid mental illness. This finding 
was higher than expected, as previous research has reported that 42 per cent of 
adolescents and adults with an ASD had a comorbid mental illness (Mosley et al., 
2011). This difference may be accounted for by the robust approach to diagnosis 
used in the Mosley et al. study, including the use of semi-structured clinical 
interviews and specific measures of psychopathology, compared to the self-report 
data collected in the present study. Additionally, this may be explained by the 
differences in the samples used, with those in Mosley’s study being largely 
dependent on others for support and having a comorbid intellectual disability 
(79%). It was also likely that those participating in this study reported a diagnosis 
received some time ago; one that may no longer be accurate. This may be due to 
an incorrect initial diagnosis, the illness abating or successful treatment. The 
practitioners who were diagnosing may have had difficulty distinguishing 
between ASD symptoms and comorbid conditions (Heidgerken et al., 2005). 
While it is difficult to determine the exact rate of comorbid psychiatric 
conditions in those with an ASD, the present study supports the consistently 
higher reported rates of comorbid mental health conditions in those with an ASD 
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when compared to the general population (Mosley et al., 2011; Morgan et al., 
2003). These comorbid conditions are reflected in higher levels of distress in 
these individuals; consequently, there is a need for adequate diagnosis and 
treatment. 
The most commonly diagnosed comorbid mental health condition was 
anxiety, followed by depression and ADHD. Those with a diagnosis of depression 
were also more likely to have a diagnosis of anxiety. The prevalence of anxiety 
and depressive disorders observed in this study appears to be significantly greater 
than the prevalence reported by neurotypical adults (e.g., Goldney, Eckert, 
Hawthorne & Taylor, 2010; Hollingworth, Burgess & Whiteford, 2010). There 
has been much debate in the literature about whether anxiety is a central 
component of ASD or is a separate condition (Gillott & Standen, 2007; Matson & 
Nebel-Shawalm, 2007). In this study, a high number of individuals reported 
diagnosis of an anxiety condition. One of the reasons for this high level of 
comorbidity may be the difficulty with differential diagnosis in this population. 
This suggests a need for clearer guidelines in determining when anxiety becomes 
pathological in those with an ASD and delineating the crossover of anxiety with 
sensory issues (Heidgerken et al., 2005). 
 The hypothesis that individuals with comorbid mental health conditions 
were more likely to be prescribed psychotropic medications was supported, both 
in terms of current use and higher number of medications. The finding that 
current use was associated with comorbid mental health conditions was consistent 
with previous research on children and adults with an ASD (Mandell et al., 2008; 
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Memari et al., 2013; Morgan et al., 2003). Moreover, the findings were consistent 
with Morgan and colleagues’ findings demonstrating that those who were using 
medication were more likely to report a diagnosis of anxiety, or anxiety and 
depression, but not depression alone (Morgan et al., 2003). The present study’s 
findings indicate a difference in medication prescription among those who 
reported anxiety, as opposed to depression alone. This result may have occurred, 
as those with anxiety tend to experience higher levels of cognitive and somatic 
arousal, and thus make their symptoms more overt to medical practitioners 
(Harvey, 2002). In contrast, those with depression are more likely to be 
withdrawn, and may not seek help in the same way (Barlow & Durand, 2005). 
Increasing research attention has been focused on the relationship between 
ASD and comorbid mental illnesses. This body of literature has reported a large 
variation in the estimates of comorbid conditions ranging from 40 to 70 per cent 
(Lugnegard, Hallerback & Gillberg, 2011; Simonoff et al., 2008; Tsakanikos, 
Underwood, Kravariti, Bouras & McCarthy, 2011). These findings, along with the 
present study, suggest that comorbid mental health conditions are common in this 
population. They are common in comparison with the neurotypical population and 
those with other disabilities (Mosley et al., 2011). Given the high level of 
medication use reported in this population, there is a need for practitioners to 
conduct thorough assessments to explore differential diagnosis among this 
population and for non-pharmacological interventions targeting comorbidity to be 
developed and trialled in adults with ASD. This would allow greater choice when 
selecting interventions for the treatment of comorbid mental health conditions. 
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Moreover, preventative health programmes may benefit this population, focusing 
on early identification and management of emotions, particularly anxiety and 
depression. 
9.6 Challenging Behaviour and Psychotropic Medication 
The findings of this study indicate that most of the participants had 
difficulty managing their behaviour ‘some’ or ‘all of the time’. Of those reporting 
difficulties with behaviour, they most commonly reported difficulty with 
emotion-related and stereotyped/self-injurious behaviours. Those reporting 
difficulties with emotions and the presence of stereotyped/self-injurious 
behaviours believed these presented as challenging behaviours. It has been 
previously suggested that both difficulty with emotions and stereotyped/self- 
injurious behaviours can be symptoms of mental illness (Matson & Nebel- 
Shwalm, 2007). This poses a diagnostic dilemma related to aetiology as it may 
not be possible to always establish the primary cause of each difficulty in this 
population. However, participants perceived these behaviours as challenging, and 
therefore it is important to consider these difficulties when working with 
individuals with an ASD. 
It was hypothesised that those who reported psychotropic medication use 
would be more likely to report difficulties with challenging behaviour (in terms of 
its both presence and number of behaviours). However, the findings did not 
support this hypothesis, instead indicating no difference in those reporting 
challenging behaviours and their medication status (current use, previous use, 
non-user), or in the mean number of behaviours reported by each group. In 
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addition, no relationship was found between medication status and the type of 
challenging behaviour reported. This was inconsistent with previous suggestions 
that those who exhibit challenging behaviour were more likely to receive 
psychotropic medication (Matson & Hess, 2011). This may be the result of 
medical professionals deeming these adults as having the capacity to engage in 
alternative interventions (e.g., CBT or social skills training). Alternatively, they 
may be self- selecting other forms of intervention (counselling, sensory skills 
training). 
9.7 Sleep and Psychotropic Medication Use 
The majority of the adult participants with ASD reported having sleep 
difficulties; a proportion of these reported they had been diagnosed with a sleep 
disorder. This is consistent with previous research suggesting that adults with 
Asperger’s disorder were more likely to report subjective sleep difficulties than 
neurotypical adults (Tani et al., 2004). However, sleep difficulties were not 
reported by any of the participants aged over 55 in the current study. The most 
likely reason for this appears to be the relatively small number of participants in 
this age group, given the large body of research indicating that sleep difficulties 
generally become more prevalent in older age (e.g., Foley, Ancoli-Israel, Britz & 
Walsh, 2004). Alternatively, sleep difficulties may abate in this population as they 
age. Given there is very little research exploring sleep in adults with an ASD in 
this age group, it is suggested that future research examine the sleep patterns of 
older individuals with an ASD. 
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The relationship between mental health diagnosis and sleep difficulties in 
those with ASD was further explored in this study. The findings indicated no 
significant relationships between the presence of depression, anxiety or ADHD 
and sleep difficulties. However, the relationship between anxiety and sleep 
difficulties did approach significance. This finding provided support for the 
suggestion by Tani and colleagues (2005) that anxiety may relate to sleep 
difficulties in this population. It is plausible that people with an ASD experience 
higher levels of cognitive and somatic arousal, thus making sleep a more difficult 
task to attain and maintain (Tani et al., 2005). 
A large variety of medications for sleep was reported, with no one 
medication being more prominent than another. The hypothesis that individuals 
who reported overall sleep difficulties were more likely to report using 
psychotropic medication was not supported in the current study. Given the high 
level of sleep difficulties observed in this study, further investigation of sleep 
patterns in independent adults with an ASD appears warranted. Moreover, it 
would be beneficial to investigate if this population have similar patterns of 
melatonin deficiency to those observed in children (Brzezinski et al., 2005, Melke 
et al., 2008). 
9.8 Limitations of the Findings 
First and foremost, this study was deemed to have insufficient power; 
therefore, the findings need to be interpreted with caution. The study should be 
viewed as exploratory, highlighting where future research could be directed. A 
more comprehensive analysis with a larger sample would allow future research to 
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make more significant contributions to the literature. As was the case with Study 
1, it is possible that individuals who hold strong views and perceptions about the 
use of psychotropic medication were more likely to participate in this study, and 
consequently a sampling bias may be present. 
The focus of this study was on those adults who were able to self-report 
and who primarily lived independently in the community. The design of the 
questionnaire required them to be able to read and write, and to have adequate 
English proficiency. It is therefore likely that individuals with more significant 
difficulties who may be residing independently, as well as those with limited 
communication skills, were excluded from the study. It is suggested that future 
research attempts to replicate the study with participants with a variety of needs, 
to increase the generalisability of the findings. 
The recruitment of only a small number of participants who had 
previously used medication was a notable limitation; as such, it restricted the level 
of analysis undertaken. This group was likely to provide key information as to 
whether they ceased medication because it was ineffective, was no longer needed 
or assisted them such that they no longer required it. It would have been 
beneficial to conduct more extensive comparisons between those who currently 
used medication with those who have previously used medication; consequently, 
this should be a consideration for future research. 
It must be acknowledged that the Drug Attitude Inventory provided a 
limited viewpoint of individuals with relation to psychotropic medication. Other 
the viewpoints and processes included in the questionnaire are likely to be 
 Psychotropic Medication and ASD
   
 
 
183 
 
identified. Moreover, the measure is designed explicitly to help to increase 
compliance with psychotropic medication which may have impacted findings. 
Further research would benefit from adopting a qualitative methodology to 
overcome problem and provide further information relating to individuals 
attitudes and views.  
A significant additional limitation was that the study relied upon on the 
accuracy of self-report. It is plausible that this study captured some participants 
who may not meet ASD criteria. Participants may also have had deficits in 
knowledge concerning the topics covered (e.g. psychotropic medication, 
challenging behaviour, mental health conditions), and as such inadvertently 
provided inaccurate information. Moreover, this study did not include objective 
measures of challenging behaviours or mental health. Future research 
investigating psychotropic medication use would benefit from including a variety 
of assessment measures to confirm ASD diagnosis, intellectual ability, mental 
health conditions and challenging behaviours, to further strengthen the findings. 
A final limitation of this study was the inability to comprehensively 
analyse and compare the dose of medications. This is a particularly difficult 
measure to obtain via online self-report. Future research may benefit from 
collecting information on dosage, as well as demographics associated with dosage 
of medication, for example weight, height and age, and comparing individual and 
informants’ perspectives across therapeutic ranges. In summary, although the  
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study was limited by a number of methodological considerations, it provides 
useful information surrounding psychotropic medication use in independent 
adults with an ASD in Australia. 
9.9 Implications and Conclusions 
This study has demonstrated that self-reporting adults with an ASD in 
Australia appear to be using psychotropic medication mainly for assistance with 
comorbid mental health difficulties, especially anxiety. The high prevalence of 
comorbid mental health conditions, and medication use to assist with these 
difficulties, has implications for those who provide care and support for this 
population. In particular, it emphasises the need for thorough mental health 
assessments and the possibility that medication may benefit those individuals with 
comorbidities. Moreover, it indicates the need for randomised controlled studies 
examining the benefit of psychotropic medications in the treatment of comorbid 
mental health conditions, most notably anxiety and depression, in this population. 
In this study, the extent of anxiety in independent adults with ASD was 
substantial; a need for future research to explore the role of anxiety is indicated. 
The relationship between anxiety and the use of psychotropic medication was 
apparent. It is apparent from the observed prevalence, as well as the relationship it 
had with sleep and depression, that anxiety appears to have a significant influence 
on those with an ASD. Further exploration of these relationships would allow 
greater understanding of not only comorbid mental health conditions, but also 
provide further insight into psychotropic medication use. In addition, it would be 
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beneficial to compare the effectiveness of psychotropic medication with other 
treatment options in this population (e.g., mindfulness, behavioural activation). 
The findings indicate that many individuals with ASD find psychotropic 
medication useful. Most do not view it as restrictive. Given the mixed views 
about the helpfulness of psychotropic medication in people with an ASD, the 
findings of this study provide a novel insight from the perspectives of those who 
take the medications. It is central that these views are considered when 
determining the effectiveness of medications in those with an ASD. 
It is important that the findings and implications of the present study are 
interpreted with caution, due to the current changing diagnostic criteria 
surrounding ASD (e.g., APA, 2013). Some of the self-reporting adults with 
Asperger’s disorder included in this study may not meet the new criteria for an 
ASD. To what extent this would affect the findings remains unclear; however, it 
emphasises the need for further research to establish the prevalence and rationale 
for psychotropic medication use across the new diagnostic categories. 
This study contributes to the understanding of psychotropic medication 
use in self-reporting adults with an ASD. It provides a unique insight into the 
views self-reporting adults on the benefits of medication, and how medication use 
relates to mental health, challenging behaviours and sleep difficulties alongside 
ASD. 
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Chapter 10: Study 3 Qualitative Analyses 
A search of available literature on psychotropic medication use in people 
with ASD highlights a dearth of narrative accounts from caregivers and 
individuals with an ASD. Quantitative analysis provides important data. 
However, it does not allow for the individual insights that can be captured from 
those who observe and experience the impact of psychotropic medication use on a 
daily basis. Qualitative research enables this to occur and focuses on the 
subjective experience of caregivers and independent adults, and the meaning of 
their responses (Storey, 2007). 
The third study of this thesis sought to enhance the quantitative data 
reported in Studies 1 and 2, by providing ‘free text’ areas for participants to 
provide greater details and personal perspectives in their response to questions. 
The goal of this study was to gain further understanding into the perceptions and 
viewpoints of caregivers and independent adults surrounding psychotropic 
medication use in people with an ASD, through narrative accounts. The intention 
of including the qualitative data was to complement the quantitative results, 
provide insight into the topics covered, capture a sense of (all) participants’ 
perspectives, and to inform future practice in this area. The qualitative data is 
presented as Study 3 in this thesis, and is comprised of two components: Study 3a 
and Study 3b. Study 3a examines the views and perspectives of caregivers 
regarding the use of psychotropic medication to manage undesirable emotions and 
behaviours associated with ASD. Obtaining an understanding of caregivers’  
 Psychotropic Medication and ASD
   
 
 
187 
 
views is imperative since they generally make decisions around the use of 
psychotropic medication in their child/dependent adult. Study 3b focuses on the 
views and perspectives of independent adults with an ASD. 
This chapter commences with an overview of the methodological 
approach used to analyse the qualitative data, followed by Study 3a results and 
discussion and Study 3b results and discussion. The limitations from both studies 
are then discussed, followed by an overall reflection on the findings. 
10.1 Methodological Approach 
Free text areas were provided in the questionnaire for participants to 
respond with their views on the reasons for use, the effectiveness of use, and their 
overall attitudes towards the use of psychotropic medication in the management 
of undesirable behaviours and emotions in people with ASD. 
10.1.1 Participants 
Of the 245 caregivers who completed Study 1, 173 provided additional 
comments that pertained to psychotropic medication use in people with an ASD 
to manage undesirable emotions or behaviours. These caregivers were providing 
care for a child/dependent adult with an ASD, who ranged in age from three to 45 
years. 
Of the 63 independent adults who completed Study 2, 46 provided 
comments that pertained to psychotropic medication use to manage undesirable 
emotions or behaviours associated with ASD. The age range of these participants 
was between 18 and 63 years. 
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10.1.2 Data analysis 
A thematic analysis, as described by Braun and Clarke (2006), was used to 
explore the perspectives of both caregiver informants and individuals 
(independent adults) with an ASD, regarding the use of psychotropic medication 
to manage undesirable emotions and behaviours associated with ASD. A thematic 
analysis was selected as it is not theoretically bound, and is adaptable to the 
nature of the data provided, in response to open ended questions (Braun & Clarke, 
2006). It allowed the researchers to organise and describe the data, as well as 
interpret its meanings. All data was analysed together, so as to not limit the 
analysis by the specific questions asked. The transcripts were initially read by the 
researchers to enable familiarity with the content. Key themes were then 
identified and meanings were generated. Statements were independently coded on 
the basis of their key concepts by two independent people, with inter-rater 
reliability found to be acceptable (caregivers r =.80; independent adults; r =.83). 
These results exceeded the suggested minimum reliability value (r =.75; e.g., 
Boyatzis, 1998; King, Baxter, Rosenbaum, Zwaigenbaum, & Bates, 2009). The 
meanings were then collated and grouped together according to clusters, with 
subthemes then identified. The thematic analysis revealed a number of emergent 
themes, with illustrative quotations available from caregivers and independent 
adults. The reported quotations include whether the person was the caregiver for a 
child/dependent adult who currently used psychotropic medication (Med), who 
previously used psychotropic medication (PMed) or who had never used such 
medication (NMed). 
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10.2 Results Study 3a 
The following section presents the findings from an analysis of responses 
provided by informant caregivers, with regard to their experiences and views on 
using psychotropic medication to manage undesirable emotions and behaviours 
associated with an ASD. Findings are presented according to five linked themes: 
caregiver identity; emotional responses to the use of psychotropic medication; 
fear of side effects, the value of psychotropic medication and the burden of care- 
giving. Underlying these themes were two key subthemes: defensive responses 
and a pervasive sense of desperation.. 
10.2.1 Caregiver identity. 
It was evident from the analysis that the caregiver identity of informants 
intertwined heavily with their view on the role of medication. The decision to 
administer psychotropic medication to their child/dependent adult appeared to be 
influenced by their individual identity and beliefs about their perceived role as a 
parent/caregiver. Some caregivers felt that medication was not warranted, or that 
they would not administer psychotropic medication because it conflicted with 
their perceived role to protect and nurture their child/dependent adult. Among 
those caregivers who administered psychotropic medication to their 
child/dependent adult with an ASD, many disclosed they struggled with this 
decision because children ‘should not’ take psychotropic medication. It appeared 
these caregivers had difficulty integrating this decision with their sense of who 
they were as a parent, their overall belief systems, and how they thought others 
perceived their decision: 
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I did not wish for my son to be prescribed any type of medication, but 
when you have a ten year old telling you he wants to kill himself it is 
terrifying. It still wasn’t until the Zoloft was prescribed for his tactile 
defensiveness that I finally succumbed. It seemed like a much more 
acceptable reason for medication than anxiety or depression. (CMed) 
A dominant theme was caregivers’ perceptions of how psychotropic 
medication use related to their ‘duty’ to their child within their care-giving role. 
The perception of ‘duty’ varied considerably. Some respondents 
emphasised a ‘duty’ to medicate to protect their child from harm at an emotional, 
social or behavioural level. Others conveyed a sense that they were failing in their 
‘duty’ to protect and nurture their child, through resorting to using this type of 
medication. These caregivers viewed the use of psychotropic medication 
negatively, and as different from medications that were for prescribed for regular 
health ailments (e.g., cold and flu). This view appeared to be the basis for many 
respondents questioning their ability to parent, whether their decision to medicate 
was in the best interests of the child, whether it was doing harm to the child, and 
whether they were meeting their parental duty. 
The complexity of the decision to use medication was evident. Many 
caregivers discussed the factors that affected their decision, which included 
individual factors, availability of informal and formal supports, level of 
interventions, and individual family situations. Caregivers stated that 
consideration of these factors needed to be balanced in deciding to medicate or 
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not. In addition, caregivers stated they felt the decision was a personal one, and 
that it should be made on the basis of each individual and their circumstances: 
ASD and the choice to use medication is a very personal decision for each 
situation. I believe it should be used as a last option and should be used 
alongside therapeutic services, help from medical professionals and 
behavioural services. (NMed) 
10.2.2 Emotional responses to the use of psychotropic medication. 
Many caregivers expressed significant guilt regarding the need to use 
psychotropic medication for their child/dependent adult with an ASD. Guilt was 
expressed in terms of how their child/dependent adult affected relationships with 
partners, with other children, between siblings, within the family, and also the 
family’s relationship with the outside community. This was observed to be a 
consideration when deciding whether to use medication: 
Having a family member with autism impacts the whole family and means 
that we all live an autistic life. (CMed) 
It was evident that caregivers experienced complex emotional responses to 
the decision, and many felt their decision had been questioned by family, friends 
and other professionals. Many disclosed they believed it was a personal failure 
that their child/dependent adult required medication to assist with their behaviours 
and emotions, and expressed guilt relating to this. They also queried whether it 
related to their own coping and parenting abilities, rather than something within 
the child: 
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I hate that he needs them [medication] that they may have long term side 
effects and that I have failed to care for him without exposing him to the 
risks of those side effects. I hate that he is learning that when you have a 
problem, you pop a pill. I hate being on the divide of the parental line and 
it’s the side that no one wants to be on and that some people would never 
cross. I hate that I have had to cross the line. (CMed) 
The feelings of guilt that many caregivers expressed appeared to be 
closely linked to a sense of desperation in their situation as a caregiver. A number 
of caregivers stated they felt totally consumed by their role as a caregiver of a 
child/dependent adult with an ASD, and that this role had become their identity. 
Some caregivers expressed concern about their capacity to continue caring for 
their child/dependent adult, with some stating they did not feel they could 
continue this role. Many caregivers specifically commented that without 
medication, they could no longer continue to care for the dependent adult/child 
with ASD. Many cited that despite tireless efforts, it was difficult to gain 
assistance from support services, and that even when they gained access, outcome 
successes were limited. These experiences led to the decision to resort to using 
psychotropic medication. 
It was also evident that many caregivers felt a sense of desperation around 
the level of challenging behaviour displayed by the child/dependent adult for 
whom they cared. For example, a number of caregivers commented they felt that 
they had no choice but to use medication, otherwise the child/dependent adult 
would be required to be physically restrained, due to assaultive or self-harming 
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behaviour. Some caregivers reported that protecting the safety of their other 
children was essential, and that without medication they may not have been able 
to care for the child/dependent adult at home, due to the risk of harm to their other 
children: 
Medication is better than my child being physically restrained by people 
who do not understand his situation. (CMed) 
A small number of caregivers specifically described their anxiety 
regarding the effort to maintain the safety of the child/dependent adult, or other 
family members. Many reported they felt desperate about the need to stop a 
specific behaviour, and acknowledged the use of medication for restraint of 
behaviour: 
A 3 year old that throws dining room chairs across the room requires 
restraint for the safety of himself and those around him. (CMed) 
Many caregivers identified the pressure they felt regarding the decision to 
use medication to manage the child/dependent adult’s ASD symptoms, as well as 
a form of ‘restraint’. Pressure to use psychotropic medication was cited from a 
number of sources including schools, family members and professionals. School 
was consistently cited as a reason for ‘restraining’ their child, with other services 
also cited, including respite and care support agencies: 
I was continually badgered to try my son on medication by his school and 
I chose not to continue with it. I was subjected to negative responses and 
attitudes. (PMed) 
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In contrast, other identified pressures came from the impact of negative 
community views on the decision to administer psychotropic medication, 
particularly in children. Specific comments on the role of the media in influencing 
how the public perceived medication use for children with an ASD were also 
provided: 
There is a great community pressure to avoid medication almost at all 
cost. Add to this the pressure to avoid any sort of medication for children 
and you have a dangerous pressure to avoid medication when it may be of 
great benefit to an individual. (CMed) 
This quote highlights the role of outside influences in decision-making by 
caregivers about medication use. It was apparent that caregivers perceived 
significant social pressure around the decision to use medication. This emphasizes 
the importance of the availability of clear and accurate information and support to 
assist families in decision making about medication use. 
10.2.3 Fear of side effects. 
It was evident through informant responses that significant concerns were 
present regarding the side effects of medication use in the ASD population. 
Caregivers reported that many children/dependent adults experienced weight gain 
associated with medication, ranging from four to 20 kilograms. Caregivers were 
concerned about the long term health effects of this weight gain. In addition, four 
caregivers reported that the child/dependent adult experienced tics or involuntary 
movements associated with the medication. Two caregivers reported their child 
experienced stunted growth, while other side effects reported by caregivers 
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included increased aggression, increased obsessional behaviours, headaches, 
stomach cramps and reduced cognitive functioning: 
He quite often had fast heart rate which distressed him and was getting 
extremely hot, he had trouble urinating and one eyelid began to droop 
after being on it for 6 weeks. (PMed) 
Many caregivers expressed concern regarding the long term outcomes of 
psychotropic medication use on children, and the effect of medication on the 
developing brain. Several stated they were aware that medications were 
prescribed ‘off-label’ to children, and some noted the lack of randomised 
controlled studies evaluating the long term effects of psychotropic prescriptions 
on this population. It was apparent that caregivers struggled with their level of 
responsibility in allowing a child/dependent adult to be medicated, when research 
was yet to extensively evaluate the evidence base for psychotropic medication in 
children, and the long term outcomes of this on the developing brain: 
Our research shows that these medications in kids this young are 
not properly researched and can have very dangerous side effects. 
(NMed) 
10.2.4 Value of psychotropic medication. 
Despite the clearly negative themes identified, the value of medication in 
providing caregivers of children/dependent adults with improved quality of life 
was evident. Improvements in quality of life were reported, not only for 
caregivers themselves, but for the family unit as a whole. Many caregivers 
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reported improved sleep, reduced stress and lower levels of conflict in the 
house. In turn, this allowed them to care for the child/dependent adult to the 
best of their ability: 
It has changed my life. He goes to sleep and stays asleep with rarely a 
problem. I feel like I can cope. (CMed) 
In regards to the impact of medication on the family, caregivers 
commented on specific improvements in the relationship between siblings. 
Specifically, siblings were reported to have a reduction in exposure to 
aggressive outbursts by the child/dependent adult with ASD, which ultimately 
improved the lives of siblings: 
I tried for many years to avoid having any medication prescribed to my 
son, preferring to use natural remedies and supplements. I now think the 
whole family would have benefited if my son had been on melatonin 
sooner as his sleep difficulties caused a lot of additional stress to everyone 
in the family, particularly his sisters. (CMed) 
In addition to the reported value of medication to quality of life, caregivers 
noted significant positive changes in the child/dependent adult. For example, 
many caregivers reported that the child/dependent adult learnt new skills 
following the commencement of medication, with a few reporting that the 
child/dependent adult began to speak. In addition, some caregivers reported 
advancements in reading ability, with one respondent reporting that their child 
commenced writing: 
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He is now a different child, he started speaking 10 days after beginning 
medication and is now sleeping better, generally happier, more engaged 
and relaxed and now shows affection. (CMed) 
…I truly believe it gives my son a better quality of life. (CMed) 
Medication was also identified as being particularly useful in reducing 
aggression in children and dependent adults, such as hitting, kicking and 
biting. Many caregivers reported that lower rates of aggressive behaviour 
meant that the child/dependent adult was more readily able to access the 
community, which improved overall family functioning: 
When not medicated he can smash windows, destroy a room in 5 minutes. 
We see kicking biting, punching etc...On medication thought processes 
seem to be slowed right down, so intervention can actually occur when he 
is heightened. This is not possible un-medicated. (CMed) 
Caregivers also noted improvements in attention and the concentration 
levels of children and dependent adults with an ASD, following the 
commencement of medication. The majority stated this allowed the person to 
participate more fully in school and home life, with some also noting improved 
social interactions: 
Both of us (parents) and his teachers at school have remarked that he has 
settled and is able to focus better for longer periods since being on 
medication. (CMed) 
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A further theme that emerged was the reduction of anxiety. Anxiety was 
identified as particularly debilitating, and often interfered with the child/young 
person’s ability to participate in life: 
 My daughter had so many fears that the anxiety was debilitating and she 
was too afraid to do just about anything… Now she can do just about 
anything. (CMed) 
Another theme that was evident was the benefit of medication in 
improving the child/dependent adults’ sleep patterns. Medication was noted to 
assist in falling asleep, staying asleep and reducing early wakening. Caregivers 
commented that with additional sleep, the child/dependent adults were often 
observed as calmer, happier and less anxious: 
Before he was prescribed Risperidone at the age of three his sleeping 
patterns were all over the place sleeping at 2, 3, 4 am etc., and waking up 
afternoon but within two weeks of taking this he went into a proper 
routine. He is also a lot calmer… a lot less hyperactive. (CMed) 
Many caregivers also reported they felt that medication reduced 
obsessional, ritualistic behaviours in the child/dependent adult. Caregivers 
reported that this often allowed for people to more fully participate in 
activities, as they were not so focused on rituals: 
It calms her down and reduces the repetitive behaviours which would get 
her so worked up. She was able to attend her school social without 
problems, something she would never have achieved prior. (CMed) 
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10.2.5 Caregiver burden. 
The burden of care giving appeared to be an influence in the decision of 
caregivers to use medication to assist the child/dependent adult with an ASD. 
Many caregivers spoke about the difficulties of being a carer, and that they often 
felt as if they could not cope without medication: 
Caring for someone with ASD is really wearing and I feel quite drained a 
lot of the time. The possibility of me working full time is really beyond 
what I could cope with and therefore we are financial disadvantaged due 
this disorder. So far medications have been a godsend for my daughter. 
(CMed) 
Although the focus of this study was on the use of medications in 
managing emotions and behaviours associated with an ASD, many caregivers 
took the opportunity to provide general comments about the difficulty of caring 
for a child/dependent adult with an ASD. In particular, how ‘isolating’ being a 
caregiver could be and that often it was ‘a thankless job’. Many spoke of feeling 
as though they were alone in caring for the child/dependent adult, and that 
decisions pertaining to their child were theirs alone, as opposed to being shared 
with professionals and family members. Several caregivers felt excluded from the 
community as a result of their child/dependent adults’ behaviours, level of 
difficulties or lack of acceptance. A few caregivers commented that it takes a 
‘community to raise a child with an ASD’; however, it was apparent this support 
was not widely available. Isolation from family, friends and community played a 
significant role in how respondents perceived their role and value as a caregiver. 
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Many felt that if they were a ‘better’ caregiver, this would not have resulted in 
social isolation. Others articulated the view that isolation stemmed from the 
negative judgment of their parenting made by the community: 
To care for someone with an ASD can be extremely challenging with 
family friends and the community to quick to judge and condemn...the toll 
on relationships is especially hard. (CMed) 
An additional theme related to the perception of informants that their 
caregiving ability was criticised by people who ought to be supporting them in 
their caring duties, including schools, teachers, psychologists and other 
professionals. A number of caregivers reported they felt dismissed by 
professionals, and that they were not treated as an expert in the child/dependent 
adult’s life. It was evident that this lack of respect affected their overall trust of 
professionals, in particular if they suggested medication: 
For people to understand they need to walk a mile in our shoes. This is 
especially when it comes to professionals who won’t listen and think they 
know your child better than their family does. (CMed) 
Caregivers reported that the lack of community acceptance and 
understanding of people with an ASD was a significant issue. This often resulted 
in the child/dependent adult being isolated from their community, family and 
friends. Also apparent was the view that medication was often used as a way to 
assist the individual with ASD to conform to societal norms and expectations 
regarding behaviour. 
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10.3 Subthemes Study 3a 
Underlying the aforementioned themes, a subtheme of defensiveness was 
evident in the responses from caregivers surrounding the decision to use 
psychotropic medication for their child/dependent adult. Numerous caregivers 
provided multiple justifications as to why they had decided to use psychotropic 
medication. It appeared many felt the need to validate and explain the rationale 
for their decision. In particular, this defensiveness appeared to arise from a 
perception that using psychotropic medication in children and dependent adults 
was ‘bad’, and only permissible if they had a diagnosed mental health condition. 
It was further identified that the defensiveness appeared to stem from a 
perception that psychotropic medication use had arisen from personal failure as a 
caregiver. This sense of failure appeared to originate from a feeling of continually 
being judged by people within their support systems, by professionals and by 
society at large, regarding the decision to administer psychotropic medication to 
their child/dependent adult. 
An additional identified subtheme was a pervasive sense of desperation in 
caregivers, which served as the basis for psychotropic medication use. It appeared 
they were experiencing burnout, and were at a loss as to how to improve the life 
of the child/dependent adult for whom they cared. Medication provided the only 
option. It was apparent that caregivers did not feel well supported and there were 
suggestions that improved access to support may curb the need for medication. To 
summarise, society was also seen as partly responsible for the need to use 
psychotropic medication in children/dependent adults with an ASD. 
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10.4 Discussion Study 3a 
The aim of Study 3a was to gain insight into the perceptions of caregivers 
about psychotropic medication use in children/dependent adults with an ASD. 
Caregivers play a pivotal role in whether their child/dependent adult with an ASD 
takes psychotropic medication. Their perspectives are thus highly valuable in 
understanding psychotropic medication use in this population. Caregivers’ 
experiences give them unique firsthand knowledge of the effectiveness of 
psychotropic medication in managing undesirable emotions and behaviours 
associated with ASD. 
 Results from the qualitative analysis of free text areas draw attention to a 
level of complexity surrounding decisions to use psychotropic medication, to 
assist in the management of undesirable emotions or behaviours in a 
child/dependent adult. It was clearly evident that caregivers endeavoured to act in 
the best interests of the child/dependent adult, and that the decision to use 
psychotropic medication affected them considerably. It was also apparent from 
the analysis that caregivers’ experiences were individual and differed; thus, 
responses varied significantly. 
Caregiver identity was found to be deeply intertwined with the decision to 
use psychotropic medication in the management of their child/dependent adult. 
Caregivers were conflicted about their caregiving ‘duty’ to their child. The 
caregivers’ identities appeared affected by their parental efficacy, meaning the 
ability to manage their child/dependent adult with an ASD. In turn, this appeared 
to affect a caregiver’s decision to use medication. Previous research has found 
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that parental efficacy is a significant predictor of parental stress (Hassall et al., 
2005; Hastings & Brown, 2002). Further, it has been shown to have a negative 
correlation with challenging behaviour in children with ASD (Schieve, Blumberg, 
Rice, Visser, & Boyle, 2007). Given that higher levels of challenging behaviour 
have been found associated with psychotropic medication use, it is plausible that 
parental efficacy is also likely to affect medication use. This highlights the 
importance of including parental efficacy as a variable when examining 
psychotropic medication use in this population. 
Little research has explored the attitudes of caregivers regarding 
psychotropic medication use. This study found that caregivers commonly 
experienced a significant negative emotional response to psychotropic medication 
use in those for whom they cared. Close reading of the transcripts underscored an 
overwhelming sense of guilt in caregivers, around the decision to use 
psychotropic medication in the management of their child/dependent adult. It was 
clear that while caregivers gave a lot of themselves in their caring capacity, they 
nonetheless felt they needed to give more, or that it was a personal failure that 
their child/dependent adult needed psychotropic medication. This guilt was 
intertwined with their identity, and they appeared to question their competency as 
a ‘care’ giver. It appeared they sought validation from health professionals, who 
were offering medication, that it was not their personal failure. The findings 
therefore indicate that the emotional responses of caregivers are important to 
consider in the context of psychotropic medication use in ASD. 
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Caregivers also reported feeling significant pressure from outside sources 
around decisions pertaining to psychotropic medication use. This was articulated 
as feeling both ‘pressure to medicate’ and ‘pressure to make decisions’ they did 
not feel skilled to make. This supports findings by Valentine (2010) that parents 
of children with ASD often feel obliged to make decisions about their child’s 
treatment, for which they feel ill-equipped. Valentine (2010) concluded that it was 
important to consider that some parents may feel disempowered in regards to 
treatment options, while others were able to be more active participants. This 
indicates the importance of further exploring the effect of caregiver confidence in 
making decisions regarding psychotropic medication. In addition, it appears 
important that caregivers are provided not only with all available information 
regarding medication, enabling them to make an informed choice, but time with a 
health professional to clarify and discuss it as a treatment option. Caregivers need 
to be empowered not only to make decisions around their child’s health needs, but 
also to assert their beliefs about what is best for their child to outside sources. 
The side effects of psychotropic medication were another central concern 
for caregivers. Consistent with previous research (Valdovinos et al., 2005), many 
reported that the child/dependent adult experienced side effects. In addition, 
caregivers held significant concerns regarding the long term outcomes of using 
these types of medications, in particular on the child’s developing brain. The 
randomised controlled trials that have been conducted for many of these 
medications have used adult participants, and there is insufficient long term data 
available, particularly for a child population (Jesner et al., 2007). For example, 
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risperidone has been trialled in children aged five to 17 years for a six month 
period, and while common side effects were identified (e.g., weight gain, 
sedation, liver problems), the long term outcomes of these side effects for 
children/dependent adults remaining on this medication are not clear (McCracken 
et al., 2002). Therefore, caregivers’ acknowledgement of fear regarding not 
knowing the long term outcomes of psychotropic medication use in children 
appears warranted. Further research is urgently required to explore the long term 
effects of these medications, to provide caregivers accurate information prior to 
placing their child on these medications long term. 
Despite the concerns of caregivers around the use of medication, 
particularly the risk of side effects, the results of this study indicated that 
psychotropic medication use in a child/dependent adult was also considered 
valuable by most caregivers. For instance, caregivers indicated significant 
improvement in many daily functioning tasks, including increased skill levels, 
reduced challenging behaviours, improved concentration and enhanced sleep 
patterns. This observation supports previous research suggesting significant 
benefit to psychotropic medication use in this population (e.g., McCracken et al., 
2002), and challenges those studies indicating no difference in a person’s 
presentation when using psychotropic medication (e.g., Antonacci, Manuel & 
Davis, 2008; Brylewski & Duggan, 1999; Gralton, James & Lindsey, 1998 ). Of 
course, it is not possible to determine the extent that reports of positive outcomes 
in this analysis accurately reflect the effectiveness of psychotropic medication. It  
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may also demonstrate a tendency for caregivers to show a positive bias to justify 
their role in the administration of psychotropic medication to their child or 
dependent adult with ASD. 
It was apparent from the findings that quality of life is a central focus for 
caregivers. They appeared to be concerned with not only their own quality of life, 
but that of the child/dependent adult, other members of the family and the family 
unit. The potential for improved quality of life appeared paramount in the 
decision to use psychotropic medication. It is widely accepted that caring for a 
child/dependent adult with an ASD can be stressful for caregivers (e.g., Gray, 
2003; Hastings & Brown, 2002) and that they often experience lower levels of 
quality of life, compared to those who provide care for offspring who are 
typically developing or who have an intellectual disability (Lee et al., 2008). The 
relationship between quality of life and psychotropic medication use in those with 
an ASD and their caregivers has largely been unexplored. However, it is accepted 
that psychotropic medication would influence a person’s wellbeing (Henderikus, 
2004). The findings of this study also suggest that psychotropic medication use 
resulted in improvements in quality of life for the child/dependent adult, the 
caregiver and the wider family. As described above, with respect to effectiveness 
of psychotropic medication, it is not possible to differentiate the true impact of 
psychotropic medication from potential bias in reporting by caregivers. There is 
clearly a need for further exploration of the relationship between quality of life 
and psychotropic medication use. 
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It was evident that the views of caregivers regarding the use of 
psychotropic medication were heavily influenced by their perceptions of others 
views. This raises the question of how society perceives psychotropic medication 
use, and whether caregiver perceptions of these are accurate. The analysis of 
caregiver responses indicated they perceived society’s views on the use of 
psychotropic medication in ASD as largely negative. Limited research to date has 
explored community attitudes regarding psychotropic medication usage in not 
only those with an ASD, but also the wider community. This type of information 
could provide a basis for assisting caregivers in their decision making. 
Alternatively, it could assist caregivers to challenge their own beliefs and coping 
with the perceptions of others on using medications to help better care for their 
children/dependent adults with an ASD. 
The findings demonstrated that the psychological burden of caregiving 
influences the decisions made by caregivers to use psychotropic medication, to 
assist the child/dependent adult with an ASD. It has been established that higher 
levels of challenging behaviour, increased aggression and comorbid mental health 
conditions relate to the level of burden reported by caregivers (e.g., Baker, 
Blacher, Crnic & Edelbrock, 2002; Dunst, Trivette & Deal, 1988; Feldman et al., 
2007; Gray, 2003). Moreover, psychotropic medication use has been shown as 
higher among those who exhibit challenging behaviour, aggression and comorbid 
mental health conditions (e.g., Eaves & Ho, 2008; Howlin, Goode, Hutton & 
Rutter, 2004). It may thus be expected that a relationship between psychotropic 
medication use and the psychological burden of parenting is reported by 
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caregivers of children/dependent adults with ASD. In addition, the burden of 
caregiving appeared to be exacerbated by feeling judged and criticised in their 
caregiving role. The findings suggested that many caregivers felt particularly 
criticised or judged by the professionals involved in the care of their offspring. It 
was highlighted that caregivers perceived a lack of both formal (teachers, doctors, 
psychologists) and informal (family, friends, community groups) support. Many 
caregivers provided information that suggested they were barely managing the 
care of their child/dependent adult; and that without medication, their family 
would not be able to function. This raises the possibility that if caregivers were 
provided with higher levels of support, other strategies to manage their child with 
an ASD (e.g., positive behaviour support, sensory skills training) and greater 
respite opportunities, there may be less cause for psychotropic medication. 
Previous research has identified that caregivers who report low levels of 
social support and high levels of parental distress perceive higher levels of 
challenging behaviour in children with ASD (Bromley et al., 2004). Higher levels 
of challenging behaviour in a person with an ASD were found to increase 
medication use (Robertson et al., 2005). Levels of social support have also been 
identified as being associated with parents’ sense of competence and parents’ self- 
esteem levels (Johnston & Mash, 1989). Therefore, it is plausible that level of 
support may be a factor in psychotropic medication use. This highlights the need 
for future research to explore the relationship between support, or lack thereof, on 
psychotropic medication use and to determine whether the choice to medicate is 
affected by the caregiver’s level of support. 
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The findings from this analysis have important implications for those 
working with caregivers of children/dependent adults with an ASD. The analysis 
highlighted that although there were common themes identified in responses, 
there was also individual variability in caregivers’ experiences, and this needs to 
be considered when working therapeutically with this population. The strong 
sense of powerlessness that was detected in many of the responses highlights the 
importance of empowering caregivers with a sense of autonomy over decisions to 
use psychotropic medication in the management of their offspring. Moreover, 
caregivers need to be provided with a range of support and options for 
interventions, such that they feel confident to manage and respond to their 
child/dependent adult with ASD. Caregiver education regarding options for the 
management of undesirable emotions and behaviours associated with ASD (with 
psychotropic medication being one of these) is also likely to be beneficial. 
Education needs to incorporate information on the evidence base for the 
effectiveness of the available options, as well as the risks, including possible side 
effects. It is imperative that caregivers be viewed as ‘experts’ in the life of their 
child/dependent adult by professionals. Taking the time to actively listen to 
caregivers and value their unique knowledge is paramount in enabling them to 
become active participants in the decision making process, and increase feelings 
of self-efficacy and empowerment. There is also a clear need for professionals to 
recognise and validate the complexity of a caregiver’s role in negotiating what is 
not only in the best interests of the child/dependent adult, but also other members 
of the family. The quality of life of all family members needs to be considered, as 
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this factor appeared to play an important role in the decision to use psychotropic 
medication. 
In conclusion, this analysis identified a range of caregiver opinions 
regarding psychotropic medication use in children and dependent adults with an 
ASD. The decision to use psychotropic medication appeared to be complex and 
influenced by individual, familial and systemic factors. The quality of life of not 
only the child/dependent adult, but also the wider family appeared to be a key 
consideration in a caregiver’s decision to medicate. The findings provided 
important evidence as to the views, attitudes and perceptions of caregivers’ 
towards psychotropic medication use in this population. The clinical implications 
are broad ranging. It appears particularly important to recognise that each 
caregiver will present with an individual set of circumstances. Consequently, 
professionals need to ensure that caregivers are provided with thorough levels of 
education around the evidence to support use of psychotropic medication in those 
with an ASD. 
10.5 Results Study 3b 
The following section provides an exploration of qualitative data provided 
in response to open ended questions by self-reporting adults with an ASD. 
Responses relate to views on the reasons for use, the effectiveness of use, and 
their overall attitudes towards the use of psychotropic medication in the 
management of undesirable behaviours and emotions in people with ASD. 
Findings are presented according to six linked themes: lack of community 
understanding and social isolation; disempowerment; individual identity and 
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social expectations; lack of other options; mental health; and quality of life. 
Underlying these themes were two key subthemes: desire for autonomy and lack 
of services. 
10.5.1 Lack of community understanding of ASD and social isolation. 
Many participants expressed the view that there was a lack of 
understanding of people with an ASD within the community, and this influenced 
their decision to take psychotropic medication. That is, they were more likely to 
take medication if they did not feel accepted. It was emphasised that participants 
did not wish to be defined by their ASD diagnosis; rather they wanted to be 
viewed as individuals. Specifically, they wanted to be provided with the same 
emotional support or guidance as others, irrespective of their diagnoses. This 
theme was endorsed by the majority of participants, and appeared to have a 
pervasive effect across all aspects of their lives, including employment, education, 
social relationships and health. 
The lack of understanding of ASD also affected relationships between 
participants and health professionals. Concerns were expressed that prescription 
of psychotropic medication might be used by health professionals as an 
alternative to other social or psychological supports for people with an ASD. In 
particular, respondents were of the opinion that health professionals viewed 
medication as an easier option for emotional and behaviour management, than a 
therapeutic approach based on addressing the reasons why the feelings or 
behaviour may be occurring: 
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Medication … is an after effect cure. (CMed) 
According to some participants, when they had sought assistance from 
doctors or other professionals, a common response was to automatically increase 
their medication. There was a clear preference expressed for consultation with 
professionals who took the time to understand their difficulties: 
To a degree I feel as though my psychiatrist ups my medication or 
prescribes more when I am upset or something sets me into a meltdown 
and I contact her, the first thing she does is medication to the rescue, why 
not just listen or be with me? (CMed) 
In addition, a number of participants commented on feelings of isolation 
and loneliness. It was apparent that for many that loneliness played a role in the 
decision to use medication. Social isolation and a lack of community support for 
people with an ASD were acknowledged as having a significant effect on their 
mental health, in particular feelings of anxiety and depression. These feelings led 
to them seeking professional assistance, which in turn resulted in them accepting 
a recommendation for medication. A few participants reported their belief that a 
lack of availability of social supports and friendships were predictors for 
medication use: 
Issues of social isolation and lack of community support are causing 
people on the Autism Spectrum to be medicated. (NMed) 
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Moreover, it was apparent that people with ASD sought acceptance and 
meaningful relationships. The difficulties experienced in these areas often 
resulted in medication use: 
Medication should be used to help feelings of anxiety and depression only 
when not caused by other issues such as loneliness, socialisation problems 
etc. which should be treated by support groups, social groups and help 
becoming part of the community etc. (PMed) 
10.5.2 Disempowerment. 
It was evident from comments provided that many participants felt disempowered 
not only in their decision to use medication, but also more generally in their lives. 
There was a sense that people with an ASD were heavily influenced by health 
professionals, and were not active participants in decision making pertaining to 
their own health. They attributed this lack of perceived power to their ASD 
diagnosis. In particular, participants reported feeling disempowered around the 
decision to use or not use medication to assist with the management of their 
behaviours and emotions. The decision to use medication was viewed as complex 
and was influenced by a multitude of external factors that participants perceived 
were beyond their control. Participants emphasised it was not a decision that was  
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made lightly, but that often people with ASD perceive the use of psychotropic 
medication as their only available coping strategy: 
I have a love hate relationship with having to take medication. I resent 
having to take a pill to feel even remotely like I want to remain living. 
(CMed) 
10.5.3 Individual identity and social expectations. 
The importance of identity presented as another significant theme. Many 
participants commented that they did not wish to take psychotropic medication if 
it took away who they were, or was used to make them conform to social norms. 
Several stated they liked being who they were, and embraced their ASD 
characteristics. Those who did take medication endeavoured to clarify the reasons 
behind this decision, with an emphasis on a need to clearly articulate who they 
were and what they believed: 
I haven’t seen a doctor since my diagnosis so have never discussed 
medication in relation to having autism. I don’t think medication should 
be a first point of call or an excuse not to deal with underlying problems 
and trauma. (NMed) 
A number of responses by participants highlighted the impact of social 
pressure behind motives for psychotropic medication use. Participants also 
identified the pressure they felt to conform to society’s norms and values. Many 
reported they thought that medication was often used in people with an ASD as a 
form of restricting one’s nature, personality and behaviour. It was further stated 
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that medications were used as a form of control to assist people with an ASD to 
conform to social expectations, and reduce behaviours or emotions that others 
deemed inappropriate. Taking medication solely to inhibit behaviours 
unacceptable to society was viewed as restraint by some participants. However, 
this was distinguished from people who chose to take medication to treat 
specified conditions. In this circumstance, medication use was not viewed as a 
form of restraint: 
Why else would you be given medication, other than to control you and 
make you quiet? (PMed) 
Some participants stated that using medication to ‘fit in’ with other’s 
expectations restricted their nature. Many respondents articulated they would 
prefer differences to be embraced, rather viewed as something to be eradicated 
with medication: 
Society expects people to conform to ‘their’ norms and puts pressure on 
people to take medications in order to fit neatly in the boxes they have 
created. Yeah I know I am a bit different it is what I am and I don’t feel 
comfortable being medicated into something that does not feel right. 
(NMed) 
10.5.4 Lack of other options. 
The majority of participants conveyed that the decision to use medication 
was affected by the lack of availability of other options to address the behavioural 
and emotional difficulties they experienced. Medication was a commonly 
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available and subsidised treatment, while alternatives such as counselling, 
auditory training, emotion skills training, and sensory assistance were often 
pursued at the expense of the person with an ASD. Essentially, medication was 
the cheapest option: 
I can't afford the auditory re-training required to fix my problems, drugs 
are the ambulance at the bottom of the hill for me. (CMed) 
It was also noted that treatment of ASD symptoms with medication was 
perceived as an easier option. Many participants felt the reason they were 
prescribed medication was for its quick-fix nature, in lieu of the time and effort 
required to conduct detailed assessments and interventions: 
Medication is the lazy cheap way to treat disorders. If there was funding 
for proper assessment and treatment medication would not be needed for 
most people. (PMed) 
Many participants claimed that medication should not be used as an 
isolated intervention for the treatment of a mental health condition, nor for the 
undesirable emotions or behaviours associated with their ASD. A couple of 
participants commented that medication should only be used within the context of 
other psychological interventions, including working with a psychologist or 
counsellor to address the complexity of issues facing a person with an ASD. A 
few participants also indicated they believed alternative interventions, including 
sensory-based activities and natural therapies were important aspects of 
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intervention. These participants believed that medication only provided limited 
assistance if used in isolation: 
Medication should not be relied upon and be the only therapeutic 
treatment. Exercise, diet, lifestyle, goals, groups, courses...Everything 
needs to be considered. (NMed) 
10.5.5 Mental health. 
Mental health was a dominant theme. It was raised by participants in terms 
of both their own misdiagnosis, as well as their desire to separate the use of 
medication for mental health purposes from medication for undesirable emotions 
or behaviours associated with their ASD. Many participants indicated they had 
received a number of diagnoses prior to receiving their ASD diagnosis, including 
depression, OCD, personality disorders, bipolar and anxiety disorders, and that 
this had negatively affected their mental health. For a number of participants, 
misdiagnosis had resulted in the prescription of inappropriate medication and a 
corresponding denial of access to alternative evidence-based interventions for 
people with an ASD: 
I feel that I was diagnosed too late in life to get the support I deserve. 
Being misdiagnosed and placed on medication that was not effective 
caused 2–3 years of harm, emotionally, physically and mentally. (PMed) 
In line with this, participants strongly emphasised the importance of 
separating psychotropic medication use for co-existing mental health conditions, 
from medication taken to assist in managing undesirable emotions and/or 
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behaviours associated with their ASD. Although the use of psychotropic 
medication for the treatment of mental health conditions was apparently viewed 
as permissible, its use for the treatment of ASD symptoms was viewed less 
favourably. 
10.5.6 Quality of life. 
A final theme evident in the responses provided by adults with ASD 
related to overall quality of life. It was frequently stated that medication was used 
as a substitute for addressing underlying issues associated with a lowered 
perceived quality of life. Some participants identified feeling distressed by having 
to rely on medication to achieve enhanced quality of life, and questioned whether 
these opportunities could be improved through avenues other than medication. 
Conversely, a few participants indicated the benefits of medication for improved 
quality of life for people with an ASD. Specifically, they reported that medication 
permitted them to engage in activities they would otherwise find overwhelming. 
These included activities of daily living, social encounters, as well as 
employment. In addition, medication provided participants with a sense of control 
over emotions and behaviours: 
Medication is overwhelmingly positive for me, my family and my friends. I 
can do more and I can join in with more things. (CMed) 
10.6 Subthemes Study 3b 
Underlying the identified primary themes was a strong sense that 
participants desired autonomy, both in terms of their decision to use psychotropic 
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medication, but also more generally in their own lives. This desire for an 
autonomous life appeared intertwined with the disempowerment they experienced 
because of their diagnosis; but it was also emphasised in terms of their 
interactions with professionals around psychotropic medication use. 
An additional subtheme identified was the lack of available services for 
adults with an ASD. It was apparent that many participants wished to be further 
engaged with services. However, services were either not available to assist them, 
or they specialised in children with an ASD. An undertone of frustration was 
particularly evident regarding the lack of subsidised options, as many of the 
evidence-based treatments (e.g., auditory training, sensory work, CBT) were 
expensive. This raises the question of whether in some cases medication may be 
prescribed as a coping strategy due to its ready availability in the face of a dearth 
of alternatives. 
10.7 Discussion Study 3b 
The aim of Study 3b was to explore the perspectives and beliefs of 
independent adults with an ASD towards psychotropic medication use. The 
analysis of the responses indicated that views of psychotropic medication use 
altered, depending on the reason for usage. For example, it appeared that many 
individuals with an ASD perceived psychotropic medication negatively if it was 
used to ameliorate ASD symptoms. This view changed if the person used 
medication to treat a comorbid mental health difficulty. Similar to the findings 
from caregivers, the decision by adults with an ASD to use medication appeared 
complex and entwined with other factors. 
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Psychotropic medication use was found to be influenced by a lack of 
community understanding towards individuals with an ASD. The findings 
specifically indicated that independent adults felt disconnected from their 
community and that this influenced their wellbeing. This is consistent with 
previous research demonstrating that independent adults with an ASD experience 
a profound sense of isolation, a longing for greater intimate relationships and a 
desire to not only participate, but also contribute to their community (Muller, 
Schuler & Yates, 2008). This study highlights that social isolation is a 
contributing factor to psychotropic medication use, and needs to be considered 
when adults with ASD present to health care services. 
It appears that many adults with ASD perceive a lack of understanding 
from the health care professionals who work with them. This raises the question 
as to whether professionals have an adequate knowledge base that enables them to 
work competently with ASD adults. Some previous research has compared ASD 
knowledge within the health care system (e.g., Heidgerken et al., 2005; Stone, 
1986). While primary health care providers and specialists have been show to 
accurately endorse the DSM-IV-TR criteria for ASD (APA, 2000), in comparison 
to health professionals working in an ASD specific organisation, they 
differentially endorsed items relating to prognosis, course and treatment 
(Heidgerken et al., 2005). Primary health care professionals may well have 
limited information as to the best interventions available for those with ASD. This 
highlights the need for further education of these professionals around the 
evidence base for available interventions. 
 Psychotropic Medication and ASD
   
 
 
221 
 
The findings demonstrate that individuals with an ASD felt disempowered 
when discussing treatment options with medical professionals. People with 
disabilities are considered some of the most marginalised individuals in the 
community, and this status is often associated with having less autonomy (Ward 
& Stewart, 2008). These results suggest that this lack of autonomy extends to 
decisions pertaining to medical needs of those with an ASD, specifically 
psychotropic medication. It emphasises the importance of conducting thorough 
assessments of those with an ASD. Further, these results suggest that 
professionals need to take time to explain and clarify the treatment options 
available to those with an ASD. This illustrates that independent adults with an 
ASD are seeking to participate more actively in their treatment, and gain further 
control over their own lives and the interventions they receive. 
The results also suggest that many individuals in this study had accepted 
and embraced their ASD symptoms, and did not wish to take psychotropic 
medication if it ‘restricted’ their individuality. This view is consistent with the 
current legislative framework within Victoria, Australia, ‘that restraint only be 
only be used if it is necessary to prevent the person from causing physical harm to 
themselves or other person’ or ‘to prevent the person from destroying property 
where to do so could involve the risk of harm to themselves or any other person’ 
(Victorian Government, 2007, p142). This poses the dilemma of the rights of the 
individual over those of others and what happens when these are not aligned. In 
addition, there is growing evidence suggesting that alternative interventions (e.g., 
positive behaviours support, social skills training) are equally, if not more 
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effective, than psychotropic medication in many circumstances and should be 
used prior to medication (Osgood, 2004). This indicates it is important to consider 
the rationale for medication use, especially if it is seen as ‘restricting’ a person’s 
individuality. 
It appears that the wide availability of psychotropic medication and the 
dearth of alternative interventions have a significant role in the decision to use 
psychotropic medication. Many individuals with an ASD turn to psychotropic 
medication as a ‘last resort’ option, to cope with mental health difficulties or ASD 
symptoms. Despite the significant evidence base for alternative treatment 
modalities (e.g., positive behaviour support for working with an ASD; Hwang & 
Hughes, 2000), these were clearly difficult for participants to access, many citing 
cost as the most significant barrier. The autism community at large has 
acknowledged the need for improved health care services and specialised 
programmes for adults with an ASD (Autism Ontario, 2008; National Autistic 
Society, 2006; White, McMorris, Weiss & Lunsky, 2012). The comments made  
by participants in this study support the view that there is a need for improved 
access to health and support services for adults with an ASD living in the 
community. 
The analysis of responses further reveals that psychotropic medication use 
is inextricably linked to mental health. The findings suggest that participants 
sought to differentiate between using medication for ASD symptoms and 
comorbid mental health conditions. Previous research has found those with ASD 
have higher rates of psychopathology than the general population (e.g., 
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Ghaziunddin, 2002; Ghaziunddin & Gredden, 1998; Ghaziuddin & Tsai, 1991; 
Matson & Nebel-Schwalm, 2007). However, this thesis contributes new 
knowledge by highlighting the distinction made by adults with an ASD 
concerning psychotropic medication use for a comorbid condition, as opposed to 
use for symptoms of ASD. This implies that individuals perceive their ASD 
differently to an associated mental health condition. These individuals felt that 
psychotropic medication should not be readily prescribed for ASD, but rather be 
prescribed for a comorbid mental health condition if needed. This raises the key 
question of how mental illness is perceived as different from ASD among those 
affected by ASD. Further research is warranted to explore the views around 
mental health conditions and treatment options among those with an ASD. 
There are several anecdotal reports of individuals with an ASD being 
incorrectly diagnosed with various other mental health conditions (Bradley, 
Lunsky, Palucka, & Homitidis, 2011; Perlman, 2000). The current findings 
suggest that misdiagnosis has a profound impact on individuals’ wellbeing, as 
well as on their subsequent use of psychotropic medication. It is evident that there 
was a significant negative impact on individuals who were diagnosed with a 
myriad of alternative mental health conditions prior to receiving their ASD 
diagnosis. In turn, this meant that individuals felt they were being incorrectly 
medicated. There is limited research investigating the impact of misdiagnosis on 
those who subsequently receive an ASD diagnosis. This raises questions as to 
whether earlier diagnosis and the ready availability of ASD specific intervention  
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could have circumvented the use of psychotropic medication. Further exploration 
of the effects of misdiagnosis on independent adults with ASD, and the role they 
believed this played in psychotropic medication use, is warranted. 
It was also apparent from the analysis of comments that quality of life is 
vital to independent adults with an ASD. Findings demonstrate that many felt they 
had poor quality of life. While quality of life was important to individuals with an 
ASD, they nonetheless believed that medication should not be used as a substitute 
to addressing the underlying issues pertaining to quality of life, such as social 
inclusion, employment, participation in day-to-day activities. This finding is 
consistent with previous research from longitudinal studies, which indicated that 
many adults with an ASD experienced ‘poor’ or ‘very poor’ quality of life in 
adulthood (Howlin, 2000; Howlin et al., 2004). Adults with an ASD have been 
found to be highly reliant on others for support, including family, friends and 
support services (Howlin et al., 2004). Support characteristics, including social 
support and professional support, have been found as significantly related to 
better quality of life outcomes in people with high functioning ASD (Renty & 
Royeurs, 2006). This indicates that if medication use allows for greater social 
interaction and participation with supports, this may ultimately improve the 
quality of life of independent adults with an ASD. 
The implications from this study are broad ranging. While independent 
adults with ASD appear largely self-sufficient, they require access to support 
services, in particular multidisciplinary assessments and interventions that are 
specifically targeted to ASD symptoms, and undesirable emotions and 
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behaviours. There also appears to be a need for further ASD education for health 
professionals, particularly regarding the recognition of ASD, interventions and 
available support services. It is especially important that primary health care 
providers have accurate and up to date information about approaches that may 
assist or benefit this group, in the event they present with difficulties. Moreover, 
there is a need for enhanced availability of these professionals for referral. There 
is also an identified need to develop better protocols around supporting those 
diagnosed with ASD later in life. They may still benefit from interventions that 
are evidence-based in younger individuals with ASD. 
In conclusion, the views and experiences of independent adults with an 
ASD are varied. Many sought to express their concern around the level of 
medication use themselves, and the lack of alternative options available to them. 
Many specifically reported a need for increased availability of alternative 
interventions to assist with undesirable emotions and behaviours associated with 
ASD. Despite this, there was a clear message that psychotropic medication use to 
manage comorbid mental health conditions was viewed as important and 
permissible. The information provided by participants in this study gave unique 
insights into the views and experiences surrounding psychotropic medication use 
by those with an ASD. 
10.8 Limitations of Study 3a and 3b 
It is possible that the respondents who participated in Study 3 held 
stronger beliefs compared to the respondents who did not participate in this part 
of the study. As a result, respondents who displayed stronger beliefs may have 
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encompassed more motivation to document information in the free text areas of 
the survey. Those who did not have strong beliefs about the use of psychotropic 
medication may have been less likely to document their responses in the free text 
areas, and thus their perspectives might not have been heard. 
A further limitation of the study was that the scope of the qualitative data 
was limited to the use of psychotropic medication, rather than incorporating all 
interventions therefore limiting the breadth of information that may have been 
extracted during the analysis. In addition, the depth of information provided was 
limited to the size of the free text areas provided in the open questionnaire on the 
three key topics. Future research may benefit from conducting face-to-face 
interviews allowing more in depth questioning and response clarification. This 
would enable greater understanding of the experiences of both independent adults 
and caregivers of children/dependent adults in using psychotropic medication to 
assist with undesirable emotions or behaviours associated with an ASD. 
As with most qualitative research, the researchers’ own biases and 
opinions will have influenced how the data has been perceived and coded. While 
the data was coded independently, both coders have a significant interest in 
psychotropic medication use, and by virtue of this will have been more inclined to 
recognise themes and subthemes fitting with their theoretical perspectives. 
10.9 Conclusions 
The current study’s qualitative analysis has provided valuable insights into 
the perspectives of caregivers and independent adults regarding the use of 
psychotropic medications in an ASD population. The responses indicated that the 
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decision to use psychotropic medication was complex and multifaceted, and that 
individual factors needed to be taken into account. The analysis revealed a clear 
desire for alternative therapeutic options to medication to be more readily 
available to independent adults, children and dependent adults with an ASD. 
There was a need for empowerment of both individuals and caregivers, to enable 
them to make collaborative decisions relating to medication use. There was also a 
necessity for more education about the evidence base of available interventions. 
Quality of life appeared to be a significant motivation to use or not use 
psychotropic medication. The importance of the wellbeing of the person with an 
ASD was a dominant theme that emerged, but there was also consideration given 
to the quality of life of those who supported and cared for them. There is a need 
for future research to focus explicitly on factors associated with quality of life in 
people with an ASD and in their caregivers, as well as the role that psychotropic 
medication use has on these factors. 
The new evidence derived from this analysis highlights the need for 
further exploration of psychotropic medication use from the perspective of 
caregivers and independent adults. The qualitative data provided here has 
enhanced understanding of the impact of psychotropic medication use in an ASD 
population, while also providing insight into the perspectives of self-reporting 
adults and caregivers of children and dependent adults with an ASD. 
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Chapter 11: Overall Reflections 
This thesis examined the use of psychotropic medication in a community- 
based ASD sample within Australia. The findings indicated that psychotropic 
medication use was common among those with an ASD. Many participants 
reported being prescribed medications for ASD-related conditions that fall outside 
the use that had been approved by regulatory bodies. For instance, children with 
an ASD in this Australian sample were being prescribed psychotropic medication, 
despite the absence of randomised controlled trials to support its use in this age 
group. These findings are a cause for concern as the health outcomes of long term 
psychotropic medication use in this population are unknown.  
The three studies that comprise this thesis differ in terms of groups 
(individuals who are self-reporting adults to those who are children and dependent 
adults), informants (self and parent/carer) and nature of the information provided 
(quantitative and qualitative).  Although these differences limit the direct 
comparability of findings, it is important to examine commonalities and 
differences in the findings. An important question raised across the studies is 
whether individuals and caregivers perceive medication as a form of ‘restraint’ as 
defined by the Victorian Government. A clear difference was apparent in 
response to this issue between individuals with ASD and carers/family members. 
Individuals with an ASD were of the belief that medication should not be used to 
restrict ‘one’s nature’ whereas a number of caregivers endorsed using medication  
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for behavioural control. It appeared that many caregivers did not perceive using 
medication as a form of restraint when given for the primary purpose of managing 
challenging behaviours.  
As the perspectives outlined within this thesis demonstrate, both the 
clinical and familial decision to use medication in this population is clearly 
complex and requires careful consideration and collaboration. Caregivers and 
individuals require education about the available intervention options and current 
literature, the effectiveness of these interventions, as well as potential side effects. 
Practitioners need to ensure that they are actively involving caregivers and 
individuals in the decision making process and empowering them to be able to 
make the decision in the best interests of the individual.  Future investigations 
into the decision making process of caregivers, individuals and medical 
practitioners to use psychotropic medications would generate  greater 
understanding, and assist in formulating best practice guidelines and treatment 
protocols for people with ASD. It is also apparent that there is a need for regular 
reviewing of the use of medications by both the individual, caregivers and 
professionals involved.  
Individuals with an ASD and their caregivers both reported that quality of 
life was central to the decision to use psychotropic medication. Participants 
indicated that medication use resulted in perceived improvements in quality of 
life. This is an important finding because it provides a rationale as to why medical 
practitioners prescribe medications to people with an ASD, when they have not 
yet been scientifically proven to be effective. It is important for practitioners 
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working with the family focus on quality of life and how this can be achieved for 
the family. Further research is warranted to examine the relationship between 
psychotropic medication use and the subjective wellbeing of both individuals and 
their caregivers. 
It was beyond the scope of this thesis to examine concurrent or alternative 
interventions among people with an ASD, in addition to psychotropic 
medications. This meant that it was unknown whether other interventions were 
used in conjunction with psychotropic medication among this sample, and how 
these may have affected psychotropic medication use or perceptions of its 
effectiveness. Currently, little is understood about the interactions between 
psychotropic medications and psychosocial interventions (e.g., Weeden et al., 
2011). Therefore, future research that investigates the combination of 
psychotropic medication use and alternative interventions is essential. 
The findings from the studies comprising this thesis highlight a potential 
disparity in the perceived effectiveness of medication compared with previous 
studies involving caregivers and individuals. While previous research has 
reported mixed results on the efficacy of psychotropic medications, the current 
findings indicated that both individuals and caregivers perceived psychotropic 
medications as both helpful and effective. Future research needs to explore this 
discrepancy as our understanding of the true effectiveness of psychotropic 
medication use in this population is limited by so few controlled studies. 
Moreover, these studies need to control for other interventions, such as applied 
behavioural analysis, communication devices, and cognitive behavioural therapy.  
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The current findings indicated that few participants ceased psychotropic 
medication use once it had commenced. This was an important issue because 
these participants also reported several side effects from taking these medications. 
Despite this, the results suggested that once an individual commenced 
psychotropic medication, this brings into question the level of review that is 
occurring with relation to the need for this medication. Consequently, it is 
suggested that the decision to commence medication should not only occur at the 
beginning of pharmacological treatment, but should  be subject to ongoing 
reviewed with caregivers and individuals, to assess the continuing need for and 
both the positive and negative effects of this form of treatment. An increased 
collaboration between individuals, care-givers, and health professionals 
(including teachers, social workers, psychologists, occupational therapists, speech 
pathologists) will likely translate into better informed choices and treatment 
outcomes. Standardised guidelines regarding the review of psychotropic 
medication among people with ASD therefore requires further consideration. 
11.1.1 Practice Recommendations 
The findings of this thesis provide much information to inform clinical 
practice within those with an ASD. The findings emphasise the need for thorough 
clinical assessment of individuals with an ASD when presenting to health care 
services, particularly if the question of medication is raised. These assessments 
need to give consideration to how co-morbid mental health conditions may 
present differently in those with an ASD. It is essential that where challenging  
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behaviours are raised, an in-depth review and functional analysis of the behaviour 
occurs, to ensure that the intervention options selected are most appropriate and 
least restrictive for the behaviours.   
For all individuals with an ASD it is important that emotional support is 
made available to them. This can be both formal, in terms of counseling, but also 
informal through empathic listening, discussing problems and spending time 
discussing the different options. Long term support needs to be available for 
individuals and their caregivers.  
Individuals need to be viewed as experts in their own lives (Valentine, 
2010). Professionals working with those affected by an ASD, need to focus on 
empowering them to make decisions about their life. There is a role for 
professionals to provide education to individuals and caregivers around 
intervention options, with a particular focus on medication. This needs to include 
information related to its mixed evidence base, efficacy, potential side effects and 
long term outcomes associated with its use.  In particular, it is important that 
those caring for children are made aware that the long term outcomes of many of 
these medications are unknown.  
One of the most significant approaches that can be offered to individuals 
and their caregivers involves the enhancement and provision of support. This 
includes both formal and informal support. Informal supports include those that 
naturally occur in one’s life, including neighbours, friends, parents, spouses, 
religious institutions who can provide psychological, emotional and physical 
support (Myers & Johnson, 2007). There is also a significant role for formal 
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supports including publicly funded programs such as early intervention, special 
education, respite services, vocational and residential services, as well as access 
to specialised health care services. It is important that support strategies focus on 
ensuring the physical and emotional health of both individuals with ASD and 
their caregivers. Support can be given through education about ASDs, 
interventions available, providing training and empowering them to make 
decisions around interventions and be active participants in the interventions.  
This thesis has contributed new knowledge to the field of psychotropic 
medication use among individuals with ASD in Australia. Since this body of 
research is still in its infancy, it is important that the administration and effects of 
psychotropic medication in this population are continually investigated. There is a 
clear need for collaboration between individuals with an ASD, their caregivers 
and professionals, to ensure that psychotropic medication is used in an 
appropriate and transparent manner. 
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Appendices 
Appendix A 
1. What medications do you currently take (Please list all) 
Medication Name  
(frequency & dosage) 
Primary Reason for 
Prescription 
Secondary Reasons 
for Prescription 
   
 
 
 
(The following section will be asked with respect to each reported medication) 
 
2. Who prescribed this medication: 
 GP 
 Psychiatrist 
 Paediatrician 
 Other, please specify, ____________________________ 
 
3. Have you been diagnosed with a mental health or behaviour disorder 
associated with being prescribed this medication? 
 No, proceed to question 12 
 Yes 
 
The condition for which this medication was prescribed is:  
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 Anxiety Disorder 
 Depression 
 Adjustment Disorder 
 Bipolar Affective Disorder 
 Schizophrenia 
 Behaviour Disorder 
 Other, please specify, ____________________________ 
 
4. Do you feel this medication helps you to manage your mental health or 
behaviour disorder ? 
 Yes  
 No 
Please comment further:   ___________________________________________ 
 
________________________________________________________________ 
 
 
 
5. Please rate how you feel about taking this medication: 
 
Totally 
Dislike        Neutral        
Totally 
Like 
 0  1  2  3  4  5  6  7  8  9  10  
                       
            
                       
 
 
 
6. Do you believe this medication is a form of restraint? 
 Yes  
 No 
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Appendix B 
Have a Say in the Debate about 
Medication 
 
 
Are you an adult with an Autism Spectrum Disorder? 
Or 
Are you a care-giver of a child or adult with an Autism Spectrum 
Disorder? 
Dr Jane McGillivray and Belinda Minett from Deakin University are conducting a study 
about the individuals and care-giver’s perspectives of medication to manage behaviour 
and emotions associated with Autism. There has been lots of debate about the use of 
medication by people with autism spectrum disorder. However, little is known about the 
perspectives of people with ASD.  
In this study, we want to find out what you think about medication. Do you take it, what 
do you take and why, how do you feel about it.  What you have to say is important to 
discussions about the best treatment alternatives for managing the conditions associated 
with ASD. Your answers are anonymous, so you can say what you want. 
 
What will you be asked to do:   If you agree to participate in this study, you will be asked 
to complete an online or paper questionnaire that will take approximately 20 minutes. 
Your involvement is voluntary and your responses will be anonymous.  The link for the 
online version of the study is http://www.deakin.edu.au/psychology/research/autismstudy 
You can request a paper version to be sent to you by contacting Belinda and Jane on the 
details below. A copy of group findings will be made available to participants upon 
request. 
 
How to get involved? If you would like to participate, or if you wish to obtain further 
information about this research please contact Jane McGillivray Ph: 03 9244 6426 or 
Belinda Minett email: bami@deakin.edu.au     
 Psychotropic Medication and ASD
   
 
 
274 
 
 
Appendix C 
DEAKIN UNIVERSITY 
PLAIN LANGUAGE STATEMENT AND CONSENT FORM 
 
TO:  Participants 
 
 
Plain Language Statement  
Date: 23rd October 2009 
Full Project Title: Pharmacology and Autism Spectrum Disorders 
Principal Researcher: Associate Professor Jane McGillivray 
Student Researcher: Belinda Minett 
 
This Plain Language Statement and Consent Form is three pages long. Please make 
sure you have all the pages.  
1. Your Consent 
You are invited to take part in this research project.  This Plain Language Statement 
contains detailed information about the research project. Its purpose is to explain to you 
as openly and clearly as possible all the procedures involved in this project so that you 
can make a fully informed decision whether you are going to participate.  
Please read this Plain Language Statement carefully. Feel free to ask questions about 
any information in the document.  You may also wish to discuss the project with a relative 
or friend or your local health worker. Feel free to do this. 
Once you understand what the project is about and if you agree to take part in it, you will 
be asked to sign the Consent Form. By signing the Consent Form, you indicate that you 
understand the information and that you give your consent to participate in the research 
project. 
You will be given a copy of the Plain Language Statement and Consent Form to keep as 
a record. 
2. Purpose and Background 
The purpose of this project is to gain an understanding of individuals with autism 
spectrum disorder and their care-giver’s perspectives of medication.  
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A total of 400 people will participate in this project. 
You are invited to participate in this research project because you or someone you 
care for has an Autism Spectrum Disorder and is currently taking medication. The 
results of this research may be used to help researcher Belinda Minett to obtain a 
Doctor of Psychology (Clinical) degree. 
3. Funding 
This research is not a funded project. 
4. Procedures 
Participation in this project will involve filling out an anonymous questionnaire which will 
take approximately 20 minutes to complete. No identifying data will be requested as part 
of the questionnaire and you are free to withdraw at any time.  
5. Possible Benefits 
We cannot guarantee or promise that you will receive any benefits from this project. 
However. this research will result in an enhanced understanding the use of medication in 
people with autism spectrum disorders. Further it will provide insight into individuals and 
care-giver's perspectives of the use of medication n this population group.  
6. Possible Risks 
There is a possible but unlikely potential for participants to experience a low level of 
stress and anxiety associated with the questions that are asked of them. However the 
benefit of gaining a greater understanding of the factors associated with medication use 
offers a new perspective. 
If participants experiences distress while completing the survey they are able to suspend 
or end their participation in the project. If any distress occurs we suggest contacting your 
local autism association, crisis support service or medical practitioner for support. 
7. Privacy, Confidentiality and Disclosure of Information 
No individual will be able to be identified who has participated in this study.  We plan to 
present findings as a conference paper and in a peer-reviewed journal, however, only 
group results will be reported. All data collected will be stored securely at Deakin 
University for a period of six years from publication.   
8. Results of Project 
A copy of summary results will be forwarded to any interested parties at the 
completion of the study by contacting us by e-mail bami@deakin.edu.au. You 
may also access the results through the following website [link]. 
9. Participation is Voluntary 
Participation in any research project is voluntary. If you do not wish to take part you 
are not obliged to. If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage until the questionnaire is submitted. Once the 
questionnaire is completed and submitted participants will not be able to be identified 
therefore it is not possible to withdraw data after submission. 
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10. Ethical Guidelines 
This project will be carried out according to the National Statement on Ethical Conduct in 
Human Research (2007) produced by the National Health and Medical Research Council 
of Australia. This statement has been developed to protect the interests of people who 
agree to participate in human research studies. 
The ethics aspects of this research project have been approved by the Human Research 
Ethics Committee of Deakin University. 
11. Complaints 
If you have any complaints about any aspect of the project, the way it is being conducted 
or any questions about your rights as a research participant, then you may contact:   
Should you have any concern about the conduct of this research project, please contact 
the Secretary HEAG-H, Dean's Office, Faculty of Health, Medicine, Nursing and 
Behavioural Sciences, 221 Burwood Hwy, Burwood, VIC, 3125. Telephone: (03) 9251 
7174, Email: hmnbs-research@deakin.edu.au” 
 
Please quote project number HEAG-H: EC00213 
12. Reimbursement for your costs 
You will not be paid for your participation in this project.  
13. Further Information, Queries or Any Problems 
If you require further information or if you have any problems concerning this project, you 
can contact the principal researcher Associate Professor Jane McGillivray on Tel: 9244 
6426 or e-mail jane.mcgillivray@deakin.edu.au.  
Or alternatively you may contact the student researcher involved in this project Belinda 
Minett on email: bami@deakin.edu.au   
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Appendix D 
Table 12.1 
Frequency of medications reported by name and class ( n of medication = 241)  
Name of Medication Class of Medication Number of Children/Dependent Adults 
Freq. 
Amitriptyline Anti-depressant 2 
Atomoxetine CNS stimulant 5 
Benzhexol Other 1 
Carbamazepine Anti-convulsant 2 
Chloral hydrate Hypnotic sedative 1 
Claobazam Anti-anxiety 1 
Clonazapam Anti-convulsant 1 
Clonidine Other 17 
Depo Provera Other 1 
Desvenlafaxine Anti-depressant 1 
Dexamphetamine Hypnotic Sedative 7 
Diazepam Anti-anxiety 2 
Duloxetine Anti-depressant 3 
Escitalopram Anti-depressant 4 
Fluoxetine Anti-depressant 33 
Fluvoxamine Anti-depressant 7 
Haloperidol Anti-psychotic 2 
Lamotrogine Anti-convulsant 3 
Lithium Anti-psychotic 2 
Melatonin Anti-depressant 23 
Methylphenidate CNS stimulant 38 
Olanzapine Anti-psychotic 6 
Pericyazine Anti-psychotic 1 
Queitipine Anti-psychotic 3 
Risperidone Anti-psychotic 54 
Sertraline Anti-depressant 4 
Sodium Valproate Anti-convulsant 10 
Talohexal Anti-depressant 4 
Venlafaxine Anti-depressant 2 
Ziprasidone Anti-psychotic 1 
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Appendix E 
Table 12.2 
Medication name, type, primary and secondary reason for prescription for those 
who currently used medication (n of medication =46) 
Medication Name Type of 
Medication 
Reason for 
Prescription 
Secondary Reason 
For Prescription 
1. Diazepam Anti-anxiety  Anxiety  
2. Risperidone Anti-psychotic Agitation   
3. Dexamphetami
ne 
Hypnotic-sedative Add  
4. Fluvoxamine Anti-depressant Anxiety Depression, mood 
control 
5. Aropax Anti-depressant Anxiety  
6. Sertraline Anti-depressant Anxiety  
7. Xanax Anti-anxiety Anxiety Sensory Overload 
8. Fluoextine Anti-depressant Anxiety  
9. Diazepam  Anti-anxiety Anxiety, panic 
attacks 
 
10. Sertraline Anti-depressant Anxiety, Obsessing 
11. Lithium Anti-psychotic Bi Polar  
12. Amitriptyline Anti-psychotic Bi-polar  
13. Sodium 
Valrpoate 
Anti-convulsant Bipolar mood 
disorder 
 
14. Endep Anti-depressant Neurological quieter  
15. Mysndol Other Calming purposes  
16. Lovan Anti-depressant Depression Anxiety 
17. Effexor Anti-depressant Depression Anxiety 
18. Mirtazon Anti-depressant Depression Sleep problems 
19. Sertraline Anti-depressant Depression  
20. Escitalopram Anti-depressant Depression OCD 
21. Paroxetine Anti-depressant Depression Anxiety 
22. (Duloxetine Anti-depressant Depression  
23. Mertazipine Anti-depressant Depression, low 
motivation 
Anxiety 
24. Sertraline Anti-depressant depression/ low 
mood 
 
25. Pristique Anti-depressant Depression/Anxiety  
26. Lamictal Anti-convulsant Epilepsy Mood Stabiliser 
27. Amitriptyline Anti-psychotic Anxiety  
28. Sodium Anti-convulsant Mood stabilizer  
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valproate 
29. Sertraline Anti-depressant Severe depression Anxiety 
30. Amitriptyline Anti-psychotic PTSD like symptoms  
31. Amitriptyline Anti-psychotic Rumination Agitation 
32. Melatonin Anti-depressant Sleep  
33. Sertraline Anti-depressant To stabilise 
emotions, sleeping 
 
34. Valdoxin Anti-depressant Sleep Disturbance  
35. Sodium 
Valrpoate 
Anti-convulsant Bi Polar   
36. Effexor Anti-depressant  Severe depression  
37. Diazepam Anti-anxiety Anxiety Anxiety related to 
routine disruption.  
38. Quetiapine Anti-depressant Racing thoughts Agitation 
39. Alprazolam  Anxiety Sleep problems 
40. Sodium 
Valrpoate 
Anti-convulsant Mood Sleep disturbance 
41. Lithium Anti-psychotic Mood Stabiliser Prevent 
recurrence of 
depression 
42. Ritalin CNS stimulant Calm racing thoughts Focus brain more 
43. Suboxene Other Past history of 
codeine abuse 
Opiate blocker, 
stops cravings 
44. Amitriptyline Anti-psychotic Sleep Problems Anxiety 
45. Diazepam Anti-anxiety Anxiety  
46. Diazepam Anti-anxiety Anxiety  
 
 
 
 
 
 
 
 
